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ABSTRACT 
 
Ashley Rachelle Johnson: Continuous Liquid Interface Production of Microneedles for 
Transdermal Drug Delivery 
 (Under the direction of Joseph M. DeSimone) 
 
 The past two decades of microneedle research has demonstrated the benefits of 
microneedle technology in transdermal drug delivery. Microneedles are arrays of sub-millimeter 
sized projections that physically pierce the outer layer of the skin to allow a therapeutic to pass 
into the body. Using microneedles to create physical channels within the skin has enabled 
transdermal delivery of many medications that would otherwise need be delivered by 
hypodermic injection. Because microneedles are so small that they evade nerve endings buried 
deep within the skin, they have enabled pain free delivery of medications, providing an 
opportunity for improved patient compliance. Biocompatible microneedles are of particular 
interest because they are thermodynamically stable at room temperature, safe for patients and 
enable controlled release of medication out of the patch. The micro-manufacturing processes 
used to manufacture such biocompatible microneedles, however, do not allow for control over 
critical microneedle design parameters, such as size, shape, aspect ratio and spacing. 
Herein, we utilize a novel additive manufacturing technique called Continuous Liquid 
Interface Production (CLIP) to manufacture microneedles for transdermal drug delivery. This 
technique is that fastest microneedle fabrication technique in the world, to date, and enables 
unprecedented control over patch design parameters. We show that CLIP microneedles can be 
produced in under 2 minutes per patch and demonstrate capability to produce microneedle 
designs that cannot be fabricated using other mold-based techniques, such as arrowhead 
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microneedles.  CLIP microneedles were produced from more than four different compositions, 
including photopolymerizable derivatives of biocompatible materials designed to dissolve, 
degrade, or swell within the skin to release a cargo. These CLIP microneedles effectively pierced 
murine skin ex vivo and released the fluorescent drug surrogate rhodamine.  
Further, the mechanical properties of these microneedle devices are investigated using 
polyethylene glycol (PEG) with varying crosslink densities. We demonstrate that the elastic 
modulus of these hydrogels is a critical design parameter that influences microneedle insertion 
into the skin. Stiff microneedles are shown to effectively penetrate porcine skin ex vivo with 
lower application forces, whereas more rubbery microneedles require a greater force to 
effectively insert into the skin.  
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CHAPTER 1 MICRONEEDLE TECHNOLOGY FOR TRANSDERMAL DRUG DELIVERY 
 
1.1 Transdermal Drug Delivery 
1.1.1 Drug Delivery Market 
The discovery and development of new therapeutics is a massive effort, both in the 
United States and abroad. Major pharmaceutical companies in the United States spend 
approximately $50 billion dollars in collective annual R&D spending, with an average cost to 
market of a new molecular entity averaging $1.8 billion dollars.1 Pharmaceutical sales in the 
United States account for approximately 40% of global sales, which are estimated at a 
formidable $1.1 trillion dollars.2 The ability to deliver these valuable active pharmaceutical 
agents (APIs) to their site of action within the body is critical to their therapeutic efficacy, but 
drug delivery remains a substantial challenge.3 Although oral delivery is the most widely utilized 
route of administration, many drugs suffer from poor oral bioavailability1 due to a variety of 
factors including poor solubility, degradation within the gastrointestinal tract, poor absorption 
through the stomach wall, and first pass metabolism in the liver and spleen4. These challenges 
are particularly significant for the delivery of protein and nucleic acid based therapeutics, which 
accounted for 71% of revenue for the top ten selling pharmaceutical products in 2012.5 Many 
strategies have been utilized to increase bioavailability, including computational approaches 
designed to improve drug properties (solubility, potency, toxicity, etc.),6,7 chemical 
modifications such as pro-drugs,8 and more sophisticated formulations, such as nanoparticulates 
and polymer-drug conjugates.9 Despite advancements in these areas, many drugs can still only be 
delivered via intravenous, subcutaneous, or intramuscular injections with a hypodermic needle.  
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1.1.2 First Generation Transdermal Drug Delivery 
One alternative to hypodermic injections is transdermal drug delivery, wherein a 
therapeutic of interest is delivered through the skin.  Transdermal drug delivery has the potential 
to improve bioavailability by enabling drugs to traffic directly through the skin and into the 
blood stream, bypassing the stomach, liver, and spleen.10-13 The transdermal drug delivery 
market is estimated at $30 billion dollars globally, making up over 12% of the total drug delivery 
market. 11 
The advancement of transdermal drug delivery technologies has been described as having three 
evolutionary “generations”,10 as shown in Table 1.1. First generation transdermal drug delivery 
refers to any transdermal drug delivery technology that introduces an API to systemic circulation 
via passive diffusion through the skin. It should be noted that ointments and creams used for the 
treatment of local skin conditions, such as sunscreen, antibiotics used to treat acne and other 
skin-laden bacterial infections, and corticosteroids used for psoriasis, eczema, and dermatitis are 
topical treatments, not transdermal delivery systems because they do not seek to deliver the API 
into systemic circulation. In 1979, the first transdermal patch was FDA approved for the delivery 
of scopolamine to treat motion sickness.11 Transdermal patches are drug-containing matrices 
(solid, liquid, or gel) attached to an adhesive backing. Since this time, 19 different drugs have 
Table 1.1 Generations of transdermal drug delivery 
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been FDA approved for systemic delivery using transdermal patches; a list of these medications 
is provided in Table 1.2. 11 Transdermal patches delivering nicotine for smoking cessation and 
ethinyl estradiol/norelgestromin for contraception have been particularly successful commercial 
products that are now commonly used.11 Over one billion transdermal patches are now 
manufactured annually.10 
Delivery of medication using transdermal patches has several inherent benefits (Table 
1.3). Unlike typical hypodermic injections, transdermal patches allow for pain-free drug delivery 
and can be self-administered without trained medical personnel.11 Most transdermal patches 
Table 1.2  List of medications FDA approved for systemic delivery using a transdermal patch. Table adapted 
from reference 11. 
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enable sustained release of the drug out of the patch to reduce required dosing frequency; one 
patch application can be equivalent to days or weeks of daily oral medication.13 For these 
reasons, delivery of medication using transdermal patches typically results in increased patient 
compliance when compared to other routes of administration. For example, a recent study of 
elderly patients with hypertension demonstrated that patients correctly applied a single 
transdermal patch 96% of the time, whereas daily oral medication was taken as directed only 
50% of the time.14 Similar improvements have been reported for contraceptives15 and for 
medications used to treat dementia of Alzheimer’s type.16 Moreover, transdermal patches prevent 
accidental needle injuries by avoiding the generation of sharp, biohazardous wastes.10 
Despite these clear advantages, the use of first generation transdermal drug delivery 
technologies has been severely limited by the structure of the skin,10-13 described in more detail 
below.  
1.1.3 Structure of the Skin 
The skin, shown in Figure 1.1A, is composed of three distinct layers: the epidermis, 
dermis, and adipose tissue1,2. The epidermis is the outermost layer of the skin, measuring 
anywhere from 50-1500µm in thickness,17 depending on genetic and environmental factors18 and 
the area of the body, with the eyelids being the thinnest and the palms and soles of the feet being 
Table 1.4 Advantages of transdermal drug delivery 
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the thickest. Depending on the region of the body, the epidermis is composed of up to 5 layers19-
20- the stratum basale, stratum spinosum, stratum granulosum, stratum lucidium (only present in 
some regions), and stratum corneum, moving from the inside outward (Figure 1.1B).  
The epidermis is constantly replenished through cellular proliferation followed by 
sequential differentiation to generate each stratified layer. 19-21 This differentiation process is 
important because it is the mechanism by which the tough, impermeable outer layer of the skin is 
eventually produced. Differentiation begins with keratinocyte cells in the stratum basale, the 
innermost layer of the epidermis.This layer also contains melanocytes, which are responsible for 
producing pigment, Langerhans cells which are involved in immunity,22 and Merkel cells which 
are involved in the sensation of touch.19 In the stratum spinosum, the keratinocytes begin to 
adhere to one another through the formation of desmosomes and to produce polar lipids, 
contained within lamellar vesicles within the Golgi body.19,21  The stratum spinosum also 
contains a high concentration of Langerhans cells. In the stratum granulosum, keratinocytes lose 
their nuclei and begin to excrete the lipid containing lamellar vesicles into the extracellular 
 
Figure 1.1 Structure of the skin A) Structure of full thickness skin B) Structure of the Epidermis. Reproduced with 
permission from reference 19. 
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space, where they are converted into nonpolar lipids that prevent water loss into the surrounding 
environment.21 Completion of the differentiation process results in the formation of the 
corneocytes that make up the outermost layer of the skin, called the stratum corneum. The 
stratum corneum is a densely packed 10-15µm thick layer of dead corneocytes surrounded by the 
nonpolar fatty acids ceramide and cholesterol.21 Together, these anucleated cells and 
extracellular lipids make up a “brick-and-mortar structure” that acts as a formidable barrier 
against foreign substances only permeated by small, lipophilic substances.21 For this reason, 
transdermal drug delivery has traditionally been limited to the delivery of hydrophobic 
compounds measuring less than 500 Daltons in size.10-13  
Beneath the epidermis lies the dermis (1-2mm thick), a network of collagen fibers that 
retains the structural and mechanical integrity of the skin. Unlike the epidermis, which is 
composed of 95% keratinocytes and a high concentration of T cells,23 the dermis also contains a 
network of capillaries, lymphatics, sweat glands, and a high concentration of macrophages, mast 
cells and resident dermal dendritic cells.19-21 Below the dermis lies the adipose tissue, laden with 
fat, blood vessels, and the nerve endings responsible for perception of pain.19-21 
1.1.4 Advancements in Transdermal Drug Delivery 
Many approaches have been developed to improve the skin’s permeability to therapeutic 
agents in an effort to enable a wider range of therapeutics to be delivered through the skin. 
Langer and Prausnitz have classified these more advanced, technological approaches as second 
and third generation transdermal drug delivery technologies (see Table 1.1). 10 
Second generation techniques seek to increase the skin’s permeability to a therapeutic by 
increasing the driving force that enables small molecule therapeutics to pass into the skin. These 
second generation techniques include chemical enhancers and iontophoresis. Chemical enhancers 
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are typically amphiphilic molecules utilized to temporarily discrupt the physical structure of the 
extracellular lipids within the stratum corneum to enable small molecule drugs to more easily 
pass into the skin.10-11 Although many chemical enhancers have been utilized, disruption of the 
skin has a tendency to cause skin irritation; the development of non-irritating enhancers is an 
ongoing effort.10-11,24 Iontophoresis, a technique that utilizes an electrical charge gradient to drive 
small molecules into the skin, has also been successfully utilized,25 but requires complex medical 
devices to enable successful delivery. 10 
Third generation technologies seek to physically disrupt the structure of the skin to create 
pores that allow the therapeutic to more easily enter the body.10 Although these techniques are 
reviewed comprehensively elsewhere,10-11,26-28 some techniques which physically disrupt the skin 
include cavitational ultrasound, jet injectors, microdermabrasion, and microneedles.10 Briefly, 
cavitational ultrasound uses ultrasound, or high frequency sound waves, to generate bubbles in a 
solution containing a therapeutic. When these bubbles grow to an unstable size, they collapse and 
create a strong pressure gradient that pushes the solution into skin.26 This highly pressurized 
fluid erodes the outer layer of the skin to enable the therapeutic to pass into the body.26 Similarly, 
jet injectors create a high velocity fluid stream (>100m/s) using compressed air or a compression 
stream; this high velocity stream creates pores in the skin measuring between 75µm and 360µm 
wide to enable the therapeutic to enter the body.27 Despite over 50 years of development and 
their ability to enhance bioavailability, jet injectors are not commonly used due to lack of 
injection reproducibility and their tendency to cause bruising of the skin.27 Microdermabrasion 
increases skin permeability by physically sanding away the dead cells that make up the stratum 
corneum to enable therapeutics to more easily pass into the body. 10,28 
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The remainder of this dissertation focuses on transdermal drug delivery using microneedle 
arrays, which are described in more detail below.  
1.2 Microneedle Technology 
 Microneedle technology was developed in the 1990s as a novel way to penetrate the skin 
for transdermal drug delivery.29 Microneedles are arrays of sharp, sub-millimeter sized needles  
(~100-1000µm in length) that physically pierce the stratum corneum to deliver therapeutics into 
the body.30 Because these needles create perforations within the skin, they eliminate the need for 
passive diffusion of the therapeutic through the stratum corneum, thereby allowing therapeutics 
of any size, ranging from small molecules31-33 to nanoparticles,34-35 to enter the body. Because of 
their small size, microneedles avoid the nerve endings responsible for pain, which are buried 
deep within the adipose layer, to enable pain free drug delivery.36-38  
The first report of microneedles was a 1998 publication by the Prausnitz lab which 
utilized silicon microneedles measuring 150µm in length to increase the permeability of the 
fluorescent drug surrogate calcein by three to five orders of magnitude.29 Since this point in time, 
the microneedle field has expanded rapidly, with 80 microneedle publications in 2014 alone 
(Figure 1.2A). Microneedles have been utilized to deliver a wide variety of therapeutics, 
including proteins,39-40 nucleic acids,41-42 small molecules,31-33 and nanoparticles34 in pre-clinical 
and clinical studies. Microneedle technology has been applied to the treatment of a number of 
different indications (Figure 1.2B), including delivery of insulin for the treatment of 
diabetes,36,39,43,44 the delivery of nonsteroidal anti-inflammatory drugs (NSAIDs) for the 
treatment of pain33, 45-46 and the delivery of chemotherapeutics for the treatment of cancer,47-48 
but the most common application of microneedles has been in vaccine delivery.49  
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Vaccine delivery is an ideal target for microneedle technology for a number of different 
reasons. Firstly, intradermal vaccination has been associated with improved protection as 
compared to intramuscular injection.50-55 The vast majority of literature indicates that vaccine 
delivery using microneedles induces a dose-sparing response, wherein a lower concentration of 
antigen delivered with microneedles produces equivalent antibody titers to higher concentrations 
 
Figure 1.2 Growth and therapeutic targets of microneedle technology. A) Number of publications involving 
microneedle technology annually. B) Number of publications delivering a therapeutic to treat various indications 
between 1998 and 2014. Data compiled from Thomson Reuters Web of ScienceTM  
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of intramuscularly administered antigen.50-53 A limited number of reports indicate higher 
antibody titers than intramuscular and subcutaneous controls.54-55 
These improvements in immune response are thought to be due to the convergence of a 
number of different factors. As mentioned previously, the skin contains a high concentration of 
immune cells, such as the Langerhans cells and dendritic T cells located in the epidermis.10-13,?? 
The ability to specifically target these immune cells using microneedle technology is thought to 
improve total immune responses.49 The skin also provides excellent access to the draining lymph 
node, where activation of dendritic cells, B cells, and T cells occurs.21,56 This improved lymph 
node access is thought to be a combination of direct migration of antigen through the skin’s 
extensive network of capillaries and lymphatics and efficient migration of innate immune cells 
(such as dendritic cells, macrophages, and mast cells) resulting from chemokine signaling in the 
skin.21,56, 57 Although a number of different investigators have suggested that improved immune 
responses are also the result of unique properties of Langerhans dendritic cells located into the 
skin, the role of Langerhans dendritic cells is largely unproven and is a subject of continuing 
investigations.56-58 
In addition to these improvements in immune response, many microneedle formulations 
are stable at room temperature over months at a time.49,59-60 This enhanced stability has the 
potential to eliminate the need for refrigeration in each step of the global vaccine distribution 
supply chain to improve vaccine access in remote or under-resourced locations.49,59-60 To this 
end, microneedles have been investigated as a promising approach for vaccination against 
seasonal61 and pandemic influenza,62 measles,63 polio,46 diphtheria,64 human immunodeficiency 
virus (HIV),41 rotavirus,65 and malaria,66 among others. The small, microgram doses required for 
vaccination are also well-suited to microneedle based delivery.10 
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1.2.1 Microneedle Configurations 
Microneedles can be classified into four distinct configurations- hollow microneedles, 
solid uncoated microneedles, solid microneedles coated with a powdered therapeutic, and 
polymeric microneedles, each of which differs in its method of application (Figure 1.3).19,30,67 
Hollow microneedles are typically made of metal or silicon containing a cylindrical bore; they 
are utilized for the delivery of liquid formulations which are pumped through the patch into the 
skin. 19,30,67  Solid microneedles, which are also typically made of metal or silicon, are 
temporarily applied to generate holes in the skin before removal. 19,30,67  A topical therapeutic 
liquid or cream agent can then be applied and allowed to diffuse through the channels created by 
the microneedle patch. 19,30,67  When microneedles are coated with a dry therapeutic coating, the 
microneedles are left in the skin to allow the coating to dissolve before removal of the patch. 
19,30,67  In addition to these metal and silicon designs, microneedles have also been fabricated 
 
Figure 1.3 Microneedle configurations. The method of application and drug release for each of four different 
microneedle configurations. Figure adapted from reference 19. 
 
12 
 
from biocompatible materials, such as natural and synthetic polymers.68 In this case, drug is 
typically directly incorporated into the microneedle matrix, which swells,69 degrades, 68 or 
dissolves68 to release the therapeutic into the skin. A pie chart showing the relative distribution of 
materials used in publications describing microneedle technology between 1998 and 2014 is 
given in Figure 1.4. Microneedles have been made of metal, silicon, and polymers (including 
natural and synthetic) with approximately equivalent frequency.  
It is worth noting that the distinctions between these different categories are approximate. 
For the purpose of this dissertation, microneedles are classified based on their drug release 
mechanism, not their composition. For example, in a few cases, biocompatible or polymeric 
materials have been utilized to make coated41 or hollow70 microneedle configurations. However, 
because a PLGA microneedle coated with a therapeutic releases the therapeutic into the body via 
dissolution of the coating, we would consider a coated PLGA microneedle to be a solid, coated 
microneedle for the purposes of this dissertation. Conversely, non-polymeric materials such as 
 
Figure 1.4  Distribution of microneedle compositions in literature from 1998-2014. Data compiled from 
Thompson Reuters Web of ScienceTM 
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Figure 1.5 Frequency of microneedle fabrication techniques and microneedle compositions A. Fabrication 
techniques utilized in microneedle publications released between 1998 and 2014 B. Frequency of each 
microneedle configuration over the same time period. Data compiled from Thompson Reuters Web of ScienceTM 
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stainless steel are considered to be biocompatible because they have no adverse reaction with 
cells in the body.71 However, because drug release from a stainless steel needle would be 
achieved via a surface coating or through a hollow bore, we would consider a stainless steel 
needle to be either solid or hollow for the purposes of this dissertation, keeping with convention 
from microneedle literature. Therefore, throughout this dissertation the term “biocompatible 
microneedle” is used to refer to a microneedle loaded with cargo which is intended to swell, 
dissolve, or degrade to release said cargo.  
1.2.2 Microneedle Fabrication Techniques 
The device type, material, desired geometry, and intended therapeutic payload influences 
which specific fabrication technology may be selected for device assembly, but the most 
commonly used microneedle fabrication techniques are given in Figure 1.5A. 
These four different configurations (solid and uncoated, solid and coated, hollow, and 
biocompatible) have been represented with approximately equivalent frequency in microneedle 
literature (Figure 1.5B). Solid, uncoated microneedles are slightly more common than solid, 
coated formulations, presumably due to the large portion of microneedle publications that do not 
involve the incorporation of a therapeutic. This roughly equivalent prevalence of all microneedle 
configurations is indicative of the fact that each configuration has its distinct advantages and 
disadvantages (Table 1.4), making the choice of an optimal microneedle configuration highly 
situationally dependent. Important factors to consider when selecting the appropriate 
microneedle configuration are described here. In general, there is a tradeoff between the 
difficulty of device fabrication and the overall utility of the device (Figure 1.6). For example, 
solid, uncoated microneedles are typically very easy to fabricate by laser cutting metal,72-73 
which can  be polished to remove burrs and then used directly (in-plane),72 or bent 90° and then  
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used (out-of-plane).73 Out-of-plane microneedles have the advantage of having multiple rows of 
microneedles that form an array, whereas in-plane techniques typically only have a single row.72-
73 Solid metal microneedles are also available from commercial sources.74-75 These simple 
fabrication techniques enable researchers to investigate how physically breaching the skin  
affects the skin’s permeability to an existing, topically-applied therapeutic without substantial 
fabrication efforts. Unfortunately, this topical administration severely limits control over applied 
dose.76 For this reason, solid, uncoated microneedles can only be used for the delivery of 
medications with a large therapeutic window.76  
The use of hollow microneedles similarly requires little fabrication effort. Hollow 
microneedles can be obtained from industrial partners and attached to a standard syringe to 
administer existing liquid formulations.77 The administration of large volumes of therapeutics is 
challenging, however, because pumping fluid through micron-sized needles can introduce 
pressure buildup within the skin.78-81 Some clinical trials have shown that this pressure buildup is 
 
Figure 1.7 Advantages and disadvantages of each microneedle configuration 
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painful to patients, thereby negating the advantage of having a pain-free microneedle based drug 
delivery system. One source of this pressure buildup is skin tissue at the microneedle tip, which 
can act as a physical “plug” that prevents fluid flow out of the needle.80 Some investigators have 
designed hollow formulations with side-openings to circumvent this issue,82-83 but the total 
volume that can be introduced is a practical limitation. Bulky devices are also sometimes 
 necessary to control the flow of viscous fluids, thereby increasing the cost and complexity of 
hollow microneedle devices. 84 Together, these disadvantages have lead to an overall decrease in 
the utilization of hollow microneedle configurations over time (Figure 1.7).  
More advanced microneedle configurations- solid, coated microneedles and water-
soluble or biodegradable microneedles- provide several advantages. Because these microneedle 
 
Figure 1.8 Percentage of each microneedle configuration in literature over time. Data is presented as the 
number of publications released of a particular composition divided by the total number of microneedle 
publications in that year. Data prior to 2003 is not not presented due to the small number of microneedle 
publications over this time period. Data compiled from Thompson Reuters Web of ScienceTM 
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configurations incorporate the therapeutic directly into the patch, they exhibit improved dose 
consistency relative to solid, uncoated needles, which rely on topical administration of the 
therapeutic.  Successful administration of medications with smaller therapeutic windows is 
possible with these improvements in dose consistency. Unlike solid, uncoated and hollow 
microneedles, more advanced configurations also stabilize therapeutic proteins through 
dehydration to enable safe storage at room temperature for several months at a time. 49,59-60  This 
long term stability provides an opportunity to simplify the global supply chain for all protein 
based therapeutics by eliminating the need for refrigeration. 49,59-60  The global distribution of 
protein-based vaccines to remote locations with little access to electricity is a particularly 
promising application for this technology.49 Together, these advantages have provided an 
incentive to develop solid, coated microneedles and biocompatible microneedles, despite the 
increased complexity of fabrication processes for these configurations.   
 Some important distinctions in the utility of solid, coated microneedles and 
biocompatible microneedle configurations can be made. Coated microneedles are arguably more 
straightforward to fabricate than biocompatible configurations.73 Typically, a two dimensional 
metal sheet is cut to the desired shape using a laser cutter and electropolished to remove burrs.73 
This metal microneedle array is then coated using one of many different techniques, which 
include dip coating, gas-jet drying, spray drying, electrohydrodynamic atomization (EDHA), or 
ink jet printing, as reviewed elsewhere.85 However, establishing coating techniques that 
reproducibly and uniformly deposit the therapeutic on the microneedle tips without coating the 
base of the array73  requires extensive optimization.  The relatively small amount of cargo that 
can be deposited on the surface of the microneedles 86 prohibits anything but the most potent 
therapeutic cargos from being administered in the matter. Further, small, metal or silicon 
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microneedle fragments accidentally deposited within the skin may trigger an immune response 
against the microneedle device. 67  
 Biocompatible microneedles are often considered the gold standard for patient safety.68,87 
The use of biocompatible materials eliminates immunological risks associated with needles 
accidentally fragmenting in the skin.67  Biocompatible microneedles that are dissolvable or 
biodegradable also eliminate the production of sharp, biohazardous wastes to prevent accidental 
needle-stick injuries and reduce disease transmission caused by needle re-use. 67-68, 88-89 Careful 
material selection also provides an opportunity to have rapid or sustained release of a therapeutic 
into the skin to optimize drug release profiles and maximize therapeutic efficacy. 67-68, 88-89  
Altogether, these benefits have led to an increase in the prevalence of biocompatible 
microneedles over time in preclinical literature (Figure 1.7). Despite these many advantages and 
the clear potential of biocompatible microneedle formulations, only one biocompatible 
microneedle system, developed by Corium International Inc. has been utilized in clinical trials.90 
The goal of this dissertation is to improve the ease and adaptability of biocompatible 
microneedle fabrication so that the many advantages of biocompatible configurations (Figure 
1.7) can be harnessed in a clinical environment.  
1.2.3 Fabrication of Biocompatible Microneedles 
Biocompatible microneedles are usually fabricated in three distinct steps: master template 
fabrication, mold casting, and mold filling.40,68,91 Even though these processes have enabled 
progress in the microneedle field, they all present challenges which hinder further advancements.  
1.2.3.1 Master Fabrication Techniques 
In a typical process, a master template is created using traditional microfabrication 
techniques, such as deep reactive ion etching,92 wet etching,93 laser ablation,41 or tilted ultraviolet 
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photolithography.68 Some examples of microneedles fabricated using each of these techniques 
are provided in Figure 1.8. 
Tilted UV photolithography is a common approach to master fabrication.68,87-88 A silicon 
wafer is first coated with a thick layer of photoresist, typically SU8, and placed in contact with a 
patterned mask containing an array of transparent squares.68,88,94The complex is then exposed to 
UV light at an incident angle that defines the resulting microneedle height. 68,88,94 The substrate is 
rotated and re-exposed a total of four times to produce a negative master containing square 
pyramidal cavities in photoresist. 68,88,94 More information regarding this process can be found in 
Han et. al.94 This technique has been successfully and extensively used by Prausnitz68,88,95 to 
generate square pyramidal microneedles of different sizes. Although this technique is robust, 
process optimization is time consuming and diffraction of the incident UV light at the tip of the 
SU8 master has been known to limit the sharpness achievable by this approach.94 It is also 
 
Figure 1.12 Microneedle masters produced using traditional techniques. Microneedle masters have been 
produced using A) Cryogenic deep reactive ion etching of silicon29 B) Wet etching of silicon93 C) Laser 
ablation34 and D) Tilted UV photolithography 
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limited to the production of square pyramidal microneedles; more complex geometries have not 
been produced.  
When utilizing deep reactive ion etching (DRIE) for the production of microneedle 
masters, a silicon wafer is patterned with an etch mask (metal or photoresist) using standard 
photolithography based techniques.96-97 This patterned wafer is then bombarded with high energy 
plasma, etching away unprotected regions to create a microneedle structure.96-97 This technique 
has been utilized to produce ultrasharp microneedles up to 150µm in height29 with etch rates on 
the order of 1-5µm per minute.98 The height and aspect ratio of generated structures can 
theoretically be controlled by altering the chemical composition of the plasma (such as the ratio 
of SF6 and O2), the plasma density, and total etch times.
96,98 This process, however, requires 
excruciatingly difficult process control to prevent undercutting of the desired structure and to 
prevent undesired structures from being created from debris in the reactor.96,98 Any change in 
microneedle size, shape, aspect ratio, or spacing requires a new etch recipe to be generated,98 
resulting in long lead times (on the order of months) for new microneedle designs.  
Wet etching uses a liquid solution (rather than a dry gas) to chemically etch a metal or 
silicon substrate. When utilized for the production of microneedles, an anisotropic etch solution, 
such as potassium hydroxide (KOH) or tetramethylammonium hydroxide(TMAH), is used to 
selectively etch the silicon along a specific crystal plane.37,93 This approach has been used by 
Wilke et. al. and others to produce microneedles ranging in size from 10 to 300µm with an aspect 
ratio of 1.5.37,93 Although this approach is capable of producing microneedles of atomic level 
sharpness, this technique is also slow (on the order of 1µm per minute) and the aspect ratio of the 
resulting microneedles is predetermined by the selectivity ratio of the etchant (related to the etch 
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rate in a particular direction) along silicon’s crystal planes.37,93 For this reason, this approach 
provides little to no ability to adjust microneedle aspect ratio.37,99  
Laser ablation provides the most control over microneedle geometry of current master 
fabrication processes.34,41, 99 A silicone substrate is exposed to a laser beam which rasters across 
the surface of the substrate in a pattern defined by a computer aided design file.99 This laser beam 
etches away the silicon to produce a mold that can be filled using a material of interest.34,41,99 
Although this technique provides substantial control over microneedle geometry, the resolution 
of the technique is limited to about 10µm;100 mold filling processes are still required after master 
fabrication.  
1.2.3.2 Mold Casting and Filling 
Following master fabrication, a mold is then cast in polydimethylsiloxane (PDMS)15,24-25 
and filled with a formulation of interest.34,68,87  Mold casting is typically the least troublesome of 
the three fabrication steps (master template generation, mold casting, mold filling), but still has 
two significant challenges. Mold casting adds an additional time consuming step 34,68,87  and in 
some cases has also been known to decrease the fidelity of very small features,101 which limits 
the achievable sharpness of microneedle structures.102  
After this mold is cast, it is filled with the material of interest, typically a natural or 
synthetic polymer such as hyaluronic acid,103 carboxymethylcellulose (CMC),68 maltose,104 
chitosan,105 Gantrez,48 polyvinylpyrrolidone (PVP),106 or poly(lactic-co-glycolic acid) 
(PLGA),107 combined with the therapeutic. Many products are efficiently and cost-effectively 
fabricated using injection molding, where final material is heated and injected into the mold 
before it is allowed to cool into the final part.108 However, the sensitive nature of target 
22 
 
therapeutics delivered via microneedle technology, such as proteins and nucleic acids, prohibits 
heating to high temperatures.68,109 For this reason, most microneedles are fabricated by mixing a 
polymer with a solvent (typically water), casting this solution over the mold, applying a 
centrifugal force to fill the mold, and then allowing the solvent to evaporate over time under 
vacuum.68.109 This process is sometimes repeated many times to fill the mold.87 The batch-to-
batch nature of these techniques combined with long evaporation times (on the order of days) 
make the mold filling process a laborious endeavor that encumbers microneedle research. 87  
1.2.4 Overarching Challenges in the Fabrication of Biocompatible Microneedles 
 Taken as a whole, current microneedle fabrication processes provide little to no 
opportunity to easily alter microneedle design. Prototyping new microneedle designs is often 
impractical because of the poorly controlled nature of micromanufacturing techniques and 
because microneedle fabrication is time consuming, with total fabrication times ranging from 14 
to 142 hours per patch.68,110 Because of the expensive equipment and substantial expertise 
required, fabrication is typically performed at advanced, centralized facilities where lead time for 
new microneedle patch designs can be greater than a month long.  The need for extensive 
process optimization causes microneedle composition and geometry to be dictated by the 
feasibility of fabrication rather than ideal design,99,111 despite substantial evidence that  
microneedle design parameters play a critical role in device efficacy, as discussed in the 
following section.    
1.2.5 Role of Microneedle Design Parameters on Device Efficacy 
There is an increasing interest in how microneedle design parameters, such as composition 
and geometry, influence device efficacy.99,111 A diagram which lists several input design 
parameters and their potential therapeutic effects is given in Figure 1.9. The relationship between 
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the input design parameters and determinants of efficacy is a complex web, where each design 
parameter affects multiple outcomes associated with device efficacy.  
Studies investigating the role of microneedle design parameters, particularly microneedle 
geometry (including needle height, aspect ratio, spacing, and shape) on device efficacy have 
been limited. Poor control of existing fabrication techniques,99 combined with their long 
fabrication times,87 prohibits efficient and cost effective modulation of microneedle design 
parameters. Nevertheless, some existing studies underscore the importance of deliberate 
microneedle design.  
 
Figure 1.14 Relationship between microneedle design parameters and therapeutic efficacy 
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For example, a 2012 study by Olantunji et al investigated how the total number of 
microneedles in an array influences the force required to insert that array into the skin. 112 
Microneedle insertion is affected by a phenomenon called the “bed-of-nails” effect where the 
total application force applied to an array of needles is divided amongst all of the needles in the 
array.112 Because a given microneedle array may have a multitude of needles, this effect can 
substantially increase the total force required to insert a microneedle array into the skin.  The bed 
of nails effect is described quantitatively in equation 1, below, where N is the total number of 
microneedles in the array. 
𝐹𝑠𝑖𝑛𝑔𝑙𝑒 𝑛𝑒𝑒𝑑𝑙𝑒 =  
𝐹𝑡𝑜𝑡𝑎𝑙
𝑁
      (1) 
  
Olantunji et. al. investigated the force required to enable microneedles made out of a poly 
methyl vinyl ether- maleic anhydride copolymer to successfully insert into the skin.112 Array 
interspacing was varied between 30 and 600µm, thereby altering the total number of 
microneedles present on an array of constant area.112  Note that regardless of interspacing 
between needles, the required insertion force per microneedle remains constant (Table 1.4), 
providing empirical evidence to support the “bed-of-nails” effect.112 Reducing the total number 
of microneedles on an array decreases the total force required to insert the array.112 Work by  
Kochhar et. al. corroborates these findings.113  Therefore, minimizing the number of needles per 
array presents a viable approach ensuring that each needle properly inserts into the skin with a 
reasonable application force. An obvious compromise is that this reduction in the number of 
needles reduces total drug loading volume. Approaches to combat this optimization problem are 
further discussed in Chapter 2, Section 2.2.9.  
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Another interesting study by Park et. al. investigated microneedle failure force  (the force 
required to break the needle) as a function of aspect ratio.107  The failure force of PLGA 
microneedles measuring 200µm across the base with aspect ratios ranging from approximately 3 
to 20 was determined using a force-displacement test station.107 This study found that the short 
microneedles were approximately three times stronger than the high aspect ratio microneedles.107 
It is important that microneedle insertion force be substantially less than failure force to provide 
a high safety margin;30 tailoring microneedle aspect ratio is therefore an important aspect of the 
design of safe and efficacious microneedle devices.  
Another study by Lee et. al. investigated the role of microneedle composition on strength 
and efficacy of insertion.68 The authors fabricated microneedles from polylactic acid (PLA), 
amylopectin, carboxymethylcellulose (CMC), and bovine serum albumin (BSA). The Young’s 
modulus of each microneedle composition was assessed and found to range from 1 to 5GPa (for 
CMC and PLA, respectively).68 The solubility of each polymer in the solution used to fill 
microneedle molds was also found to play an important role in the mechanical properties of the 
resulting microneedle devices.68 The authors suggest, using mathematical modeling, that these 
differences in Young’s moduli will affect microneedle failure force, but no empirical validation 
Table 1.5 Force required for microneedle insertion as a function of spacing between needles, the total number 
of microneedles per array, and the velocity of insertion. Forces are given as both Newtons per array and Newtons 
per microneedle on that array. Table adapted from reference 112. 
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is provided.68 Nevertheless, this work suggests that microneedle composition is also a critical 
factor influencing microneedle insertion into the skin.68  
Other publications have also investigated the role of aspect ratio on failure forces,114 the 
influence of microneedle height on skin permeability in vitro,115 the role of microneedle 
sharpness on insertion forces,116,117 and the role of microneedle application force on depth of 
penetration.111 Altogether, these results underscore the importance of investigating microneedle 
design parameters in a high throughput fashion, but the time intensive and poorly controlled 
nature of current fabrication techniques hinders such investigations. Therefore, this dissertation 
seeks to develop a rapid, robust and tunable method of fabricating microneedle devices for 
transdermal drug delivery. We seek to use recent advancements in additive manufacturing to 
 
Figure 1.15 Overview of the additive manufacturing process. A computer model is computationally sliced into 
individual layers. Each two dimensional (2D) layer is stacked on top of the previous layer to create the desired 
three-dimensional part (3D) 
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bring an unlimited design space to microneedle manufacturing in order to facilitate a better 
understanding of how a multitude of different design parameters influence device efficacy. 
1.3 Additive Manufacturing Overview 
Additive manufacturing, more colloquially known as “3D Printing”, may provide an 
opportunity to rapidly alter many of the design parameters associated with microneedle 
fabrication with little to no lead time. These factors include microneedle composition, height, 
aspect ratio, interneedle spacing, patch size, and microneedle shape, among others. Additive 
manufacturing, developed in the 1980s, is defined by ASTM F2792-12a as “a process of joining 
materials to make objects from 3D model data, usually layer upon layer, as opposed to 
subtractive manufacturing methodologies” where a bulk material is machined down to produce 
the desired part.118 Although many different types of 3D Printing have been developed, the vast 
majority of 3D printing technologies follow the overall process shown in Figure 1.10.119-120 First, 
a computer aided design (CAD) file of the desired part is created using 3D modeling software 
such as Solidworks or AutoCAD. This digital part is then computationally sliced along the z axis 
to produce many layers.119-120 Each of these layers is then sequentially stacked on top of the 
previous layer to form the desired part.119-120 Typically, each layer is either added as a liquid or 
powder which is solidified via either a thermal or photochemical phase transition to form a solid 
part. 119  
The most common types of 3D Printing are fused deposition modeling (FDM), selective 
laser sintering (SLS), polyjet technology, and stereolithography (SLA), shown in Figure 1.11. 119 
121 These techniques are reviewed comprehensively elsewhere,119-121 but a short summary of each 
method is also included here. Fused deposition modeling and selective laser sintering both form 
parts utilizing a thermal phase transition, where the final part is generated though heating and 
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cooling of the material.119-121 Fused deposition modeling (FDM) can be thought of as a robotic 
hot glue gun, where a plastic filament, commonly acrylonitrile butadiene styrene (ABS), Nylon 
12, or polycarbonate (PC),126  is heated above its melting temperature and squeezed through a 
pressurized nozzle. This nozzle moves to cover a shape defined by the CAD file to produce each 
layer of the part; the nozzle then moves upward to generate the next layer, stacking sequential 
layers to produce a 3D part.119-121 Major manufacturers of FDM based systems include MakerBot 
and Stratasys.126-127 Selective laser sintering is a technique in which a layer of powder, typically 
made of metals (such as steel, titanium, and alloys), ceramic, polyamide (nylon), or glass, is 
heated at a specified location using a laser beam.119 This laser beam rasters over the part in a 
 
Figure 1.18 Types of additive manufacturing. A) Fused deposition modeling, B) laser sintering, C) polyjet, and 
D) stereolithography are different types of additive manufacturing that form solid parts via either a thermal or 
photochemical phase transition. Images reproduced with permission from references 121-124. 
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shape defined by a computer aided design file, melting the powder together to form a solid mass. 
After every layer, a new layer of powder is rolled over the part, and the laser traces the next 
layer. This process is repeated in a layer-by-layer fashion to produce the final part.119-121  
Unlike FDM and SLS, polyjet and stereolithography based systems rely on a 
photochemical reaction to form the solid part. A liquid resin containing a photoreactive 
monomer, such as an acrylate or epoxy, is mixed with a photoinitiator. This photoinitiator 
absorbs light to form a free radical which reacts with monomer via free radical polymerization to 
from a solid part.126 Polyjet technologies, such as the Stratasys PolyJet 3D and Hewlett-Packard 
(HP) Multi Jet Fusion, utilize arrays of small nozzles (similar to inkjet printers) to dispense 
photosensitive liquid droplets at a particular location.126 Each of these liquid droplets is exposed 
to light in a layer-by-layer fashion to form a solid part via photopolymerization.126  
1.3.1 Stereolithography 
Stereolithography (SLA) is most similar to Continuous Liquid Interface Production 
(CLIP), which is used throughout the remainder of this thesis. SLA was first developed in 1986 
 
Figure 1.19 Digital light processing (DLP) chip. A) Scanning electron micrograph (SEM) of a DLP chip showing 
the array of micromirrors B) Schematic showing mechanism for turning each “pixel” or micromirror on and off. 
Images reproduced with permission from reference 120 and 150, respectively 
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by 3D Systems,127 but a number of other manufacturers including Envisiontech and Formlabs 
have manufactured SLA based additive manufacturing systems since this point in time.126 Like 
polyjet techniques, stereolithography produces parts via photopolymerization of a liquid resin.126 
However, rather than depositing resin onto a substrate using inkjet nozzles, the SLA process 
produces parts via spatially localized polymerization of a vat of resin.126,127 The location of 
photopolymerization is controlled via a either a rastering laser or via light reflected off of a 
Digital Light Processing (DLP) chip.127 DLP chips, which have been utilized in projectors and 
big screen televisions, computationally control the shape of a light projection using an array of 
micromirrors,127 such as those shown in Figure 1.12. Each of these micromirrors, which typically 
range in size from ~7 to 14µm in width,128 can be turned on and off by adjusting the tilt angle of 
the mirror, as shown in Figure 1.12B. When the micromirror tilts to face the incoming light 
source, it is in the “ON” position; when it faces away from incoming light it is “OFF”. Therefore, 
 
Figure 1.20 Layer by layer results in tradeoff between fabrication time and resolution 
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the specific pattern of mirrors that are turned on and off defines the shape of the light that 
projects onto the liquid resin. 
DLP based systems typically provide faster fabrication speeds because the entire layer is 
cured simultaneously, whereas systems that rely on laser rastering typically have slower 
fabrication times due to the time required to trace the desired object with a thin laser beam.127 
Laser-based stereolithography typically has higher resolution, however, because the laser beam 
provides extremely localized photopolymerization.127 
In addition to classifying stereolithography systems based on the nature of the light 
source, stereolithography systems can also be classified as either “bottom-up” or “top-
down”.126,127 In a “top-down” system, the light illuminates the resin vat from the top, as shown in 
Figure 1.11D. After each sequential light exposure, the part is then dipped further into the bath; 
the top of the structure is then re-coated with resin before the next exposure. “Bottom-up” 
systems, in which light illuminates the bath from the bottom, are becoming increasingly 
common. In this case, the light typically illuminates through the bottom of a UV transparent vat. 
After each successive exposure, the part is mechanically separated from the bottom of the bath, 
pulled upward and repositioned prior to the next exposure. This approach provides several 
advantages when compared to the “top-down” approach, particularly that renewing the build area 
with fresh resin is simpler because gravity pushes new resin to the bottom of the vat. 127However, 
the mechanical force required to physically separate the part from the bottom of the vat after it 
cures can be up to 60N.131 These high forces often damage parts, especially delicate high 
resolution parts, during production.131 The process of separating and realigning the part is the 
rate-limiting step in this process, limiting production speeds to millimeters per hour in the 
z direction.132 A new approach to overcoming some of these challenges will be discussed in 
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section 1.5, but first we will overview approaches to use existing additive manufacturing 
technologies to fabricate microneedles for transdermal drug delivery. 
1.3.2 Layer-by-Layer Approaches to Additive Manufacturing of Microneedles 
All existing approaches are inherently “layer-by-layer” approaches to manufacturing, 
where a 3D part is fabricated by stacking two dimensional cross sections on top of one another. 
The fabrication of small parts, such as microneedles, requires high resolution systems. For layer-
by-layer additive manufacturing techniques, the z resolution is defined by the thickness of each 
layer; this thickness impacts the quality of the overall part, as shown in Figure 1.13. Although 
traditional stereolithography systems are not amenable to the production of microneedles 
because each layer is too thick (approximately 25-100µm thick each),127 some investigators have 
utilized custom additive manufacturing devices to fabricate microneedles, as discussed in more 
detail below.133-136 In general, these approaches decrease the thickness of each layer, resulting in 
lengthened fabrication times due to the need to realign between each layer.127, 133-136  
One report of additive manufacturing of microneedles was published by Lu et. al. at The 
University of Akron. A custom microstereolithography apparatus was designed to produce the 
2x2 mm array of poly(propylene fumarate) microneedles shown in Figure 1.14A-C.133 The 
custom apparatus is made up of a mercury lamp, lightgate prism, an achromatic doublet lens, and 
a DLP chip from Texas Instruments with individual micromirrors measuring 13.68µm square.133 
Each slice measures 20 µm thick in the z direction. These microneedles produced using this 
custom apparatus measure approximately 1000µm in length and 200 µm in width.133 Overall 
fabrication times for these microneedle arrays are on the order of hours.133 Similar findings have 
been presented by Yun et. al. 134 
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Roger Narayan and coworkers have also impressively utilized an additive manufacturing 
technique called two photon polymerization for the production of microneedles (Figure 1.14D-
G). 135 This process utilizes a rastering laser pulse to initiate photopolymerization based on two 
photons with nano-scale accuracy; photopolymerization only occurs in a small volume located at 
the tip of the laser.135 Although this technique has been able to produce delicate microneedle 
structures from a variety of different materials, including Ormocer® ceramic materials and 
eShell 200,136 master fabrication times are still long (on the order of days).135 For this reason, two 
photon polymerization is typically used to create microneedle master templates, which are 
subsequently replicated via the micromolding processes previously described. 
This previous work in additive manufacturing of microneedles demonstrates proof of 
concept that additive manufacturing can be used to provide additional flexibility in microneedle 
device design. However, due to the long fabrication times that are still associated with these 
additive manufacturing techniques, they have only been utilized to produce master templates for 
 
Figure 1.23 Microneedles produced via additive manufacturing A-C) Microneedle produced by Lu et. al. D-
G) Microneedles produced by Narayan and coworkers. Images reproduced with permission from references 133 
and 135 
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subsequent micromolding. Time-consuming mold casting and mold-filling processes are still 
required. The work presented in this dissertation can be differentiated from these previous 
approaches by 1) the reduction in fabrication time relative to other additive manufacturing 
techniques and 2) the ability to directly fabricate microneedle arrays in a single, mold-
independent step using potentially biocompatible materials. 
1.3.3 Continuous Liquid Interface Production (CLIP) 
In an effort to bring a virtually unlimited design space into microneedle fabrication and 
enable rapid prototyping of such designs, this thesis seeks to apply a new additive manufacturing 
technique called Continuous Liquid Interface Production (CLIP), invented by the startup 
company Carbon3D, to the fabrication of biocompatible microneedles for transdermal drug 
delivery.  
Of the additive manufacturing systems discussed in this chapter, CLIP is most similar to 
bottom-up stereolithography with a DLP light source. The difference between CLIP and bottom-
up stereolithography is shown in Figure 1.15. As mentioned previously (see Section 1.41.), 
bottom-up stereolithography works by photopolymerizing within a vat of liquid resin in a layer-
by-layer fashion to produce a solid part. This process involves several steps. First, the 
photosensitive resin is exposed to light projected through a UV transparent window under the vat 
of resin. This light cures the resin under the build elevator, shown in dark blue, to the glass 
window shown in green. Because this curing step adheres the part to the glass window, the part 
must be mechanically separated from the glass window to allow resin to flow into the build area. 
The part must then be realigned before exposing the next layer. The process of moving the part 
up and down to rip it off of the window and realign takes several seconds, limiting build speeds 
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to millimeters per hour. Mechanical strain on the part limits the size and delicacy of parts that 
can be created.  
 In contrast, CLIP systems have a UV transparent, oxygen permeable window beneath the 
vat of resin. This special window enables oxygen to diffuse into the resin. Because oxygen is a 
well-known inhibitor to photopolymerization, this special window creates a “dead-zone” in 
which no photopolymerization occurs. This physical gap between the building part and the 
window prevents the part from adhering to the window, thereby eliminating the need for 
mechanical separation and realignment. This enables the build elevator to move upward 
continuously, allowing continuous rather than “layer-by-layer” production of the part. 
Continuous production affords several advantages, including 1) the potential to produce small, 
delicate, and intricate parts without fear of damaging those parts during processing and2) the 
 
Figure 1.25 Differences between stereolithography and CLIP 
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ability to fabricate parts from infinitesimally thin slices without slowing down production. These 
advantages make this an ideal method for additive manufacturing of microneedles for 
transdermal drug delivery. 
1.4 Summary and Hypothesis 
Microneedles are simple devices that show promise for painlessly delivering a wide 
variety of different therapeutics into the body through the skin. However, current approaches to 
manufacturing microneedles are costly, complicated, and time consuming, and provide little 
ability to alter critical microneedle design parameters such as microneedle height, aspect ratio, 
spacing, and geometry, which can influence efficacy. This thesis seeks to utilize a new additive 
manufacturing technique called CLIP to fabricate biocompatible microneedles for transdermal 
drug delivery to enable complete and rapid control over microneedle design, as proposed in US 
Patent 9,211,678.137 
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CHAPTER 2 FABRICATION OF MICRONEEDLES USING A MODEL RESIN 
2.1  Introduction  
The aim of this research is to fabricate microneedles using a new additive manufacturing 
technique called Continuous Liquid Interface Production (CLIP). As described in Chapter 1, 
CLIP provides unique potential to rapidly generate high resolution structures because it enables 
continuous, rather than “layer-by-layer” production of a part. Continuous production eliminates 
the mechanical separation steps that can damage small structures and enables very thin slicing of 
the part without increasing fabrication times (Figure 2.1A). A schematic diagram of a CLIP 
system is shown in Figure 2.1B. 
As described in Chapter 1, CLIP systems contain a light source that illuminates a DLP 
chip. A DLP chip is an array of computationally controlled micromirrors that generates a UV 
 
Figure 2.1 CLIP schematic A) The continuous CLIP process eliminates the tradeoff between slice thickness 
and fabrication time to enable rapid production of high resolution parts B) Diagram showing the essential 
components of a CLIP system 
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light movie in the shape of a Computer Aided Design (CAD) file.  This UV movie illuminates 
through a series of lenses that focus the light on an oxygen permeable window in the bottom of a 
vat of photoreactive resin. A build elevator moves continually upward as the UV movie plays, 
allowing the desired part to grow on the build elevator via photopolymerization of the resin. A 
detailed description of the steps required for successful Continuous Liquid Interface Production 
and some theoretical considerations involved with each step are provided here.  
2.1.1 Step 1- Generation and Slicing of CAD File 
As mentioned in Chapter 1, additive manufacturing processes start with a computer aided 
design (CAD) file of the desired part. This part is then computationally sliced into cross-sections 
along the z axis. In a typical “layer-by-layer” stereolithography process, a single cross-section is 
projected onto the window for a specified length of time to cure the first layer onto the build 
platform by photopolymerization (Figure 1.15).1 This layer is then mechanically separated from 
the window and realigned prior to exposing the resin to the projection that forms the next layer. 
The process of curing the resin and mechanically separating and realigning the part is repeated to 
form the final part in a “layer-by-layer” fashion.  
CLIP’s deadzone eliminates the need for mechanical separation and realignment of the 
part, enabling part production to proceed continuously, rather than in a “layer-by-layer” fashion 
(Figure 1.15). Because the mechanical separation and realignment steps are rate-limiting in 
traditional processes, CLIP’s continuous movement reduces fabrication times for high resolution 
objects by enabling infinitely thin slicing of the computer aided design file without concomitant 
increases in fabrication times. Such infinitely thin cross-sectional slices are projected off of a 
DLP chip in rapid succession (as opposed to long, discrete frames) to form a UV movie. An 
example of such cross-sectional slices is shown in Figure 2.2. Of note, the DLP chips used 
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throughout this dissertation have refresh rates on the order of 4,000 to over 32,000 Hz.2-3 
Therefore, DLP refresh rate is not a rate limiting step to CLIP. For example, the maximum build 
speed for an object sliced at one micron spacing would be over 4 millimeters per second, or 14.4 
meters per hour, for these DLP chips if build speed were limited by DLP refresh rate alone. The 
fastest build speeds utilized in this dissertation are on the order of hundreds of millimeters per 
hour. Other factors, namely the rate of the polymerization reaction, have been shown to play a 
more important role in maximizing build speed. 
This UV projection induces the photopolymerization that produces the final part. Image 
projection is described in further detail in the following section.  
2.1.2 Step 2- Projection of the Image 
As shown in Figure 2.1, a light source (UV LED, λ=370nm) is projected onto a DLP 
chip. This DLP chip is a series of micromirrors, which typically range in size from ~7x7 to 
 
Figure 2.2 Representative image of a computationally sliced microneedle patch. Several microneedle array 
cross-sections moving from the A) microneedle patch backing, through B-F) the base and tip of the microneedles 
within the array. Note that only a small number of the thin cross-sections are displayed.  
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~13x13µm in width.2-3 Each mirror can be turned on or off by adjusting the tilt angle of the 
micromirror relative to the incoming light. When the micromirror tilts to face the incoming light 
source (the “ON” position), the light is reflected off of the micromirror towards the build 
window.  Conversely, when the micromirror faces away from the incoming light source (the 
“OFF” position), light is not reflected off of the micromirror towards the build window. 
Computationally controlling the micromirror array creates a patterned light projection in the 
shape of the CAD file; micromirrors within the specified object are turned “ON”, whereas 
micromirrors outside of the specified object are turned “OFF”.  
The light intensity distribution at the window surface influences the maximum resolution 
of the additive manufacturing system and the size and shape of the resulting part. Importantly, 
the light intensity distribution at the window surface is differs from the light intensity distribution 
reflecting directly off of the micromirror array because of the way that the system’s lenses focus 
incoming light onto the build window. The differences between the light projecting off of the 
DLP chip (input) and the light distribution at the window surface (output) are described here, 
first according to the basic theory of ray optics followed by a more nuanced discussion of 
Gaussian optics. The fundamental difference between these two models is that the first assumes 
that light propagates in straight lines along a single direction, whereas the second model also 
considers the periodic nature of propagating electromagnetic wavefronts. 
2.1.2.1 Image Magnification as Predicted by Ray Optics  
The magnification of an image, M, can be calculated using traditional geometric optics 
using a ray diagram, such as the one shown in Figure 2.3. Such a ray diagram is based off of the 
basic postulates that light is propagated in straight lines in homogenous medium, but refracts 
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according to Snell’s law as it passes through distinct media. The magnification of the imaged 
object is defined by 
𝑀 = −
ℎ𝑜
ℎ𝑖
     (2.1) 
where hi is defined as size of the image and h0 is the size of the original object. Using basic 
trigonometry, it can be shown that the magnification at the focal point can be equivalently 
represented by the equation 
𝑀 =
𝑑𝑜
𝑑𝑖
      (2.2) 
where do is the distance between the object and the lens and di is the distance between the object 
and the lens. Substituting Equation 2 into the thin lens equation (Equation 2.3)  
 
1
𝑓
=
1
𝑑𝑜
+
1
𝑑𝑖
     (2.3) 
yields an alternate solution for the magnification, as a function of the focal length of the lens and 
the distance between the object and the lens relative to its focal point.  
 
Figure 2.3 Ray diagram of an object imaged by a double convex lens 
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𝑀 =
𝑓
𝑓−𝑑𝑜
      (2.4) 
Therefore, the size of an individual pixel (e.g. pixel magnification) at the build area can be 
altered by changing a lens’s focal length and the distance between the lens and the DLP chip. 
This pixel size is an important determinant of optical resolution. The minimum size of an object 
that can be produced, and the minimum spacing between such objects, is theoretically equal to 
this pixel size. Pixel size can also be utilized (in combination with the spacing between pixels) to 
calculate how many pixels per square inch (PPI), equivalently called dots per square inch (DPI) 
are used in this projection. DPI is another commonly used metric for resolution. 
It is important to note that while the magnification of an individual pixel is an important, 
tunable variable in the design of a CLIP system, the total object magnification is typically held 
constant at one in our studies because we seek to fabricate an object that matches a CAD file. 
The total number of pixels used to project an object increases as pixel size decreases to maintain 
constant object magnification.  
2.1.2.2 Image Projections Predicted by Gaussian Optics 
Light propagates in waves, with each wave satisfying the wave equation (Equation 2.5) 
𝑑2𝑢
𝑑𝑡2
− 𝑐2∇2𝑢 = 0     (2.5) 
where c is the velocity of light, t is time, and u is a scalar function for positions as a function of 
time. This linear wave function is subject to the principle of superposition, in which the total 
wave form is formed by addition of the individual waves. This interference between waves 
complicates the simplistic representation of light intensity distributions represented using ray 
optics. Further, although ray optics assumes that light travels in a line wave fronts actually travel 
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in all directions. Due to the highly complex nature of summing electromagnetic radiation in all 
directions, a paraxial (or Fresnel) approximation is often used, where only light making small 
angles with the direction of propagation is considered.4  This assumption can be considered valid 
when the imaging plane is close to the lens (typically at the focal length or closer). It allows 
propagating waves to be summed to determine the total light intensity distribution that results 
from a focusing lens. 
While ray optics predict that the lens simply magnifies or de-magnifies the image, real 
lenses are subject to diffraction and various aberrations. Some aberrations include spherical 
aberrations, caused by the fact that most lenses are spherical rather than a more ideal partial 
ellipsoid and achromatic aberrations introduced by differences in the wavelengths of incoming 
light rays, among others. Even in the absence of such aberrations, however, all lenses are limited 
by diffraction. For a perfect, diffraction-limited lens, a perfect point source is projected as an Airy 
disc (Figure 2.4), which results from interference of interacting wave forms. The Airy disk is 
 
Figure 2.4 Airy Disk. An airy disk is the point spread function of a diffraction-limited lens  
53 
 
called the system’s point spread function (PSF), defined as the focused response (output) of a 
system when the input is a perfect point source.4 This PSF can also be more generally termed an 
impulse response for a system that is not in perfect focus. The first null of this Airy disc is often 
approximated as a Gaussian function with a radius (or “spot size”) given by Equation 2.6 
2𝑤0 =
1.22𝑓𝜆
𝐷
      (2.6) 
where w0 is the radius of the spot, f is the focal length of the lens, λ is the wavelength of the 
input light, and D is the aperture of the lens.4  If a lens produces a spot size that is close to the 
predicted size w0, the lens is said to be “diffraction-limited”. If the spot size produced by the lens 
is much larger than w0, the lens is said to be “instrument-limited”.  
In addition to diffraction and aberrations, many optical systems are subject to imperfect 
focus, which also affects the system’s response to a given input. As shown in Figure 2.5, the 
width of a beam of light is the smallest at the “beam waist”, which is located at the focal point of 
the lens.4 Therefore, a diffraction-limited lens projecting a point source in perfect focus would 
have a beam waist with a radius defined by Equation 2.6, as previously established. However, as 
 
Figure 2.5 Beam width is minimized at the focal plane but is wider than the point predicted by ray optics 
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the image plane moves further and further from the focal point, the width of the beam increases, 
thereby decreasing the resolution of the system. The increase in the radius at the imaging plane 
as it moves away from the focal point can be described by Equation 2.7. 4 
𝑤(𝑧) =  𝑤0√1 + (
𝑧
𝑧𝑅
)2    (2.7) 
where w0 is, again, the radius of the spot at the focal plane, z is the distance of the imaging plane 
from the focal plane, and zR is the Raleigh length given by Equation 2.8.  
𝑧𝑅 =
𝜋𝑤0
2
𝜆
     (2.8) 
The Raleigh length is defined as the distance from the focal point to the point at which the spot 
size doubles (measured along the axis of light propagation). Therefore, accurately focusing at the 
focal length is important to ensuring optimal performance of the optical system.   
Together, these effects (magnification, wave interference, lens diffraction, and accuracy 
of focus) provide a theoretical basis for differences in light distributions before and after 
interaction with a focusing lens. These mathematical calculations assume that the light input is a 
perfect point radiator. However, no such point source exists in nature; this point source is simply 
a mathematical construct used to model and understand optical imaging systems.  When 
modeling a real system, the image produced by the lens is actually represented by the 
convolution of the input light distribution and the lens’s impulse response at the imaging plane. 
Although complete modeling of the optical system used in CLIP additive manufacturing systems 
is outside of the scope of this dissertation, these fundamental relationships will be useful to 
understanding the experimental results presented in this chapter. 
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2.1.3 Step 3- Photopolymerization of the Part 
2.1.3.1 Photopolymerization Kinetics 
The shape and intensity of the resulting light projection directly affects the structure of 
the photopolymerized part. Photopolymerization is known to proceed in three different steps: 
initiation, propagation, and termination, which are described by the chemical equations below.5 
Initiation occurs when an initiator I is irradiated to produce an excited state by absorption of light 
photons, which subsequently undergoes hemolysis to produce two free radicals R.  
𝐼 + ℎ𝑣 →   𝐼∗     (2.9) 
𝐼∗ → 2𝑅 ∙      (2.10) 
𝑅 ∙ +𝑀 → 𝑅𝑀 ∙     (2.11) 
This free radical can then attack a double bond within a photoreactive monomer, using one of the 
electrons within the double bond to form a single bond between the initiator and monomer. This 
complete process (Equations 2.9-2.11) is termed “initiation”. The other electron from the double 
bond returns to the second atom, which forms another free radical that continues to propagate the 
chain. Subsequent addition of monomer to the growing chain is termed “propogation” (Equation 
2.12). The mechanism of free radical polymerization of acrylate monomer is shown in Figure 
2.6. 
𝑅𝑀 ∙  +𝑀𝑛 → 𝑅𝑀𝑛+1     (2.12) 
Termination of the polymer chain can occur via one of three different mechanisms: 
combination, disproportionation, or chain transfer. Combination occurs when two active chain 
ends join together to form one long chain (Equation 2.13), as shown below. 
𝑀𝑚 ∙ +𝑀𝑛 ∙ → 𝑀𝑚 − 𝑀𝑛    (2.13) 
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Disproportionation occurs when a hydrogen is abstracted from one chain end to produce 
one polymer with a terminal saturated group and another polymer with a terminal unsaturated 
group (Equation 2.14), as shown below. 
𝑀𝑚 ∙ +𝑀𝑛 ∙ → 𝑀𝑚 + 𝑀𝑛    (2.14) 
Lastly, chain transfer occurs when the free radical on the growing polymer chain is abstracted by 
another molecule (XR’), which begins to propagate a new chain (Equation 2.15).  
𝑀𝑚 ∙  +𝑋𝑅
′ → 𝑀𝑚 + 𝑋𝑅′ ∙    (2.15) 
Basic combination of the rate equations for each of these steps yields Equation 2.16 for 
the total rate of radical photopolymerization, as described elsewhere.5  
𝑅𝑝 = 𝑘𝑝[𝑀] (
𝑅𝑖
𝑘𝑡
)
1
2
     (2.16) 
 
Figure 2.6 Mechanism of free radical photopolymerization of acrylates. Figure reproduced with permission 
from reference 6. 
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where kp is the polymerization rate constant, [M] is the monomer concentration, kt is the 
termination rate constant, and Ri is the rate of initiation given by Equation 2.17 
𝑅𝑖 = 2ɸ𝑘𝑑[𝐼]      2.17) 
where ɸ is initiator efficiency, [I] is the concentration of initiator, and kd is the rate constant for 
dissociation of photoinitiator. Therefore, polymerization rates are dependent on the amount of 
initiator and the efficiency of its dissociation as well of the amount of monomer and the 
efficiency of monomer combination.  The rate limiting step of such photopolymerization 
reactions, however, is typically the rate of initiation, because the rate constant for hemolysis is 
typically much smaller than the rate constant for propagation of the polymer chain. The 
quantitative relationship between light intensity distributions and the size and shape of the 
resulting part will be discussed both in Chapter 3 and Appendix B. Here, it is sufficient to state 
that the amount of light required to initiate photopolymerization must be above a certain 
threshold. Above this threshold, photopolymerization of the part occurs whereas below this 
minimum amount of light, no photopolymerization forms and the part is not formed. In this way, 
polymerized parts can provide insight into the light distributions projected by additive 
manufacturing systems.  
2.1.4 Chapter Objective 
Using early prototypes of CLIP systems, this chapter presents investigations into the role 
of four important variables on the morphology and dimensions of CLIP microneedle arrays. 
These variables are 1) the intensity of the light source, given in mW/cm2, 2) the build speed 
given in mm/hr, 3) the optical system responsible for focusing the image from the DLP chip onto 
the build window, and 4) the software system that converts a CAD file into instructions for the 
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DLP chip.  The theory presented in this introduction will serve as a useful platform for 
interpreting experimental results.  
We demonstrate that proper optimization of these four variables enables production of 
microneedle arrays via CLIP. This additive manufacturing based approach can be utilized to 
rapidly alter microneedle design parameters, including microneedle size, shape, spacing and 
aspect ratio with the potential to improve therapeutic outcomes.  
2.2 Results and Discussion  
2.2.1 CLIP File Path  
In order to generate parts using CLIP, a series of steps were taken. First, a CAD file of a 
desired microneedle array was designed using Solidworks 2014 3D modeling software and saved 
in standard tessellation language (.STL) format. This file format defines the surface topology of 
the part as a series of triangles. It eliminates unneccesary information typically associated with 
the CAD file, such as color, lighting and surface texture. The .STL file was then sliced in 1µm 
sections along the z axis using the opensource software Slic3r to generate a Scaleable Vector 
Graphics (.SVG) file containing the object’s coordinates on each slice. This .SVG file is 
referenced by a component of Carbon3D’s custom software called a graphic device interface 
(GDI), which converts the .SVG file to a bitmap sent to the DLP chip. This bitmap controls 
which micromirrors are turned on and off at each point during production of the part.  The 
 
Figure 2.7 CLIP file path 
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components of the CLIP system, including the light source and build elevator, are controlled by a 
LUA script written by the user. More information regarding .LUA scripts is provided in 
Appendix A.  A graphic outlining the file path used in the CLIP process is given in Figure 2.7  
2.2.2 Role of Light Intensity and Build Speed on Microneedle Production Using an Early 
Prototype 
We first sought to determine the impact that light intensity and build speed have on the 
fabrication of microneedles using CLIP. Of note, throughout this dissertation, the terms “build 
parameters” or “print parameters” will be used to refer to a particular combination of light 
intensity and build speed. In this chapter, we utilize a model resin composed of 
trimethylolpropane triacrylate (TMPTA) mixed with 2.5 wt% diphenyl (2,4,6- trimethylbenzoyl) 
phosphine oxide (TPO) as a photoinitiator. TMPTA was chosen because it is a fast-reacting, low 
viscosity material that has previously been used in stereolithography.6 TPO is a type 1 
photoinitiator selected based on it solubility, high efficiency, and absorbance at 365-370nm. The 
structure and absorption spectrum of TPO and the structure of TMPTA are given in Figure 2.8.  
 
Figure 2.8 Stucture and absorbance of resin components A) Structure of TMPTA B) Structure of TPO 
and C) Absorption spectrum of TPO over wavelengths of 260 to 450nm 
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In order to determine the effect light intensity and build speed on microneedle 
morphology, a computer aided design file containing microneedles measuring 1000 µm tall and 
333µm wide was generated (Figure 2.9) and sliced along the z axis.  CLIP3, an additive 
manufacturing system prototype, was then utilized to produce microneedles with a range of light 
intensities and build speeds. Scanning electron micrographs (SEMs) of microneedles produced 
using 1 to 4 mW/cm2 of light at build speeds ranging from 25mm/hr to 200mm/hr are shown in 
Figure 2.10.  
Several important observations regarding the effect of light intensity and build speed 
were made. Microneedles produced with 1 mW/cm2 of light (Figure 2.10 A-C) generally looked 
“under-exposed”, meaning that the microneedles are shorter and thinner than the input CAD file  
shown in Figure 2.4. In some cases (Figure 2.10C), the base of the microneedle array even failed  
to cure, leaving large holes in the substrate. Increasing speed (moving from left to right in Figure 
2.5) while holding light intensity constant further reduced the cured volume; both the size of the 
microneedles and the amount of curing between needles decreased with increasing speeds. This 
reduction in the cured volume occurred because the total exposure time per slice decreased with 
increasing speed, thereby reducing the total amount of light utilized to produce the part. The 
specific mechanisms that dictate cured volume will be further discussed in Chapter 3. When a 
 
Figure 2.9 Microneedle CAD file. A CAD File of an 8x8 array of1000µm tall microneedles measuring 333µm in 
width spaced at 333µum on a 1mm thick backing was used throughout chapter 2 
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higher light intensity is used (4 mW/cm2, Figure 2.10 D-F), microneedles became much larger. 
Although some structures looked more similar to the desired CAD file (Figure 2.10E) than 
others, much of the material between needles cured at this higher light intensity. Similarly to the 
series produced with 1 mW/cm2 of light, increasing build speed reduced the dimensions of 
structures  produced with 4 mW/cm2 of light. Together, these results suggest that light intensity 
and build speed have opposite effects on part dimensions. Increasing light intensity increased 
part   dimensions, whereas increasing build speed decreased part dimensions. Importantly, 
however, these results demonstrate that no combination of light intensity and build speed 
produced high quality microneedles. Therefore, we sought to make improvements to this 
initial printer prototype to enable microneedle fabrication.  
  
 
Figure 2.11 Impact of light intensity and build speed on microneedle morphology. Top row is produced using 
1 mW/cm2 of light at build speeds of A) 25mm/hr, B) 100 mm/hr, and C) 200 mm/hr. Bottom row is produced 
using 4 mW/cm2 of light at build speeds of D) 25 mm/hr E) 100 mm/hr and F) 200 mm/hr 
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2.2.3 Effect of System Optics on a Resolution Test Pattern 
The poor microneedle morphology exhibited in Figure 2.5 established a need to improve 
the performance of CLIP prototypes for microneedle production. In order to more easily compare 
the performance of each new prototype, a test part called a resolution test pattern (RTP) was 
designed. This RTP, shown in Figure 2.11G, contains sets of four squares measuring 500µm x 
500µm, 250µm x 250µm, and 125µm x 125µm, moving from bottom to top right, respectfully. 
All squares are spaced at one width apart. Because each of these sets of squares represents the 
cross section of microneedle arrays of different sizes, this RTP provides an easy way to 
determine the dimensions of the smallest microneedles that could be produced using a given 
CLIP system.  
 
Figure 2.13 Effect of lens focal length on resolution. The top row is fabricated using an initial, low resolution 
lens setup with focal lengths of 50 and 75mm at A) 50 mm/hr B) 100mm/hr and C) 150 mm/hr. The bottom row 
is fabricated using a high resolution lens setup with focal lengths of 75 and 100mm at D) 50 mm/hr E) 100 mm/hr 
and F) 150 mm/hr G) CAD file used to print the RTP.  
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 An experiment was designed to determine whether improvements to the prototype’s 
optical system could improve microneedle morphology. The RTP shown in Figure 2.11G was 
printed using two different lens setups. The first lens, containing two achromatic doublets with 
focal lengths of 50 and 75mm, was replaced with a different lens, containing two achromatic 
doublets with focal lengths of 75 and 100mm. Lenses were spaced at 25.4 cm apart for both 
systems. The distance between the lens and the window surface was adjusted until the image 
appeared to be in focus. The combined focal length of each system was determined to be 14.8 
mm and 21.2 mm for the original and replacement lenses, respectively. As described in Equation 
2.4, increasing the focal length de-magnifies each pixel, thereby reducing the size of each 
projected pixel from 16µm x16 µm to 8µm x 8µm (convolved with the unknown impulse 
response of the system). Decreasing pixel size increases the number of dots per inch (DPI) to 
improve the theoretical resolution of the system.  
 SEMs of of the RTP fabricated using the two different lens setups are given in Figure 
2.11. Figure 2.11A-C are produced using the low resolution lens setup at 50mm/hr, 100mm/hr 
and 150mm/hr, respectively. Figure 2.11D-F are produced using the high resolution lens setup 
with equivalent build speeds. Reducing the pixel size by changing the lens was observed to 
dramatically increase the quality of the produced part. Notably, the 250x250µm features that are 
not resolved with the low resolution lens setup in Figures 2.11A-C, begin to separate into distinct 
squares in Figure 2.11F. The quality of the larger, 500x500 µm squares, which are fairly circular 
when printed with the low resolution lens setup, also substantially improves when using the high 
resolution lens setup (Figure 2.11D-G). Therefore, we concluded that although light intensity 
and build speed have an effect on part dimensions and quality, the printer’s optical system 
is the primary driver of the quality of parts produced on a small scale. This can be expected 
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because the input light distribution coming off of each individual pixel is smaller. Even though 
the impulse response of the system is unknown, it could be expected that the output light 
distribution would be smaller if the input light distribution is smaller, even after convolution with 
the impulse response.  It is worth noting that the optical system produced using the replacement 
lenses was very non-ideal. Using Equation 2.6 to calculate the radius of the spot size for a 
diffraction limited 4F system containing a 75mm and 100mm doublets produces a diffraction 
limited spot size of less than 1nm. Therefore, our system is clearly instrument limited rather than 
diffraction limited. Further optimization of the optical system should lead to improved 
resolution. We consequently chose to focus on continuing to improve printer optics using the 
 
Figure 2.15 Circularity improves with improved printer optics A) Method for calculating 
circularity. Circularity of 500µm squares printed with B) 2 mW/cm2, C) 4 mW/cm2, D) 6 mW/cm2 and 
E) 8 mW/cm2 of light. Minimizing circularity results in improvements in the quality of the 500µm 
square 
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square resolution test pattern. In total, four different optical systems were investigated over a 
range of different light intensities and build speeds.  
To compare the quality of the RTP resulting from each optical system and build 
parameter combination, a quantitative measure of the quality of the squares produced was 
developed. This measure, termed “circularity”, quantifies how rounded the corners of each 
fabricated square are (Figure 2.12). Briefly, circularity is calculated by taking the area of a circle 
whose radius is the radius of curvature of the corner of the square and dividing it by the total area 
of the square  (Figure 2.12A). For a round circle, this function is one. For a perfect square with 
infinitely sharp corners, this function is zero. Therefore, we sought to minimize circularity by 
improving the printer’s optical system.  
 
Figure 2.16 Circularity calculation and validation A) Method for calculating circularity. Circularity of 500µm 
squares printed with B) 2 mW/cm2, C) 4 mW/cm2, D) 6 mW/cm2 and E) 8 mW/cm2 of light. Minimizing 
circularity results in improvements in the quality of the 500µm square 
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In order to establish that circularity is a valid approach for assessing the quality of a 3D 
printed square, RTPs were produced using light intensities ranging from 2 mW/cm2 to 8mW/cm2 
at a build speed of 100 mm/hr. The circularity of a 500 µm x 500µm square from each array was 
calculated as shown in Figure 2.12.  
Therefore, we compared the circularity of 500µm squares printed using four different 
optical setups and a range of different print parameters in an effort to identify the best optical 
system. The specifications for each CLIP system are provided in Table 1 and Table 2 for the 
CLIP7 and CLIP3 respectively (see materials and methods). An ideal system would minimize the 
circularity of each square. The results of this study are shown in Figure 2.13. Of the four 
different optical systems tested (CLIP3 low resolution, CLIP3 high resolution, CLIP7 
Greenlight, CLIP7 updated), the updated CLIP7 optical system was most effective, producing 
the sharp 500µm square shown in yellow. With these improvements to the optical system, we 
moved forward with the production of microneedles for transdermal drug delivery in Section 
2.2.4.  It should be noted that a more thorough, mathematical analysis of the impulse response of 
the optical system could provide further improvements in optical performance. However, 
because the ultimate goal of this work was to fabricate microneedles for transdermal drug 
delivery, we moved forward with microneedle production. 
2.2.4 Role of Light Intensity on Microneedle Dimensions Using Updated CLIP7 
 After improving the optical system, which was shown to play a dominant role in part 
quality (section 2.2.2), we revisited the effect of light intensity on microneedle production. 
Because light intensity and build speed were found to have opposite effects on microneedle 
dimensions (Figure 2.10), we chose to isolate the effect of light intensity by holding build speeds 
constant at 100 mm/hr throughout this experiment. This constant 100mm/hr build speed provides 
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fast build times (less than two minutes per patch), but is slow enough to reduce any potential 
defects due to incomplete resin flow into the build area. 
CLIP microneedles were generated using light intensities ranging from 2mW/cm2 to 
14mW /cm2 (Figure 2.14). In general, these microneedles exhibited more desirable structures 
than compared to the first CLIP3 microneedles in Figure 2.10, confirming that the improvements 
to the system’s optics improved microneedle structure. Some observations regarding the effect of 
light intensity were made. Similarly to the CLIP3 studies shown in Figure 2.4, as the light 
intensity of the CLIP7 increased, more curing was observed, resulting in both an increase in the 
height and the width of an individual microneedle with increasing light intensity (Figure 2.15). 
This increase in curing was especially evident when printing with 11mW/cm2 or 14mW/cm2 of 
light, which also produces unwanted curing between microneedles. However, although we hoped 
to identify the appropriate light intensity for the production of dimensionally accurate 
 
Figure 2.19 TMPTA Microneedles produced using different light intensities. Microneedles were produced 
using A) 2mW/cm2, B) 5mW/cm2, C) 8mW/cm2,  D) 11mW/cm2, and E) 14mW/cm2 of UV light. Build speed 
was held constant at 100mm/hr. Scale bars measure 500µm 
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microneedles, all microneedles were truncated in the z direction relative to the 1000µm CAD file 
(Figure 2.15). Together, these observations suggest that print parameters such as light 
intensity are as important to determining the size and shape of the resulting part as the 
CAD file utilized to produce the part. While this experiment suggests that further increases in 
light intensity may produce tall enough microneedles, the microneedles are already wider than 
the desired width; increases in light intensity would exacerbate this issue. Therefore, an alternate 
strategy is necessary to enable production of dimensionally accurate needles.  
Furthermore, the microneedles produced here (Figure 2.14) have a stair-stepping surface 
texture that is present regardless of the light intensity used. The stair-stepping is visually 
undesirable and may prevent smooth insertion into the skin. Furthermore, the reason for this 
unexpected stair-stepping pattern is unknown. Therefore, the next section seeks to determine the 
 
Figure 2.21 Dimensions of TMPTA microneedles produced with varying light intensity. The dotted red line 
represents the height of the CAD file. The dotted blue line represents the width of the CAD file. Error bars represent 
the mean ± SD (n=3) 
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underlying cause of the stair-stepping and develop methods to eliminate stair-stepping to produce 
microneedles with smooth sidewalls.  
2.2.5 Visualization of Individual Pixels Causes Stairstepping 
It was hypothesized that the undesirable stair-stepping texture present in Figure 2.14 
could be the result of either Hypothesis A- uneven movement of the build elevator during part 
production or Hypothesis B- the visualization of individual pixels within the micromirror array. 
Hypothesis A is that if the build elevator vibrates or catches as it moves upward, some ridges 
may be created due to uneven movement during photopolymerization. Hypothesis B is further 
explained in Figure 2.16. One could imagine that a microneedle measuring 110µm X 110µm at 
the base would be projected as a 11x11 pixel image, where each of the instrument’s micromirrors 
is a 10µm X 10µm pixel at the build area. As the width of the microneedle decreases moving 
towards the microneedle tip, fewer and fewer pixels are illuminated. However, because each 
 
Figure 2.23 Discrete pixels may produce stairstepping 
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pixel is a discrete unit that can be turned on or off, the resolution of the system is limited to a 
10µm step size, creating a stair-stepping pattern along the side of the microneedle array.  
In order to differentiate between these two alternate hypotheses, microneedles of three 
different aspect ratios were printed on a single array. If Hypothesis A is true and the elevator 
movement is the cause of the stair-stepping surface texture, all three aspect ratios should have the 
same step size, which is dictated by the elevator’s movement. If Hypothesis B is true and the 
stair-stepping is the visualization of individual pixels, microneedles of different aspect ratios 
should have different step heights due to the differences in the sidewall slopes. The theoretical 
step height for each aspect ratio can be calculated according to Equation 2.18, below, if stair-
stepping is the result of visualizing individual pixels.   
 
Figure 2.25 Height of stair step vs. aspect ratio A) SEM image of microneedles of aspect ratios 2, 3, and 4, where 
each horizontal line is an undesirable “stair-step”. B) Comparison of the experimental step height between horizontal 
lines as compared to the theoretical step height calculated using Equation 1. Error bars represent the mean ± SD 
(n=3). Scale bar measures 500µm. 
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𝐻𝑆𝑡𝑒𝑝 =  
𝐻𝑀𝑁
# 𝑜𝑓 𝑠𝑡𝑒𝑝𝑠
=  
𝐻𝑀𝑁
𝑊𝑀𝑁/(2∙𝑊𝑝𝑖𝑥𝑒𝑙)
   (2.18) 
where HStep is the height of each step, HMN is the height of each microneedle, WMN is the width of 
each microneedle and Wpixel is the width of each pixel. Using Equation 2.18 and the heights and 
widths of microneedle CAD files, the expected step height of each microneedle could be 
calculated, as shown in Figure 2.17B.   
An ESEM image of microneedles of three different aspect ratios produced using CLIP is 
shown in Figure 2.17. The height of each step in the stair-stepping surface texture is different for 
each of the three aspect ratios, suggesting that the stair-stepping pattern is due to the 
visualization of individual pixels. A comparison of the theoretical and experimental step heights 
is provided in Figure 2.17B. All experimental step heights fall within one standard deviation of 
the theoretical step heights, indicating that this surface topology is indeed due to the visualization 
of individual pixels within the printed part.   
2.2.6 Application of Antialiasing to CLIP 
Stated in another way, the stair-stepping pattern is caused by discrete spatial sampling of 
a continuous line once every 10µm at the location of an individual micromirror on the DLP chip. 
This sampling creates an “alias”, or distortion of the signal, which results in the production of 
jagged sidewalls. An example of aliasing is provided in Figure 2.18, below, where a desired 
continuous line (Figure 2.18A) is displayed as a jagged line (Figure 2.18B) composed of discrete 
pixels.7 Aliasing is a common issue affecting the resolution of graphics projected onto pixel-
based screens, such as computer screens and TV monitors. It primarily affects the representation 
of small objects, areas containing complicated details, and the edges of an object.8 Figures 2.14 
and 2.17 demonstrate that aliasing also affects 3D printing of parts on a small scale.  
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When graphics are displayed on computer monitors, televisions, or on gaming systems, a 
process called antialiasing is used to correct for distortions.  A number of different antialiasing 
algorithms have been developed; their mechanisms are comprehensively reviewed elsewhere.7-9 
Here, we considered three different approaches to antialiasing and their application to the CLIP 
3D printing process. These three approaches are 1) reducing the size of each pixel 2) defocusing 
the image and 3) applying an antialiasing algorithm called supersampling. 
The first, and most obvious, antialiasing approach is to increase the resolution of the 
system’s hardware by adding additional pixels to resolve finer details.8 This approach has been 
widely utilized to improve the resolution of DLP based television screens, but typically 
substantially increases the cost of the system.  When applied to 3D printing of microneedle 
arrays, this approach necessitates decreasing the pixel size by either 1) increasing the number of 
micromirrors on the DLP chip or 2) shrinking the UV image projection to reduce pixel size at the 
cost of total available build area. However, because utilizing a larger DLP chip would require 
 
Figure 2.28 Visible effects of spatial imagealiasing. The desired image is distorted by spatial sampling at each 
pixel, causing the display to contain an alias, or distortion of the original signal. Reproduced with permission from 
reference 2. 
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redesigning the printer’s optical system and reducing the build area is undesirable, the remaining 
two approaches were considered.  
A second approach to antialiasing is defocusing the image so that jagged sidewall profiles 
are less noticeable. Although this approach is simple, the image loses sharpness that is retained 
using other antialiasing methods. However, we decided to assess the role of system focus on 
microneedle antialiasing due to the simplicity of this approach and its potential to generate 
microneedles with smooth sidewalls. Defocusing was achieved by moving the lens setup away 
from the window platform, further from the focal point of the lens. TMPTA microneedles were 
printed at different focal distances including at the focal point of the lens (Figure 2.19A), 2 mm 
away from the focal point (Figure 2.19B) and 4 mm away from the focal point of the lens (Figure 
2.19C).  Poor focus results in the production of wider, shorter microneedles than those produced 
using an in-focus system, demonstrating that microneedle dimensions are also dictated by the 
focus of the system as well as the CAD file used and the print parameters. Although defocusing 
had visible effects on microneedle morphology, the stair-stepping pattern was still evident at all 
focus levels. The system reached an unacceptable level of sharpness (Figure 2.19C), but still 
exhibited aliasing effects visible as horizontal lines across each microneedle. Therefore, 
defocusing is not a suitable method to eliminate stair-stepping.  
 
Figure 2.30 Effect of system focus on microneedle structure. Microneedles of three different aspect ratios are 
fabricated A) In focus, with the lens at its focal point B) with the lens 2mm below its focal point and C) with the 
lens 4 mm below its focal point. Scale bars measure 500µm. 
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The third and most attractive approach to antialiasing is introducing grayscale using an 
antialiasing technique called supersampling.8 Object edges can be blended to create the illusion 
of a continuous line by using gray pixels, rather than only relying on pixels that are either black 
(“OFF”) or white (“ON”). Figure 2.15 is an example of supersampling the typeface lowercase 
letter “a”. When using black and white pixels only, this system appears to have poor resolution, 
with individual pixels very clearly visible (Figure 2.20A). However, the use of grayscale values 
along the object’s edges (Figure 2.20B) visibly improves resolution. This supersampling 
approach shown here is very similar to methods currently used for commercial projection 
systems and DLP televisions.8 
More specifically, when a supersampling antialiasing algorithm is applied, the pixel’s 
grayscale value is calculated by averaging light intensity of all of the objects falling within a 
single pixel, according to Equation 2.19, below.  G is grayscale value, A is the area occupied by 
a particular object within a single pixel, and i is the number of objects that fall within that pixel.  
𝐺𝑝𝑖𝑥𝑒𝑙 =
∑ 𝐺𝑖𝐴𝑖
𝑖
1
∑ 𝐴𝑖
𝑖
1
  `   (2.19) 
 
Figure 2.31 Supersampling of typeface letter A. A) An aliased version of typeface letter A has jagged edges B) 
Supersampling the typeface letter  visibly improves resolution. Reproduced with permission from Reference 10. 
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Typically, this grayscale value is a number between 0 (black) and 255 (white), based on a linear 
red, green, blue (RGB) color scale. In some cases, it is also given as percent of maximum light 
intensity. 
In order to apply supersampling to 3D printing, a method of assigning a grayscale value 
to each micromirror had to be developed. DLP chips are inherently discrete systems, in which 
each micromirror is either “ON” or “OFF” at a given moment in time, but high frequency 
dithering, or oscillation, of each micromirror can be utilized to create the illusion of grayscale. 
For example, if a micromirror is in the “ON” position for 50% of the duration of the frame and in 
the “OFF” position for the remaining 50% of the frame, the pixel appears to project 50% of the 
Table 2.1 Comparison of GDI and GDI+ Pixel Grayscale Assignments 
 
 
 
Figure 2.32 Comparison of GDI and GDI+ Grayscale Assignments 
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maximum light intensity. Likewise, a pixel assigned to 75% of the maximum light intensity 
would be in the “ON” position for 75% of the duration of the frame and in the “OFF” position 
for the remaining 25% of the frame. Visualizing the bitmap used to control the DLP chip enables 
us to identify whether any antialiasing algorithm is being applied during projection of the image.  
The grayscale value of each pixel is controlled by a component of the system’s software 
called the graphic device interface (GDI). Two different graphic device interfaces- Windows 
GDI+, which used for the production of stairstep microneedles, and Windows GDI, an alternate 
version, were compared to determine how each version assigns grayscale values to an image.  
Grayscale assignment was determined by capturing a screenshot of the bitmap image that 
controls the DLP chip for several different test images. Input test images were simple squares of 
a specific sizes at a particular location on the build area (Table 2.1). The results of the 
experiment are given in Figure 2.21 and described in detail in the next paragraph.  
The GDI and GDI+ interfaces differ in the way that they assign an input image to a 
bitmap that controls grayscale values on the DLP chip. When the input image exactly align’s 
with the DLP’s micromirrors, no approximation is required. For example, when a 3x3 pixel 
square is located at the origin (Figure 2.21A), the entire 3x3 pixel square is projected at 
maximum light intensity, shown in white, regardless of the graphic device interface that is used. 
Similar results are seen when a 2x2 pixel square is located at the origin; a 2x2 pixel square is 
projected at maximum light intensity (Figure 2.21B). However, when this 2x2 pixel square is 
translated such that it does not directly align with the DLP’s micromirrors, the system must 
approximate the specified image when it is projected to account for each partial pixel. The GDI 
and GDI+ interfaces perform this approximation in different ways. Windows GDI+ rounds each 
partial pixel up to the next largest pixel, projecting a 3x3 pixel image at maximum light intensity 
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(Figure 2.21C). Windows GDI performs the desired supersampling procedure and approximates 
each partial pixel in grayscale (Figure 2.21D) 
In order to better understand the antialiasing algorithm and appreciate how it may affect 
microneedle fabrication as well as the fabrication of other small objects, the grayscale values for 
each pixel in Figure 2.21C-D were calculated. These grayscale values are shown in Figure 2.22. 
As expected, the GDI+ interface “rounds-up” to the next largest pixel, projecting the entire 
object at the maximum light intensity (Figure 2.22). The grayscale values resulting from use of 
the GDI interface are calculated using equation 1, where each grayscale value is proportional to 
the percentage of that pixel that is covered by the original object. For example, because 25% of 
the each corner pixel is covered by the original object, the corners are projected at 25% of the 
maximum light intensity. 
To represent the potential effects of these antialiasing algorithms on the production of 
microneedles using CLIP, squares of decreasing size were projected. These squares represent the 
 
Figure 2.34 Grayscale Assignments for a 2x2 Pixel Object Shifted by One Half Micromirror. A) Grayscale 
value resulting from use of the GDI+ Interface B) Grayscale value resulting from use of the GDI Interface. An 
outline of the original object is provided in red.  
Figure 2.35 Difference Between Windows GDI+ and Windows GDI Projections of Microneedle Crossections 
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cross-section of an individual microneedle in the array, moving from the microneedle’s base to   
the tip of the needle.  A printscreen of the bitmap sent to the DLP was visualized to determine 
the grayscale value assigned to each individual pixel. As shown in Figure 2.23, Windows GDI+ 
produces an abrupt transition between pixels, whereas Windows GDI utilizes grayscale to create 
a smooth transition moving from microneedle base to tip. Therefore, we moved forward with 
applying supersampling to microneedle production using Windows GDI in hopes that this 
approach would generate smooth microneedle sidewalls.  
2.2.7 Application of Antialiasing to Microneedle Production 
In order to determine whether this antialiasing algorithm effectively eliminates stair-
stepping along microneedle sidewalls, microneedles were fabricated using the GDI version of the 
digital graphics interface according to previously established methods. A range of different light 
intensities, from 2mW/cm2 to 14mW/cm2 was investigated with build speed held constant at 
 
Figure 2.36 TMPTA Microneedles produced using Windows GDI. Microneedles were produced using A) 
2mW/cm2, B) 5mW/cm2, C) 8mW/cm2, D) 11mW/cm2, and E) 14mW/cm2 of UV light. Build speed was held 
constant at 100mm/hr. Scale bars measure 500µm. 
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100mm/hr. The ESEMs of these microneedles shown in Figure 2.24 demonstrate that the 
addition of an antialiasing algorithm eliminates the stair-stepping effect at all light intensity 
values. Therefore, we concluded that a supersampling antialiasing algorithm can be used to 
eliminate the visualization of individual pixels (“stair-stepping”) on the small scale to enable the 
production of parts with smooth sidewalls. 
2.2.8 Selection of Appropriate Build Parameters 
After successfully eliminating stair-stepping to produce microneedles with smooth 
sidewalls, we revisited the role of light intensity on microneedle dimensions. The microneedles 
printed using a range of light intensities in Figure 2.24 were measured to assess dimensional 
accuracy, with results given in Figure 2.25.  
Overcuring between needles at high light intensity (11mW/cm2 and 14mW/cm2) is 
somewhat reduced when using the GDI interface as opposed to the GDI+ interface, presumably 
 
Figure 2.38 Microneedle Dimensions vs. Light Intensity Using Windows GDI. Error bars represent the 
mean ± SD (n=3). 
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due to decrease in the light intensity (introduction of grayscale) of each microneedle’s exterior 
pixel. However, although we hoped to identify the appropriate light intensity for the production 
of dimensionally accurate microneedles using the new GDI interface, all microneedles were  
truncated in the z direction relative to the 1000µm CAD file (Figure 2.9). A hypothesis to 
explain this truncation is provided in Appendix B. While further increases in light intensity may 
produce tall enough microneedles, the microneedles are already wider than the desired width; 
increases in light intensity would exacerbate this issue. Therefore, microneedles were produced 
using the light intensity that resulted in an appropriate width (8mW/cm2) and scaled in the z 
direction (z scale factor=1.175, e.g. the initial CAD file was scaled to a height of 1175µm) to 
produce microneedles measuring approximately 1000µm tall (Figure 2.26). At 100mm/hr, the 
total print time for this microneedle array is 78.3 seconds, which is the fastest fabrication time 
for a microneedle array presented in literature, to our knowledge. We estimate that these 
production speeds are approximately 400-1600X faster than traditional etching techniques used 
to fabricate microneedles, which are typically accomplished at 1-5µm per minute.11-13 The 
 
Figure 2.39 1000µm tall TMPTA Microneedles Produced Using CLIP.  A) Image of CLIP Microneedles 
showing sharp tip radius B) Dimensions and fabrication time for microneedles in Figure A. Data are represented as 
mean ± SD 
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average tip radius of each microneedle in the array is 2.3µm, which is approximately three times 
sharper than the sharpest polymeric microneedles in literature.14  
2.2.9 Control Over Microneedle Geometry 
As previously mentioned, utilizing additive manufacturing to fabricate microneedles may 
provide unprecedented control over microneedle design parameters, such as microneedle size, 
shape, spacing, and aspect ratio. Design alterations should be achievable by simply exchanging 
the input CAD file with little to no additional process optimization for new designs. In order to 
test this hypothesis, a number of different microneedle designs were fabricated using the model 
resin TMPTA.  
2.2.9.1 Fabrication of Microneedles of Different Heights 
Microneedles of different heights are useful for controlling depth of penetration in the 
skin and to alter the volume available for cargo loading. Controlled depth of penetration may 
enable targeting of specific cell types within the skin, such as targeting the basal layer for basal 
cell carcinomas. Controlling microneedle penetration depth may also alter the rate and/or degree 
of therapeutic exposure to systemic circulation. CAD files of mic roneedles of different heights, 
measuring 1000µm, 700µm, and 400µm tall, were generated with aspect ratio held constant 
(AR=3). Using the light intensity and build speed previously identified for production of 1000 
Table 2.2 MNs of Different Heights Truncate without Z Scale Factor. Dimensions of all MNs show truncation in 
z direction, but minimal shrinkage in the x-y direction. Data are presented as mean±SD, n=9 
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µm tall microneedles (8mW/cm2, 100mm/hr), microneedles of different heights were fabricated 
(z scale factor=1) and measured to assess dimensional accuracy (Table 2.2). Microneedle width 
was initially found to be within 5% of the intended dimensions, indicating that these build 
parameters were appropriate for setting the width of the needles.  Microneedle heights, however, 
were approximately 100µm too short, regardless of the initial height. This 100µm difference 
accounts for a larger and larger portion of the total height as the microneedles become smaller 
(Table 2.2). Therefore, a z scale factor was added to scale the microneedles to an appropriate 
height, shown in Figure 2.27. After scaling, all microneedle heights and widths were found to be 
within 5% of intended dimensions.  
2.2.9.2 Fabrication of Microneedles of Different Geometries 
The geometry of a microneedle array is known to affect its cargo loading volume, failure 
force,15 and ability to effectively insert into the skin. 15-18 In order to determine whether CLIP can 
 
Figure 2.42 CLIP MNs of Different HeightsMNs produced from a CAD file measuring A) 1000µm tall and 
333µm wide, B) 700µm tall and 233µm wide, and C) 400µm tall and 133µm wide. D) Dimensions of all MNs show 
truncation in z direction, but minimal shrinkage in the x-y direction. Data are presented as mean±SD (n=9). Scale 
bars measure 500µm. 
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be utilized to rapidly adjust patch geometry, we fabricated CLIP microneedles with different 
shapes, aspect ratios and spacings.  
In order to adjust microneedle aspect ratio, CAD files of microneedles having ARs 
ranging from 2 to 4 were generated. Microneedles were then fabricated using the light intensity 
and build speed previously optimized for TMPTA microneedles (8mW/cm2, 100mm/hr), as 
shown in Figure 2.28A. Similar adjustments in microneedle aspect ratio have been previously 
shown to impact microneedle strength;15 aspect ratio is therefore an important determinant of 
efficacy. Similarly, CAD files of microneedles spaced at 0.5 and 1.5 base widths apart were 
readily generated and utilized to produce CLIP microneedle patches with adjustable inter-needle 
spacing (Figure 2.24B-C). Microneedle height was held constant at approximately 1000µm. 
More closely spaced microneedles have more volume available for cargo loading per unit patch 
 
Figure 2.44 TMPTA Microneedles of Different Shapes A) TMPTA microneedles of aspect ratio 2, 3, and 4 (left 
to right). 1000µm tall TMPTA microneedles with spacing of B) 0.5 base widths and C) 1.5 base widths. Complex 
microneedle geometries such as D) Arrowhead microneedles E) Tiered microneedles and F) Turret microneedles 
may improve mechanics of insertion into the skin. Scale bars measure 500µm 
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area. Unfortunately, increasing the total number of needles also increases the total force required 
to insert microneedles into the skin due to the “bed-of-nails” effect discussed in Chapter 1. 
Therefore, inter-needle spacing is another important design parameter that can be optimized 
using the CLIP platform. 
Although conical and square pyramidal microneedles have been the mainstay of 
microneedle technology, more complex geometries may afford improved penetration into the 
skin. Therefore, we aimed to use CLIP to fabricate microneedle geometries that would be 
difficult to impossible to fabricate using other microfabrication techniques. For example, 
arrowhead microneedles may improve the consistency of needle penetration by resisting the 
elastic nature of the skin to remain embedded at their maximum penetration depth.19-20 
Successful microneedle penetration into the skin is also known to be inhibited by the “bed-of-
nails” effect, wherein the total insertion force is divided evenly amongst every microneedle in an 
array, increasing the total force required for insertion.15 The design of “tiered” microneedles, 
which contain microneedles of different heights on a single array, may reduce required insertion 
forces by concentrating the force on fewer needles at a given moment in time. Lastly, traditional 
square pyramidal microneedles of different aspect ratios are thought to present a trade-off 
between ease of insertion and microneedle strength wherein wider needles provide mechanical 
stability, but thinner needles more easily insert into the skin.14 “Turret” microneedles containing 
sharp tips with a wide base may easily puncture the skin, but also afford improved mechanical 
strength.  
CLIP was utilized to fabricate arrowhead microneedles, “tiered” microneedles, and 
“turret” microneedles, shown in 2.23D-F, respectively. This work demonstrates proof of concept 
that CLIP can be utilized to rapidly generate an almost infinite library of computationally defined 
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microneedle geometries, which can be used to systematically investigate how microneedle 
geometry influences efficacy. 
2.3 Conclusions 
Herein, we have demonstrated that microneedle structures composed of the model resin 
TMTPA can be produced via CLIP in less than 90 seconds per patch. This process is the fastest 
microneedle production technique in the world, producing the sharpest polymeric microneedles 
in literature. Therefore, CLIP shows promise as a microneedle fabrication technique due its 
speed and unprecedented control over microneedle geometry. Further, CLIP enables novel 
microneedle geometries, such as arrowhead microneedles, to be produced, with the potential to 
improve microneedle insertion into the skin. Such geometries are difficult to impossible to 
fabricate using other techniques. CLIP microneedles will be further discussed in Chapter 4, 
which focuses on the development of CLIP microneedles designed to encapsulate and release a 
therapeutic cargo. 
The data presented in this chapter also demonstrates important fundamental information 
about the CLIP process, which provides useful guidelines for the fabrication of any small part via 
CLIP. First, the characteristics of the optical system that focuses the image from the DLP chip 
onto the build window were found to be of paramount importance to the structure of small 
objects. Second, in order to produce small parts with smooth surfaces, a technique called 
antialiasing must be applied during production. A specific type of antialiasing called 
supersampling was employed, blurring distinctions between pixels with grayscale to produce 
small objects. Third, microneedle build parameters, particularly speed and light intensity, were 
shown to play as big of a role in part dimensions as the dimensions of the input CAD file. More 
specifically, increasing light intensity was shown to increase part dimensions, whereas increasing 
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build speeds was shown to decrease part dimensions. Therefore, judicious control over speed and 
light intensity are of paramount importance to effective use of CLIP. Chapter 3 will continue to 
explore the role of printer optics, light intensity and build speed on part dimensions, with the 
ultimate goal of applying a predictive mathematical model to CLIP that could automate selection 
of CLIP build parameters.  
Altogether, these findings establish proof of concept that CLIP can be utilized to fabricate 
microneedles and provide a foundation for utilizing CLIP for the production of micron-scale 
parts for a variety of different applications.  
2.4 Experimental 
2.4.1 Materials 
Diphenyl (2,4,6- trimethylbenzoyl) phosphine oxide (TPO) and trimethylolpropane 
triacrylate (TMPTA) were obtained from Sigma Aldrich and used as received. DLP chips were 
obtained from Texas Instruments, with specifications given in Tables 2 and 3 for the CLIP3 and 
CLIP7, respectively. Lenses were purchased from Edmund Optics, with specifications given in 
Tables 2 and 3 for the CLIP3 and CLIP7, respectively. 
2.4.2 TPO Absorption Spectrum 
2mL of TPO at 10ppm in dimethylacetamide (DMAC) was added to a quartz cuvette with 
a path length of 1mm. The aborption spectrum was taken over 260 to 450nm using a UV Vis 
system.   
2.4.3 CLIP Instrument Specifications 
The parts produced in this chapter were made using either the CLIP3 or CLIP7 additive 
manufacturing systems provided by Carbon 3D, Redwood City. Specifications for each system 
are given in Table 2.2 and Table 2.3 for the CLIP3 and CLIP7, respectively.  
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The CLIP3 system is composed of a mercury lamp and a DLP 3000 DLP chip containing 
a 608x684 array of micromirrors measuring 7.6µm x 7.6µm each. Light reflects off of the DLP 
chip through a lens composed of two achromatic doublets, off of a mirror, and onto the build 
window. Depending on the focal length of the lenses (Edmund Optics), each of these 
micromirrors was projected at a 1:2.1 or 1:1.05 ratio on the build window such that each 
micromirror forms a 16µx16µm or an 8µx8µm pixel, convolved with the impulse response of the 
system, on the build surface  
The CLIP7 system is composed of an ultraviolet light emitting diode (UV LED) emitting 
light at a wavelength of 370nm. Light emitted from the LED is reflected off of a DLP7000 DLP 
Table 2.5 CLIP 3 Specifications 
 
Table 2.6 CLIP 7 Specifications 
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chip containing a 1024x768 array of micromirrors measuring 13µm x 13µm each. This light then 
travels through two achromatic doublet lenses and is focused on the build window at a 1:0.754 
magnification to produce a maximum image size of 10.3mm x 7.7mm.  Each micromirror, 
therefore, produces a single pixel of ligh  t measuring 9.803µm x 9.803µm at the window 
surface.  
2.4.4 TMPTA Part Fabrication 
TMPTA and 2.5 wt% TPO were mixed in an amber bottle on a magnetic stirplate with a 
stirbar at 60°C until TPO solubilized. Parts were designed using Solidworks 2014 3D modeling 
software and saved as .STL files. The .STL file was then sliced in 1µm sections along the z axis 
using the opensource software Slic3r to generate a .SVG file containing the object’s coordinates 
on each slice. This .SVG file is referenced by a .LUA script which controls the CLIP system’s 
light source and build elevator.  More information regarding .LUA scripts is provided in 
Appendix A. Parts were then fabricated using a CLIP3 system with a high resolution or low 
resolution lens setup or a CLIP7 system with Greenlight® or updated lenses from Edmund 
Optics. All of the parts in this dissertation are produced in continuous mode, where the light 
illuminates thoughout the entire build and the build elevator moves upwards continuously.  
To produce microneedles of different heights, CAD files of square pyramidal 
microneedles measuring 1000, 700, and 400 µm tall with an aspect ratio of 3 (aspect ratio= 
height/width) were generated using Solidworks 2014. All microneedles were spaced at one base 
width apart on a base measuring 6x6x1mm. CAD files were then sliced at 1μm slice thickness 
using the open source software Slic3r. Microneedles were then produced using a CLIP additive 
manufacturing system (Carbon 3D, Redwood City, CA) in a mixture of trimethylolpropane 
triacrylate (Sigma Aldrich) and 2.5wt% Diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide 
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(Sigma Aldrich) with 5.4mW/cm2 of UV light (λ=370nm LED) as measured by the Dymax 
AccuCalTM50 (Dymax Corporation) or 8mW/cm2 as measured using an in-house photometer. at 
100mm/hr Z scale factors of 1.175, 1.175, and 1.6 were added during scaling to counteract z-axis 
truncation visualized without scaling. All microneedles were visualized using an environmental 
scanning electron microscope (FEI Quanta 200) in low vacuum mode.  
To demonstrate ability to alter microneedle size and shape, CAD files were created and 
sliced as previously described. The CAD file used to generate microneedles of varying aspect 
ratios contained microneedles measuring 1000µm in height and 500µm, 333µm, and 250µm in 
width for aspect ratios of 2, 3, and 4, respectively. These microneedles were spaced at 333 µm 
apart. CAD files for microneedles of varying spacing measured 1000µm in height and 500µm in 
width with spacing at 250 µm or 500µm apart.  
Arrowhead microneedles measuring 1000µm tall and 500µm wide were fabricated from 
TMPTA + 2.5wt% TPO and 0.1wt% 2-(3’-tert-butyl-2’-hydroxy-5’-methylphenyl)-5-
chlorobenzotriazole (Sigma Aldrich) at 41mm/hr with 5.4mW/cm2 of UV light (Dymax). Tiered 
microneedles, measuring 1000µm, 800µm, and 600µm tall and 400µm wide, and turret 
microneedles measuring 1000µm tall and 500µm wide were fabricated at 25mm/hr with 
1.35mW/cm2 of UV light (Dymax). 
 All part images were obtained using electron microscopy. Figures 2.5-2.9 were obtained 
using the FEI Quanta 200 in low vacuum mode. Figures 2.12 and 2.14 were sputter coated with 
3nm of gold and imaged using an FEI Helios and Hitachi S-4700, respectively. All image 
measurements were obtained using ImageJ. 
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2.4.5 Analysis of Antialiasing Algorithms 
The effect of antialiasing algorithms on CLIP microneedles was determined using custom 
software provided by Carbon3D equipped with either Windows Graphic Device Interface or 
Windows Graphic Device Interface Plus. Bitmap images were obtained by taking a screenshot of 
the image sent to the printer. Grayscale values of these bitmap images were obtained using the 
eyedropper tool in Windows Paint.  
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CHAPTER 3 CONTROLLED RELEASE OF THERAPEUTICS FROM CLIP MICRONEEDLES 
 
3.1  Introduction  
As outlined in Chapter 1, numerous different types of microneedles have been fabricated 
for transdermal drug delivery. These microneedles are typically classified into four different 
configurations- 1) solid, uncoated microneedles, 2) solid, coated microneedles, 3) hollow 
microneedles and 4) biocompatible microneedles.1-2 Each of these configurations differs in its 
mechanism of drug release (Figure 1.3).1-2 Biocompatible microneedles are typically made of 
natural or synthetic polymer that swells,3 dissolves,4 or degrades5 to release a therapeutic into the 
skin. Biocompatible microneedles are particularly promising because they eliminate the risk of 
accidently depositing hazardous materials into the skin during microneedle use.1,6 Biocompatible 
microneedles have a large volume available for encapsulation of the therapeutic and provide 
more control over the applied dose than other microneedle configurations.1 Biodegradable or 
water soluble microneedles also eliminate sharp, biohazardous wastes thereby preventing needle 
stick injuries and disease transmission due to needle re-use. Importantly, biocompatible 
microneedles also present a unique opportunity to control drug release rates into the skin through 
careful matrix selection. 
All controlled release systems aim to improve the effectiveness of therapeutics by altering 
drug concentration versus time profiles within the body.7-8 Medications should be delivered at 
concentrations that are within a therapeutic window, i.e. higher than the minimum effective dose 
(MED) required to have a therapeutic effect, but well below the maximum tolerated dose (MTD) 
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where toxic side effects begin to occur.7-8 For agents intended to have a long duration of action, 
maintaining therapeutic concentrations often requires frequent dosing (Figure 3.1). The use of 
controlled release systems can reduce undesired fluctuations in drug concentration to maximize 
therapeutic effects while minimizing side effects (Figure 3.1).7-8 These controlled release 
systems also provide an opportunity to minimize dosing frequency to improve patient 
compliance. 7-8 Microneedles may provide an ideal platform for a controlled release device 
because they can be deposited in the skin without a need for injection or surgical implantation.   
In Chapter 2, we demonstrated the ability to fabricate microneedles using a new additive 
manufacturing technique called Continuous Liquid Interface Production (CLIP). This technique 
provides unlimited control over microneedle geometry, with prototyping speeds that are 400-
1600X than traditional etching based techniques. Microneedles fabricated in Chapter 2 were 
composed of a model resin containing trimethylolpropane triacrylate (TMPTA) and 2.5wt% 
 
Figure 3.1 Advantage of Controlled Release Systems. Controlled release systems reduce fluctuations in drug 
concentrations to keep drug concentrations within the therapeutic window. Reproduced with permission from 
reference 8. 
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diphenyl (2,4,6- trimethylbenzoyl) phosphine oxide (TPO) as a photoinitiator. This resin served 
as a positive control for chemistry throughout process development due to its previous use in 
stereolithography applications.9 However, because TMPTA produces a non-degradable, tightly 
crosslinked hydrophobic network upon photopolymerization, it is not a suitable material for drug 
release applications. TMPTA also causes severe skin irritation upon contact,10 and is therefore 
not a suitable material for a clinically translatable CLIP microneedle device. To take advantage 
of the potential to control drug release from microneedle devices, we endeavored to produce 
CLIP microneedles fabricated from biocompatible polymers designed to incorporate and and 
control the release of therapeutics.  
A number of different polymeric materials, both natural and synthetic, have been utilized 
for the incorporation and release of therapeutics for drug delivery applications. Release of the 
therapeutic is typically accomplished via one of three mechanisms- dissolution, degradation, or 
swelling of the matrix.7 Appropriate dissolvable polymers are uncrosslinked, hydrophilic 
polymers that dissolve in aqueous environments. Some common examples of water-soluble 
natural and synthetic polymers used in drug delivery are polyvinylpyrrolidone (PVP), polyvinyl 
alcohol (PVA), lactose, and maltose, among others. 11 When uncrosslinked, These materials 
usually rapidly dissolve within the body, but dissolution rates can also be tailored by altering 
molecular weight and hydrophilicity of the polymer or the geometry of the device, depending 
upon the application.  
Biodegradable polymers have components that chemically break down within the body. 
A variety of polymers have been used, including natural, synthetic, crosslinked, and 
uncrosslinked systems. In most cases, breakdown occurs via either hydrolysis (for synthetic 
systems) or enzymatic degradation (for natural systems) of the polymer backbone.12-13 Therefore, 
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uncrosslinked systems typically undergo complete degradation, whereas crosslinked systems 
typically leave non-degradable crosslinks behind after degradation of the backbone.  
Hydrolytically cleavable groups include esters, anhydrides, carbonates, amides, and urethanes, 
among others. 12-13 The most commonly utilized groups are poly(α-esters), such as polygycolide, 
polylactides, polycaprolactones, and their copolymers.12-13 Key advantages of such systems 
include their FDA approval and the ability to tune solubility and release rates by altering 
copolymer ratios. For example, poly(lactide-co-glycolide) (PLGA) copolymers degrade more 
quickly as the LA/GA ratio decreases because of the faster degradation rate of the polyglycolic 
acid (PGA); 85/15 blends of poly(lactide-co-glycolide) typically degrade over the course of 5-6 
months, whereas 50/50 blends typically degrade over the course of 1-2 months.12-13 
Enzymatically cleavable natural polymers including proteins (collagen, elastin, albumin) and 
polysaccharides (hyaluronic acid, chondroitin sulfate, chitosan, alginate) have also been utilized 
for drug delivery applications.12 These natural polymers have some interesting 
bioactive/bioregenerative properties, but also tend to exhibit high patient to patient variability in 
degradation rates due to differences in endogenous enzyme levels. 12  
Lastly, non-degradable, crosslinked hydrophilic networks called “hydrogels” have been 
developed for pharmaceutical applications.14-16 These hydrogels swell in aqueous environments 
to release therapeutics via diffusion through a crosslinked mesh.14-16 Some commonly used 
hydrogels include crosslinked polyethylene glycol, polyvinylpyrrolidone (PVP), polyvinyl 
alcohol (PVA), polyacrylamide, polyacrylic acid, and hyaluronic acid, among others.14-16 These 
materials provide opportunity to closely control release rates by altering the molecular weight 
between crosslinks (crosslink density), the hydrophilicity of the polymer chain, and electrostatic 
interactions between the cargo and the polymer backbone.14-16 Stimulus-responsive hydrogel 
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systems have also been developed to control release in response to changes in temperature, pH, 
antibody binding, and glucose levels, among others.15 
Given the range of biocompatible materials and pharmaceutical applications, there is no 
one system available that could be considered ideal for every case. The characteristics of the 
therapeutic (size, charge, solubility) and its desired release profile (rapid vs. sustained release) 
must be considered. Therefore, an ideal microneedle fabrication technique would allow for rapid 
optimization of microneedle composition for a given application.  To this end, we aimed to use 
CLIP to fabricate microneedles from a wide variety of different biocompatible materials. More 
specifically, we aimed to show that CLIP could be used to fabricate biocompatible microneedles 
designed to control the release therapeutics via each of the three different release mechanisms- 
rapid dissolution, hydrolytic degradation, and swelling.   
3.2 Results and Discussion 
3.2.1 Selection of Biocompatible Materials 
In selecting a biocompatible material suitable for use as a CLIP microneedle matrix, it 
was important to identify a low viscosity resin that would produce a strong microneedle after 
photopolymerization. Low viscosity resins are well suited for use with CLIP because they 
quickly flow into the build area as the build elevator moves upward throughout production.  Low 
viscosity resins can be either a neat solution of liquid monomer/oligomer or a solid photoreactive 
monomer/oligomer dissolved in a liquid reactive or non-reactive diluent. For the purposes of this 
research, we chose to formulate solvent-free resins that do not contain any non-reactive diluents.  
Eliminating such a solvent from the system avoids 1) the formation of solvent-induced pores, 
which may decrease the strength of the microneedle, 2) chain transfer to solvent during the 
reaction 3) post processing steps required to remove solvent after microneedle fabrication and 4) 
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undesirable and poorly controlled evaporation of the solvent during processing due to the heat of 
polymerization. Photopolymerizable derivatives of materials that are Generally Recognized as 
Safe (GRAS) by the United States Food and Drug Administration (FDA) were selected in order 
to provide the most opportunity for patient safety and to increase potential for clinical translation 
of a CLIP microneedle device.  
Polyethylene glycol 550 dimethacrylate (PEG550-dMa), a 550g/mol PEG chain 
functionalized with methacrylate endgroups (Figure 3.2A) was selected to generate a 
microneedle designed for sustained release of hydrophilic cargo via swelling of the matrix. Upon 
photopolymerization, PEG-dMa forms a crosslinked hydrogel that swells in aqueous 
environments.  The molecular weight of the oligomer is critical to both the strength and release 
rate of the resulting polymer network and can affect the viscosity of the resin. Low molecular 
weight oligomers polymerize to form tightly crosslinked networks, which are strong but also 
have slow release rates due to the high density of the polymer; high molecular weight oligomers 
 
Figure 3.2 Structure of Monomers Utilized for Microneedle Fabrication. A) Polyethylene glycol 550 
dimethacrylate, n=9 B) Polycaprolactone trimethacrylate, n=2  C) Acrylic acid 
 
 
 
Figure Error! No text of specified style in document..1 Structure of Monomers Utilized for 
Microneedle Fabrication A) Polyethylene glycol 550 dimethacrylate, n=9 B) Polycaprolactone 
trimethacrylate, n=2  C) Acrylic acid
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polymerize to form loosely crosslinked networks which release cargo more quickly, but are 
mechanically weaker. PEG550-dMa is among the highest molecular weight PEG-dMa that is still 
liquid at room temperature. We hypothesized that this low viscosity oligomer has a high enough 
molecular weight to allow cargo to escape over a reasonable period of time, but low enough 
molecular weight to form a strong microneedle capable of skin penetration. Methacrylate 
endgroups were chosen, as opposed to acrylates, due to their lower toxicity in vivo.17  
To generate a microneedle designed for sustained release of hydrophobic cargos through 
degradation, a polycaprolactone triol was functionalized with methacrylic anhydride to form a 
polycaprolactone trimethacrylate (PCL1110-tMa) with a molecular weight of 1110 g/mol (Figure 
4.2B). Although other polyesters may result in a stronger needle and/or allow for faster cargo 
release,12-13 this material was chosen due to the commercial availability of the PCL triol, which 
allowed for functionalization with photoreactive endgroups. 
The production of uncrosslinked, dissolvable microneedles using CLIP is more 
challenging. Because most uncrosslinked polymers are soluble in their own monomer, 
uncrosslinked CLIP parts typically dissolve inside the vat of monomer before part fabrication 
can be completed. Polyacrylic acid (PAA) provides a unique opportunity for use with CLIP 
because it belongs to a small class of polymers that are insoluble in their own monomer (due to 
the polar nature of the PAA, which makes it much more hydrophilic than the monomer).18 This 
unique property enables the PAA polymer to precipitate out as it is formed in the vat of acrylic 
acid (AA) monomer to form a solid part. For this reason, AA was chosen as a monomer utilized 
to produce water-soluble polyacrylic acid microneedles.  
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All oligomers were mixed with 2.5wt% diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide 
(TPO) as a photoinitiator.  
3.2.2 Stereolithographic  Working Curves 
Chapters 2 underscores the critical importance of light intensity and build speed for the 
production of parts via CLIP. In Chapter 2, all light intensities and build speeds were determined 
empirically. Each new biocompatible resin used here will have its unique set of curing properties 
(polymerization rate, reaction volume, etc.). Therefore, rather than empirically selecting new 
build parameters for each new biocompatible resin, we endeavored to develop a more 
efficient method of determining build parameters through use of working curves that have 
previously been used in stereolithography.19-20 Throughout this chapter, the terms “appropriate 
build parameters” is used to refer to light intensities and build speeds that produce dimensionally 
accurate parts.  
 
Figure 3.3 Sterolithographic working curve. Reproduced with permission from reference 20. 
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In the field of stereolithography, a calibration curve called a “working curve” has been 
utilized to determine the appropriate exposure time for the production of a part with a specific 
resin.19-20 Exposure, in this case, is defined as the product of the light intensity given in mW/cm2 
with the exposure time given in seconds. Therefore, a part produced with 1mW/cm2 of light with 
an exposure time of 2 seconds and a part produced with 2mW/cm2 of light with an exposure 
time of 1 second both experience the same total light exposure. The working curve relates this 
applied light exposure per layer to resin cure heights. The exposure that allows each layer to 
cure to the appropriate height (specified by the CAD file slice thickness) is used for part 
fabrication. For example, a part that is 1cm in height could be sliced into one hundred layers, 
each measuring 100µm. Such a part would be exposed to a given intensity of light for the 
amount of time that enables the resin to cure to 100 µm tall. The working curve can be 
mathematically defined by Equation 3.1: 
𝐶𝑇 =
1
𝛼
𝑙𝑛(
𝐸
 𝐸𝑐
)      (3.1) 
where CT is the cured thickness of the resin in µm, E and Ec are the actual and critical exposures, 
respectively, in units of mJ/cm2, and α is the absorption coefficient of the resin in µm-1. A graph 
of a working curve, plotted on a log-linear scale, is given in Figure 3.3.  
This working curve is fundamental to stereolithography and can be directly derived from 
the Beer-Lambert law, as described in the following section. 
3.2.3 Derivation of the Working Curve from Beer-Lambert Law 
The Beer-Lambert law, which describes the attenuation of a light source through an 
absorbant material, can be described by Equation 3.2: 
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𝐼(𝑧) = 𝐼0𝑒
−𝛼𝑧      (3.2)  
where I is the intensity of the light source in power per unit area, α is the absorption coefficient 
of the resin, and z is the depth of light penetration into the sample, in our case, a vat of resin. 
Multiplying the equation by exposure time yields 
𝐼𝑡 = 𝐼0𝑡𝑒
−𝛼𝑧      (3.3) 
Which is equivalent to 
𝐸 = 𝐸0𝑒
−𝛼𝑧      (3.4) 
In order for liquid resin to solidify to a particular depth (𝑧𝑐𝑡), a critical exposure is required for 
cure. This is called the critical exposure (𝐸𝑐) 
𝐸𝑐 = 𝐸𝑒
−𝛼𝑧𝑐𝑡       (3.5) 
Solving for zct gives cured thickness as a function of the resin parameters α and 𝐸𝑐 
𝑧𝑐𝑡 =
1
𝛼
𝑙𝑛(
𝐸
 𝐸𝑐
)      (3.6) 
which can be determined from the slope and intercept, respectively of the working curve. 𝐸𝑐 can 
therefore be considered the minimum light exposure required to produce a solid structure. 
3.2.4 Application of Working Curves to CLIP 
Tumbleston et. al. investigated whether this working curve can be utilized to calculate 
appropriate light intensity and build speed for part fabrication via CLIP.3 In order to generate a 
working curve, resin sitting on top of a glass wafer was exposed to a single frame of light. This 
frame was projected at different light intensities for different amounts of time (Figure 3.4A) 
using a CLIP device. The authors found that working curves could be generated to describe the 
relationship between exposure and cure height of the resin on the glass wafer. (Figure 3.4B). By 
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fitting this working curve to Equation 3.1, the absorbance of the resin, α, and critical exposure, 
Ec, could be determined. Therefore, generation of working curves was possible using a CLIP 
device. 
The application of working curves to CLIP is more complex than standard layer-by-layer 
based stereolithography systems because of the continuous movement of the build elevator. 
Nevertheless, the appropriate exposure per frame can be identified based on the rate of upward 
movement of the build elevator over time. For example, if the build elevator were to move 
upward at a rate of 100mm/hr through a 1mm slice, the exposure that cures the resin to 100 µm 
  
Figure 3.4 CLIP working curves enable part production A) Method for producing working curve. B) Working 
curve generated on a CLIP system. Figures are reproduced with permission from reference 3. 
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thick within 1/100th of an hour would be selected for fabrication. These are not reasonable 
values, but are chosen for simplicity of explanation. This working curve method was used to 
produce a variety of different parts, including the gyroid, Eiffel tower, and shoe cleats in Figure 
3.4C-E.  
We then designed an experiment to determine whether this working curve based 
“calculator” could be used to calculate appropriate build parameters for small parts, such as 
microneedles. A test part was designed to have one “large” feature measuring 4mmx1mmx1mm 
(LxWxH) and several smaller microneedles measuring 1mm in height (Figure 3.5B). The width 
of these microneedles was 500µm, 333µm, 250µm, and 100µm  moving from right to left along 
the test part. The large part served as a positive control for the utility of the working curve 
calculator for larger parts; the smaller microneedles were added to determine whether the 
calculator could be used for small parts. The optimal build speed for a given light intensity was 
identified using a TMPTA working curve developed by Carbon3D for TMPTA mixed with 
2.5wt% TPO.  
Figure 3.5A-C is an image of the test part printed with parameters identified using the 
working curve. All three parts were printed with equivalent exposures, but different 
combinations of light intensity and build speed. Although the height of the large rectangle and 
the microneedles are both 1mm in the CAD file, the microneedles are shorter than the rectangle 
for all fabricated parts. Quantification of the height of each object on each part is given in Figure 
3.5E. The large 4mm wide rectangle was found to be within 5% of its intended height, 
confirming that the working curve based calculator does accurately identify build parameters for 
large parts. The percent reduction in height was also quantified for all microneedles (Figure 
3.5E). As feature width decreases, the error in part height increases, suggesting that the 
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calculator is not well suited for identifying appropriate build parameters for very small parts. We 
hypothesize that the difference in the height of small and large scale parts is due to differences in 
the quantity of light projected per unit area, caused by superposition of light distribution from 
neighboring pixels. This hypothesis is further investigated in Appendix B. Part width was found 
to be within 5% of the intended dimensions, regardless of part size (data not shown).  
The results demonstrate the working curve “calculator” could correctly identify 
appropriate build parameters for the fabrication of large parts. Microneedles, however, 
were shorter than the intended CAD file when fabricated with these build parameters. 
Therefore, appropriate build parameters are dependent on the size of the object on the 
small scale. Appendix B presents a hypothesis to explain the difference in appropriate build 
parameters as a function of size.  
 
Figure 3.5 Appropriate Build Parameters are Size Dependent on Small Scale. TMPTA test parts fabricated with 
A) 1mW/cm2 of light at 50mm/hr B) 2mW/cm2 of light at 100mm/hr and C) 4mW/cm2 of light at 200mm/hr. D) 
CAD file of the test part with 1mm tall microneedles with base widths ranging from 100µm to 500 µm and a large 
square measuring 4mmx1mmx1mm. E) Percent reduction (percent error) in height of all structures in A-C 
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We did, however, hypothesize that working curves could be utilized to 
mathematically convert build parameters that were empirically determined to be effective 
for the production of TMPTA microneedles to build parameters appropriate for the 
production of microneedles using new, biocompatible resins, as explained in the following 
section. 
3.2.5 Adaptation of Working Curves to Microneedle Fabrication 
In order to test this hypothesis, a working curve was established for TMPTA, PEG, PCL, 
and PAA. Methods were adapted from Tumbleston et. al.19 A picture of the experimental setup 
used to produce the working curve is given in Figure 3.5A. Briefly, a dot of resin was placed on 
a cover slip on top of the printer window and exposed to a specified amount of light (Figure 
3.5A), where exposure is defined as the product of light intensity (in mW/cm2) and exposure 
time (in seconds). The height of the resulting object was determined and plotted on a log-linear 
scale (Figure 3.6A), where the best fit line between individual data points is defined by the 
working curve equation 
CT =
1
𝛼
𝑙𝑛(
𝐸
 𝐸𝑐
)     (3.6) 
where CT is the thickness of a cured dot, α is the absorption coefficient of the resin in units of 
µm-1, E is exposure of an individual frame (the product of light intensity and exposure time, 
given in mJ/cm2), and 𝐸𝑐 is the critical exposure required to induce polymerization of the resin in 
units of mJ/cm2. The absorption coefficient α and critical exposure 𝐸𝑐 of the resins (as reported 
in Figure 3.6B) could then be determined from the slope and x intercept of the best fit line, 
respectively.  
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The working curves for all four microneedle resins are shown in Figure 3.7. All resins 
have approximately equivalent slopes, indicating that they have an approximately equivalent 
absorbance. This equivalent absobance is expected because all of the resins contain the same 
concentration of photoinitiator (2.5wt% TPO) and the absorbance of the oligomers at λ=365 is 
negligible. PEG, PCL, and TMPTA resins have similar critical exposures, whereas the AA resin 
requires approximately six fold more light to solidify. The mechanism behind these trends in  
critical exposure is currently unconfirmed. Although one explanation may be differences in 
reaction rates, one would expect the AA monomer to react more quickly than methacrylated 
oligomer because of the increased reactivity of the acrylate relative to the methacrylate.21 
 
Figure 3.6  Stereolithographic Working Curve and Resin Properties. A) The cure depth of microneedle resins 
as a function of applied dosage B) Absorption coefficient and critical exposure of microneedle resins determined 
from the working curves in figure A 
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Measuring reaction rates using photo-DSC would be a useful way to test this hypothesis. 
Alternatively, the higher Ec of AA but may be related to the increased molecular weight of 
PEG550-dMa, PCL1110-tMa, and TMPTA as compared to AA, which would result in a greater 
increase in part volume per converted bond for these resins as compared to the AA. Differences 
in the functionality of the oligomer may also contribute to these trends.  
Calculated critical exposures and absorption coefficients were used to convert empirically 
determined TMPTA microneedle build parameters to parameters used for fabricating 
microneedles with new resins.  The appropriate exposure per frame was calculated by selecting 
the exposure that produces a cure thickness equivalent to TMPTA after exposure to a single 
frame, according to Equation 3.7 and Equation 3.8, below.  
𝐶𝑇,𝑇𝑀𝑃𝑇𝐴 = 𝐶𝑇,𝑅𝑒𝑠𝑖𝑛𝑋     (3.7) 
1/𝛼𝑇𝑀𝑃𝑇𝐴 𝑙𝑛(E𝑇𝑀𝑃𝑇𝐴/ 𝐸𝑐,𝑇𝑀𝑃𝑇𝐴) = 1/𝛼𝑅𝑒𝑠𝑖𝑛𝑋 𝑙𝑛(E𝑅𝑒𝑠𝑖𝑛 𝑋 / 𝐸𝑐,𝑅𝑒𝑠𝑖𝑛𝑋)  (3.8) 
During a continuous print, the applied exposure per frame (assuming constant slice thickness) is 
proportional to the applied light intensity divided by the build speed, given in mm/hr in the z 
direction, as shown in Equation 3.9  
𝐸𝑎𝑝𝑝𝑙𝑖𝑒𝑑 ∝
𝐿𝑖𝑔ℎ𝑡 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
𝐵𝑢𝑖𝑙𝑑 𝑆𝑝𝑒𝑒𝑑
    (3.9) 
Table 3.1 Build parameters for biocompatible CLIP microneedles 
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Because the absorption coefficients of microneedle resins are approximately equivalent (Figure 
4.4), substituting into Equation 3.9 into Equation 3.8 yields 
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦𝑇𝑀𝑃𝑇𝐴
 𝐸𝑐,𝑇𝑀𝑃𝑇𝐴∙𝑆𝑝𝑒𝑒𝑑𝑇𝑀𝑃𝑇𝐴
=
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦𝑅𝑒𝑠𝑖𝑛 𝑋
 𝐸𝑐,𝑅𝑒𝑠𝑖𝑛𝑋∙𝑆𝑝𝑒𝑒𝑑𝑅𝑒𝑠𝑖𝑛𝑋
    (3.10) 
A build speed of 25 mm/hr was selected for fabrication of biocompatible microneedles to 
minimize the potential for defects due to incomplete resin flow into the build area at higher build 
speeds. Therefore, the light intensity required for microneedle fabrication using an arbitrary 
Resin X could be calculated using Equation 3.11, below 
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦𝑅𝑒𝑠𝑖𝑛𝑋 =
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦𝑇𝑀𝑃𝑇𝐴∙𝐸𝑐,𝑅𝑒𝑠𝑖𝑛𝑋∙𝑆𝑝𝑒𝑒𝑑𝑅𝑒𝑠𝑖𝑛𝑋
𝑆𝑝𝑒𝑒𝑑𝑇𝑀𝑃𝑇𝐴∙𝐸𝑐,𝑇𝑀𝑃𝑇𝐴
  (3.11) 
Using Equation 11and the critical exposures in Figure 3.6B, build parameters for the new resins 
could be calculated. These build parameters are given in Table 3.1.  
 
Figure 3.7  Dimensions of Biocompatible MNs Produced Using Parameters from Working Curve. Height 
and width of TMPTA, PEG, PCL, and PAA microneedles. Intended dimensions are marked with a dotted line. 
PAA microneedle height and width were determined to be significantly different from all other compositions at a 
p<0.0001 significance level. Data are presented as mean ± SD 
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3.2.6 Production of Biocompatible CLIP Microneedles  
Using the build parameters established in section 3.2.5 (Table 3.1) and a z scale factor of 
1.175 (previously established for TMPTA microneedles in Chapter 2) biocompatible CLIP 
microneedles were fabricated. The dimensions of all microneedles produced using this technique 
were compared (Figure 3.7) to determine whether the working curve provided an effective 
method of producing equivalent parts from different resins. No statistically significant difference 
in dimensions of TMPTA, PEG, and PCL microneedles was found, but PAA microneedles 
truncated significantly relative to the other compositions (Figure 3.7)  This may indicate that 
either 1) the working curve is not an effective method for selecti ng the correct build parameters 
for any material or 2) the working curve is only effective for selecting build parameters for 
crosslinked systems due to differences in the mechanism of formation of linear and crosslinked 
systems. This question will be revisited in Chapter 4 using a range of resins. To correct PAA 
 
Figure 3.8  Biocompatible microneedles. ESEM images of A) Polyethylene glycol B) Polycaprolactone and C) 
Polyacrylic acid microneedles measuring approximately 1000µm in height and 333µm in width D) Dimensions, 
print times, and tip radii of biodegradable microneedles (n=9) shown in Figure 3. Scale bars measure 500µm. All 
data are represented as mean ± SD 
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microneedle dimensions for use in this chapter, microneedles were re-scaled in the z direction 
(the z scale factor was increased to 1.6, resulting in a 1600µm tall CAD file), to enable 
production of the desired 1000µm tall microneedles, as shown in Figure 3.8.  
Using this technique, fabrication of CLIP microneedles composed of PEG, PCL, and 
PAA was achieved (Figure 3.8A-C) and the structure of the CLIP microneedles was found to be 
consistent between resins.  Microneedles measured approximately 1000µm in height with an 
aspect ratio (AR=height/width) of 3, with all microneedles measuring within ±10% of their 
intended dimensions (Figure 3.8D). Tip radii for these biocompatible microneedles measure less 
than approximately 10µm, with fabrication times under 10 minutes per patch (Figure 3.8D).  
3.2.7 Microneedle Skin Insertion Tests 
In order to successfully deliver a cargo into the skin, CLIP microneedles must be capable 
of physically penetrating the statum corneum. The ability of CLIP microneedles to puncture the 
skin was assessed using murine skin ex vivo. Microneedle penetration studies have been 
commonly performed ex vivo; a number of animal models have been used as a source for skin, 
 
Figure 3.9  Skin insertion tests. Sites of skin penetration from CLIP Microneedle arrays made of A) PCL B) 
TMPTA C) PEG and D) PAA on murine skin can be visualized using a tissue marking dye. E) No insertion sites are 
visualized on a piece of control skin to which no microneedles were applied. Scale bars measure 1mm. 
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including nude mice, rats, and pigs. Murine skin is much thinner than human skin (murine skin is 
typically 300-500μm in thickness, whereas human skin varies widely in thickness, ranging from 
600-3,000μm, depending on location).22-24 Murine skin has also been shown to have vastly 
different mechanical properties than human skin.25 Nevertheless, full thickness skin excised from 
nude mice was utilized for testing ex-vivo due to availability and continuity with potential pre-
clinical in vivo studies. Further investigation of microneedle penetration using porcine skin, 
which is a better animal model, is performed in Chapter 4.  
Microneedles of all four different compositions (TMPTA, PAA, PCL, and PEG) were 
applied to murine skin ex vivo by pressing firmly on the back of the microneedle patches with the 
thumb for 10 seconds. The microneedle patches were then removed and a green tissue marking 
dye that selectively marks sites of skin penetration was applied.  All four microneedle 
compositions were observed to successfully breach murine skin (Figure 3.9A-D), whereas no 
sites of penetration were observed on untreated skin (Figure 3.9E). Some qualitative differences 
in the penetration efficacy of the four different microneedle compositions were observed. For 
example, the TMPTA and PAA microneedles appear to produce larger sites of penetration within 
the skin than the PCL and PEG microneedles, perhaps suggesting deeper penetration into the 
skin due to the superior mechanical properties of these compositions. Nevertheless, these results  
indicate that all four microneedle compositions exhibit sufficient strength to pierce murine skin. 
These materials may therefore be suitable for transdermal drug delivery in the form of CLIP 
microneedles.  
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3.2.8 Loading and Release of Fluorescent Drug Surrogate 
In order to determine whether CLIP microneedles can be utilized to encapsulate and 
release a therapeutic cargo, the fluorescent drug surrogate rhodamine was loaded into CLIP 
microneedles. Rhodamine was encapsulated by mixing 0.1wt% rhodamine into the 
photopolymerizable resin before fabricating the microneedle using the previously described 
methods. In order to demonstrate that cargo loading does not affect microneedle structure, 
microneedles were characterized by ESEM after cargo encapsulation (Figure 3.10 A-C). In order 
to assess cargo distribution within the microneedle matrix, rhodamine containing microneedles 
were also imaged via confocal microscopy (Figure 3.10 D-F). Results show that CLIP 
microneedles retain their structure after cargo incorporation. Rhodamine is uniformly distributed 
throughout the microneedle matrix.  
 
Figure 3.10 Rhodamine loaded CLIP MNs. Incorporation of rhodamine does not alter structure of A) PEG, B) 
PCL or C) PAA MNs characterized by ESEM. Rhodamine distributes throughout D) PEG, E) PCL, and F) PAA 
MNs needles visualized via confocal microscopy. The rhodamine channel is displayed in purple. Scale bars measure 
500µm.  
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To assess drug release rates out of CLIP microneedles in solution, rhodamine containing 
microneedle arrays were submerged in 1mL of phosphate buffered saline (PBS). Rhodamine 
release was assessed via fluorescence over one week for PCL and PEG microneedles, and over 
the course of one hour for PAA microneedles. 500µL of solution was removed for quantification 
at each timepoint and replaced with an additional 500µL of PBS. Rhodamine release rates as a 
percentage of theroretical loading are reported in Figure 3.11. Both the PEG and PCL 
microneedles release rhodamine slowly. Over the course of one week, PCL microneedles release 
less than 1% of their cargo, whereas PEG microneedles release about 5.5% of cargo (Figure 
3.11A). This slow, sustained release is expected due to the high crosslink density and slow 
degradation rates of PCL (typically on the order of months) and the highly crosslinked nature of 
the PEG matrix. The PAA microneedles, on the other hand, rapidly released all of their cargo by 
dissolution within 15 minutes. It is worth noting that release rates in aqueous media are likely to 
be more rapid than release rates in skin tissue (which is approximately 60-70% hydrated).26 
Nevertheless, release rates in solution provide a helpful mechanism for approximating release 
rates in skin. Together, these results indicate that CLIP microneedles can be utilized to tailor 
 
Figure 3.11 Rhodamine release rates Rates of rhodamine release from A) PEG, PCL and B) PAA MNs loaded 
with 0.1wt% rhodamine 
115 
 
drug release rates via appropriate matrix selection. Further consideration of the desired release 
rate and the properties of the desired cargo, such as solubility, charge, and size, would be 
necessary to select an optimal matrix for translational applications.  
3.2.9 Dissolvable PAA Microneedles Release Cargo in Skin  
Rapid release is ideal for applications being investigated within our laboratory, such as 
the delivery of insulin for diabetes treatment. Therefore, we continued to characterize cargo 
release from PAA microneedles both in solution and within murine skin ex vivo. In addition to 
rapidly releasing cargo, PAA microneedles should completely dissolve upon application, 
providing an opportunity to eliminate the production of sharp, biohazardous wastes.  In order to 
confirm that PAA microneedles are completely dissolvable, rhodamine containing PAA 
microneedles on a PCL backing were imaged before and after submersion in aqueous media 
(Figure 3.12).  Complete dissolution of the rhodamine containing PAA microneedles is observed 
within 15 minutes, leaving behind the water-insoluble PCL backing.  
We then wanted to determine whether PAA microneedles are capable of delivering cargo 
to the skin. Rhodamine containing and blank PAA microneedles were administered to murine 
 
Figure 3.12  Dissolution of Rhodamine Containing PAA Microneedles 
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skin ex vivo by applying a firm 10 second force of thumb to the back of the patch. Blank 
microneedles were removed after the 10 second application, but rhodamine containing 
microneedles were left in the skin for a period of 30 minutes to allow time for microneedle 
dissolution. Skin sections that came in contact with blank microneedles were then fixed, 
cryosectioned and stained with hematoxalin and eosin. Microneedle induced disruption of the 
stratum corneum can be observed in Figure 3.13A, whereas untreated skin sections remained 
intact (Figure 3.13B). Skin samples that came in contact with rhodamine containing PAA 
microneedles were then fixed, cryosectioned, and imaged with a fluorescence microscope. 
Rhodamine could be observed within the treated skin (Figure 3.13C), whereas no fluorescence 
could be observed in untreated sections (Figure 3.13D).  
Together, these results indicate that CLIP can be utilized to produce completely water 
soluble microneedles that breach the stratum corneum to deliver a fluorescent drug surrogate into 
the skin.  
 
Figure 3.13 Ex-vivo skin penetration and dye release. H&E stained skin sections show A) epidermal breach upon 
application of PAA microneedles but B) no epidermal breach in untreated control. C) The application of rhodamine 
containing polyacrylic acid microneedles releases rhodamine into the skin. D) No fluorescence is visualized in 
sections to which no microneedles were applied. All scale bars measure 100µm. 
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3.2.10 Production and Skin Testing of Tip-Loaded Microneedles  
The results in section 3.2.9 indicates that CLIP microneedles may be promising for 
transdermal drug delivery. However, microneedles have traditionally suffered from poor 
consistency of the dose delivered to the skin. A recent review of microneedle penetration depth 
into the skin showed that microneedles insert to anywhere between 10 and 80% of their total 
length.27  For biocompatible microneedle configurations, this variability in penetration depth 
directly correlates to variability in delivered dose. This variability is a concern for a majority 
(52%) of health care providers, who agreed that they “would not be confident that [they] had 
delivered the correct dose of a drug when using microneedles” in a 2011 survey published by 
Birchall et. al.28 
One approach that has been widely utilized in microneedle literature to combat dose 
inconsistency is concentrating the therapeutic in the tip of the microneedle.29-30 Tip-loaded 
microneedles have been shown to deliver a higher portion of the intended dose than traditional 
 
Figure 3.14  Tip loaded CLIP microneedles. The base of the microneedle is composed of PCL and rhodamine. 
The tip of the microneedle is composed of polyacrylic acid encapsulating fluorescein as a fluorescent drug 
surrogate. Scale bar measures 500µm. 
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needles;30 they also compensate for patient-to-patient variability in depth of penetration. 
Therefore, we aimed to produce tip-loaded CLIP microneedles.  
Tip-loaded CLIP microneedles were fabricated with a PCL base and PAA tip. 
Fluorescein was selected as a drug surrogate incorporated into the PAA tip, rhodamine was 
incorporated into the PCL base to enable visualization of the base via confocal microscopy. Both 
resins contained 2.5 wt% TPO as a photoinitiator. Fabrication of tip-loaded microneedles was 
achieved by exchanging the resin in the middle of the production process. The microneedle base 
was first fabricated using the PCL resin before pausing the build. The support plate was then 
lifted above the PCL resin pool, which was removed and replaced with acrylic acid resin. The 
remainder of the microneedle tip was then fabricated using the AA resin. 
A confocal micrograph of the tip-loaded microneedles is given in Figure 3.14. The 
rhodamine channel is displayed in red and the fluorescein channel is displayed in green; the 
overlay is displayed in yellow.  These results demonstrate that it is possible to localize a desired 
cargo, in this case the fluorescent drug surrogate fluorescein, to the tip of a CLIP microneedle.   
Importantly, this work also demonstrates the ability to combine rapid and sustained 
release of one or more therapeutic agents from a single microneedle device. Rapid release from 
the microneedle tip would be followed by sustained release from the base of the microneedle. A 
multitude of different applications could benefit from such a device. For example, a recent 
publication by DeMuth et. al. demonstrated that combining rapid and sustained release of soluble 
ovalbumin and poly I:C from microneedles for vaccine applications resulted in more T cell 
activation than rapid or sustained release alone.29 Coordinated delivery of multiple 
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chemotherapies to also holds promise to combat tumor heterogeneity and drug resistance, while 
minimizing toxicity.31-32  
In order to determine whether tip-loaded CLIP microneedles are capable of delivering 
their entire payload to skin, tip-loaded CLIP microneedles were applied to murine skin ex-vivo 
with 10 seconds of firm thumb pressure. In this case, microneedles containing a blank PCL base 
and rhodamine containing PAA tips were used to enable easy visualization of the red rhodamine 
tip. Microneedles were left in the skin for a period of 30 minutes prior to removal.  As shown in 
Figure 3.15, the rhodamine containing PAA tips completely dissolve within the skin, leaving the 
water-insoluble PCL base behind.  
3.2.11 Biocompatibility Testing 
As mentioned previously, the materials used in this chapter are photopolymerizable 
derivatives of materials that are Generally Recognized as Safe (GRAS) by the United States 
Food and Drug Administration (FDA). GRAS materials have undergone extensive testing to 
show that they are safe for human use; they are commonly used as food additives and in medical 
devices.  Adapting these GRAS materials for photopolymerization introduces additional 
 
Figure 3.15  Tip-loaded CLIP microneedles release entire payload in skin. Scale bars measure 1mm. 
120 
 
challenges that face all photopolymerized medical devices. These challenges include potential 
toxicity associated with 1) the photoinitiator, 2) any unreacted monomer/oligomer and 3) any 
non-degradable crosslinks created during photopolymerization, which need to be within a 
molecular weight range that is effectively cleared from the body.  
Unreacted acrylates and methacrylates, in particular, have been associated with 
cytotoxicity induced by non-specific cell membrane disruption.31 Nevertheless, methacrylate 
functionalized monomers and oligomers, particularly methyl methacrylate, have been widely 
utilized in biomedical applications as UV curable dental cements32 and as bone cements used to 
affix joint replacements to native bone.33 For these applications, minimizing the amount of 
unreacted monomer/oligomer is imperative to reducing side effects; reaction endproducts are 
biologically inert.  
Establishing the biocompatibility of a medical device, such as a CLIP microneedle patch, 
is a complex and lengthy process guided by International Standard ISO-10993, “Biological 
Evaluation of Medical Devices Part 1: Evaluation and Testing”. Although verifying complete 
biocompatibility of CLIP microneedle devices is outside of the scope of this dissertation, this 
section describes some in vitro cytotoxicity studies designed to probe the biocompatibility of 
CLIP microneedle devices, with a particular focus on the role of unreacted monomer/oligomer 
on biocompatibility. 
3.2.11.1 Cytotoxicity of CLIP Microneedle Arrays 
In order to test the biocompatibility of CLIP microneedles, a transwell cytotoxicity study 
was designed as shown in Figure 3.16A. One PEG, PCL, or PAA microneedle patch was placed 
inside of a cell culture insert (“transwell”) incubating with A549 human non-small cell lung 
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cancer cells in a 24 well plate. A549 cells were selected as a model cell line due to availability 
and easy handling. Cell viability was assessed after 24, 48, or 72 hr of incubation via MTT assay 
and compared to control cells incubated in the absence of a microneedle patch (Figure 3.16B). 
Cells incubated with either a PEG or a PCL microneedle patch showed a slight decrease in 
viability over the 72 hour time period, but viability remained greater than 80% for all timepoints, 
indicating that the PEG and PCL microneedles show promise for use as a biocompatible medical 
device. Longer term studies would need to be performed to analyze the toxicity of the 
degradation products. The PAA microneedles, on the other hand, show extreme toxicity, killing 
nearly all cells within 24 hours.  
In order to further characterize the biocompatibility of PEG and PCL microneedles, the 
study was repeated using both A549 and human umbilical vein endothelial cells (HuVECs). 
Performing testing on both cancerous and healthy cell lines provides additional information to 
indicate how these microneedle devices may interact with cancerous and healthy cells within the 
body. Although the previous study (Figure 3.16) investigated the cytotoxicity of microneedle 
patches with a 1mm patch backing, the patch backing was reduced to ~100µm thick for this 
 
Figure 3.16  Microneedle transwell study. A) Diagram of experimental design, which shows the microneedle 
containing porous transwell incubating in a cell culture plate B) MTT Assay for A549 cells incubating with one 
PEG, PCL, or PAA microneedle patch over 24 to 72 hr 
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study. This reduction in patch backing thickness provides a more accurate representation of an 
in vivo environment, where the patch backing is unlikely to significantly interact with cells 
within the body.  Cell viability for HuVEC and A549 patches incubated with PEG and PCL 
microneedles over 24, 48, and 72 hr is shown in Figure 3.17. All cells were found to have 
approximately 80% viability or higher over all timepoints, indicating that these materials show 
promise for utilization as a biocompatible microneedle device.  
The cytotoxicity of the PAA microneedles is further discussed in the remainder of this 
section, which seeks to understand the cause of PAA microneedle cytotoxicity through further 
characterization of the PEG, PCL, and PAA microneedle patches. 
3.2.11.2 Resin Cytotoxicity 
Differences in the biocompatibility of the three tested materials (PEG, PCL, PAA) may 
arise from one or more of several sources. These include potential differences in 1) the toxicity 
of the polymer, 2) the toxicity of the monomer/oligomer, 3) the quantitiy of unreacted monomer 
 
Figure 3.17  Cell viability of A549 and HuVEC cells incubated with A) PEG and B) PCL MNs over 24, 48, and 
72 h. Data are presented as mean±SD with n=3 wells per timepoint 
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/oligomer and/or initiator inside the microneedle, and 4) the rate of release of monomer/oligomer 
and/or photoinitiator out of the microneedle into cell culture medium. Experiments presented in 
this section aim to better understand the underlying cause of differences in microneedle toxicity 
between the compositions in an attempt to improve the biocompatibility of the PAA 
microneedles.  
The toxicity of unreacted oligomers (PEG550-dMa, PCL1110-tMa, AA) was assessed by 
serially diluting oligomers into to cell culture medium, starting with 1 v/v% oligomer in culture 
medium. A549 and HuVEC cells were then incubated with the solution of cell culture medium 
and oligomer. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay at 72 hr and compared to cells incubated with cell 
culture medium in the absence of oligomer (Figure 3.18). Although the HuVEC cells are more 
sensitive to oligomer than the A549 cells, both cell lines show that the AA monomer is more 
toxic than the PEG550-dMa and PCL1110-tMa oligomers. Higher toxicity of the AA monomer 
 
Figure 3.18  Oligomer toxicity and IC50 values. A) Toxicity of monomers on A549 cells B) Toxicity of 
monomers on HuVEC cells C) IC50 values of monomers on A549 and HuVEC cells. Concentrations are given 
as volume of monomer divided by total solution volume. 
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is expected because the reactive vinyl group is highly concentrated in this resin at one mole per 
72g monomer.  The reactive group is present at only one mole per 275g of the PEG550-dMa and 
one mole per 375g of the PCL1110-tMa by comparison. Therefore, the higher overall 
concentration of reactive groups in the AA resin is almost certainly one cause of the increase in 
toxicity of this resin relative to the others. Acrylate endgroups are also known to be more toxic 
than methacrylate endgroups,31 which would also contribute to the high toxicity of the AA 
monomer.  Therefore, this study suggests that differences in oligomer toxicity (caused by 
differences in both the concentration and reactivity of reactive groups)  are a contributing factor 
to the increased toxicity of PAA microneedles relative to other microneedle formulations.  
It is worth noting that the resins used for CLIP also contain photoinitiator that was not 
tested in these cytotoxicity studies due to poor solubility of TPO in cell culture medium. This 
poor solubility creates a turbid solution that interferes with the assay. For this reason, initiator 
toxicity is not investigated here, but is an important avenue for future investigation.  
3.2.11.3 Characterization of Unreacted Fractions 
In order to further investigate whether residual monomer is the cause of microneedle 
toxicity, the final composition of CLIP microneedle patches was characterized. For PEG and 
PCL microneedles, the soluble fraction of the microneedles was measured by swelling 
microneedle patches in methanol to extract residual oligomer and then removing solvent under 
heat and vacuum. Microneedles were then left to equilibrate to ambient humidity overnight prior 
to weighing to determine percent weight lost during extraction. Figure 3.19A shows the soluble 
fraction of the PEG and PCL microneedles. The maximum total wt% soluble acrylate is also 
plotted, calculated by multiplying the soluble fraction by the fraction of each monomer (wt%) 
made up of methacrylate endgroups. Although this approach assumes that the entire soluble 
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fraction is monomer (which is unlikely), it presents a useful “worse case scenario” for the 
concentration of soluble acrylate. Both the PEG and PCL microneedles have low soluble 
fractions near 1wt%, with total weight percent solublee acrylate at or below 0.25wt%.  
The soluble (“sol”) fraction, or the portion of a sample that is not reacted into a 
crosslinked network, is not an appropriate metric for an uncrosslinked polymer such as PAA. 
Water soluble materials like PAA are more typically dissolved and analyzed by aqueous gel 
permeation chromatography (GPC) to obtain a molecular weight distribution. Due to lack of an 
available aqueous GPC system, an alternate method was developed to estimate how much 
unreacted AA remained in the microneedle. Characterization was accomplished by soaking PAA 
 
Figure 3.19  Soluble and low molecular weight fraction of PEG, PCL, and PAA MNs 
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microneedle patches in acetone to extract AA monomer and low molecular weight oligomer 
from the patch; PAA is insoluble in acetone and is therefore not extracted. The acetone extract 
was then diluted in water and titrated to determine the concentration of acid. The “low molecular 
weight fraction” was calculated by taking the acid mass in the extract and dividing it by the total 
mass of the PAA microneedle patch (Figure 3.19B). In general, a large fraction (between 2wt% 
and 12wt%) of the PAA microneedle was found to be soluble in acetone. A portion of this 
extract may be toxic, unreacted AA monomer.  
Several purification processes were investigated in an attempt to eliminate unreacted 
monomer from the PAA microneedle. These processes included postcuring the microneedles 
under a mercury lamp for 10 minutes to complete the reaction and heating the microneedles 
under vacuum to remove residual monomer (Figure 3.19B). These purification steps do reduce 
the low molecular weight fraction from approximately 12wt% to approximately 2wt% (Figure 
3.20B), but do not completely eliminate the extractable fraction. One would expect the monomer 
 
Figure 3.20  Cytotoxicity of Purified and Unpurified PAA MNs. Unpurified MNs were tested directly after 
printing plus a brief acetone wash. Purifed MNs were tested after the brief acetone wash plus post cure plus 48 
hours of heating at 120°C for 48 hr 
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to be completely removed after 48 hr of incubation under vacuum at 120°C due to the volatility 
of the AA monomer (its vapor pressure is 0.4 kPa at 20°C and boiling point is 141°C). 
Therefore, we hypothesize that the remaining 2wt% is either dimer or low molecular weight 
oligomer, which may still be cytotoxic in cell culture.  
In order to determine whether purification of the PAA removed a sufficient amount of 
monomer to enable cytocompatibility, the transwell experiment described in Figure 3.17A was 
repeated. Unpurified PAA microneedles and PAA microneedles that were postcured and heated 
to 120°C under vacuum were added to porous cell culture inserts and allowed to incubate with 
cells for 24, 48, or 72 hours. Figure 3.20 shows that the purification steps used to remove 
residual monomer do improve the cellular response to the PAA microneedles, but even the 
purified microneedles are still toxic after 72 hours.  
We then decided to compare the calculated extractable for each of the three different 
microneedle compositions (PEG, PCL, PAA) to the IC50 values for monomer toxicity 
established in Figure 3.18 to determine whether unreacted monomer is the cause of toxicity. A 
Table 3.3 Comparison of extractable fractions and monomer IC50 values. When complete release of the 
extractable fraction produces concentrations (row 1) that are higher than the IC50 value, the IC50 value is shown in 
red. When complete release of the extractable fraction produces concentrations (row 1) that are lower than the IC50 
value, the IC50 value is shown in green.  
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conclusive determination of the concentration of unreacted monomer within each extractable 
fraction is not possible because it may contain low molecular weight oligomers as well as 
monomers. Nevertheless, if we assume that the entire extractable fraction is monomer, this 
fraction can then be converted to volume percent monomer in cell culture medium and compared 
to the monomer IC50 values (Table 3.2). Calculations assume complete release of the extractable 
fraction into cell culture medium. 
Interestingly, the cytotoxicity predicted by this calculation differs from the measured 
cytotoxicity (Figures 3.16 and 3.17). Complete release of the PAA extractable fraction would 
produce concentrations of monomer that are higher than the IC50 value of AA on cells. 
Therefore, PAA microneedles are predicted to be cytotoxic on the basis of monomer 
concentrations alone, and were confirmed to be toxic in Figure 3.16.  However, complete release 
of the soluble fraction from PEG or PCL microneedles should also be cytotoxic to HuVECs, 
despite their measured cytocompatibility. Therefore, we hypothesize that cytotoxicity results are 
also heavily influenced by the rate at which the soluble fraction is released into cell culture 
medium. Assessing PEG and PCL microneedle cytotoxicity at longer time points and/or in vivo 
toxicity studies are necessary to confirm that PEG and PCL microneedles have no adverse effects 
even after complete release of the soluble fraction. 
3.3 Conclusions 
Herein, we report the fabrication of CLIP microneedles from three different materials 
(PEG, PCL, and PAA), which were designed to encapsulate and release therapeutic cargo via 
swelling, degradation, or dissolution, respectively. All microneedles effectively breached murine 
skin when applied with firm thumb pressure, indicating that these materials may be strong 
enough to be utilized as microneedle devices. All materials were loaded with the fluorescent 
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drug surrogate rhodamine, which released at different rates, ranging from complete release 
within 15 minutes to less than 1% release over 7 days, depending on microneedle composition. 
When tested on murine skin ex vivo, PAA microneedles demonstrate the ability to release 
rhodamine into skin. Excitingly, CLIP also enabled tip-loaded microneedles to be produced, 
which release all of the encapsulated cargo into the skin. Some initial studies were also 
performed to assess the biocompatibility of CLIP microneedle devices. PEG and PCL CLIP 
microneedles were nontoxic in cell culture, but PAA microneedles exhibited severe cytotoxicity. 
 
Figure 3.21  Reaction scheme for PCL-trimethacrylate synthesis. PCL was functionalized by reacting hydroxyl 
groups from a PCL-triol with methacryloyl chloride. 1H NMR spectrum confirms methacrylate functionalization 
with peaks at 6.08 (c), 5.54 (b) and 1.93 ppm (d).  Degree of functionalization was determined to be 89% by 
comparing the peak areas corresponding to the vinyl protons (c and b, 6.08 and 5.54 ppm) to the protons of the 
methyl group in the PCL backbone (a, 0.89 ppm). 
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The concentration and release rate of unreacted monomer are hypothesized to be primary drivers 
of the in vitro cytotoxicity. Future work will continue to investigate the biocompatibility of CLIP 
microneedle arrays in an attempt to develop a safe and efficious CLIP microneedle device for 
transdermal drug delivery.  
3.4 Experimental 
3.4.1 Synthesis of Polycaprolactone Trimethacrylate  
Polycaprolactone trimethacrylate (PCL-tMa) was synthesized from a commercially 
available poly-ε-caprolactone (PCL) triol (Sigma Aldrich) with an average molecular weight of 
900g/mol (55.14 g, 61.3 mmol). The reaction scheme is given in Figure 3.21. 
PCL triol was dried in a vacuum oven prior to use. A reaction flask was equipped with an 
addition funnel, sealed with rubber septa, and placed under magnetic stirring and N2 flow. 
Distilled dichloromethane (DCM, 200mL, Fisher Scientific) and triethyamine (TEA, 275.9 
mmol, Fisher Scientific) was added to a flask placed under magnetic stirring and N2 flow in an 
ice bath.  Methacryloyl chloride (MAcCl, 275.7 mmol, Sigma Aldrich) was added dropwise from 
the addition funnel over one hour and the reaction was allowed to proceed overnight.  The 
byproduct TEA•HCl salt was filtered off and the filtrate was washed with sodium bicarbonate, 
dried over magnesium sulfate, and the DCM was removed by rotary evaporation.  Confirmation 
of the final product was done by 1H NMR (Figure 3.21). 
3.4.2 Determination of Critical Exposure 
Methods for the determining critical exposure were adapted from Tumbleston et. al.19 
Briefly, 500µL of resin was placed on a cover slip on top of the printer window. Resin was 
exposed to a specified dosage of light (λ=365nm LED) in a circle pattern and residual, unreacted 
monomer was removed using an acetone wash. The height of polymerized circles was then 
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measured using a Mitutoyo Electronic Indicator (McMaster Carr). Resins utilized in this study 
were acrylic acid (Acros Organics, 99.5% purity), a poly-ε-caprolactone (PCL) trimethacrylate 
synthesized in house, and poly (ethylene glycol) dimethacrylate (Mn 550, Sigma Aldrich) mixed 
with 2.5 wt% Diphenyl(2,4,6-trimethyl-benzoyl-)phosphine oxide (Sigma Aldrich) as a 
photoinitiator.  
3.4.3 Fabrication of Biocompatible Microneedles 
To produce microneedles of different heights, CAD files of square pyramidal 
microneedles measuring 1000µm tall with an aspect ratio of 3 (aspect ratio= height/width) were 
generated using Solidworks 2014. All microneedles were spaced at one base width apart on a 
base measuring 6x6x1mm. CAD files were then sliced at 1μm slice thickness using the open 
source software Slic3r. Microneedles were then produced using a CLIP additive manufacturing 
system (Carbon 3D, Redwood City, CA) using polycaprolactone trimethacrylate (PCL1110-
tMa), polyethylene glycol550 dimethacrylate (PEG550-dMa), or acrylic acid (AA), each mixed 
with 2.5wt% diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide (Sigma Aldrich) (TPO) as a 
photoinitiator.  PAA microneedles, PCL microneedles, and PEG microneedles were all printed at 
25mm/hr, with 8.9, 1.5, and 1.2 mW/cm2 of light(λ=370nm LED), respectively. All needles were 
washed briefly with acetone and dried using compressed air. Microneedles were imaged using an 
environmental scanning electron microscope (FEI Quanta 200) in low vacuum mode.  
Tip-loaded microneedles were fabricated from polycaprolactone trimethacrylate mixed 
with 0.05wt% rhodamine B base (Sigma Aldrich) and acrylic acid mixed with 0.05wt% 
fluorescein (Sigma Aldrich). Both resins contained 2.5wt% TPO as a photoinitiator. Slices 1 
through 1700 were fabricated using PCL prior to lifting the build elevator, removing residual 
resin, and continuing to fabricate the remainder of the microneedle (slices 1701 through 2000) 
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using acrylic acid. Microneedles were post-cured under a mercury lamp for 10 min between 
compositions and after fabrication was complete.  
3.4.4 Microneedle Dissolution and Rhodamine Release Studies in Solution 
To model drug release profiles, all microneedle compositions were loaded with 0.1wt% 
Rhodamine B Base (Acros Organics). All microneedles were fabricated on a blank base 
containing no rhodamine. The resin was then replaced with resin containing rhodamine prior to 
fabricating the microneedles using the build parameters given in Section 1.4.3. One microneedle 
patch was added to 1mL of phosphate buffered saline (PBS) in an Eppendorf tube (n=3 for each 
composition). The Eppendorf tubes were placed in a 37°C water bath. 0.5 mL of the supernatant 
was removed at each time point and replaced with an additional 0.5mL of PBS. Quantification of 
released rhodamine was performed by measuring fluorescence of the supernatant using a plate 
reader with excitation and emission of 544 and 590nm, respectively. Fluorescence was correlated 
to a standard curve to determine rhodamine mass released, then taken as a percent of theoretical 
rhodamine loading, calculated from microneedle volume and density.  
To test for acrylic acid microneedle dissolution, one patch with a polycaprolactone base 
and polyacrylic acid microneedles contining 0.1wt% rhodamine was submerged in 10mL PBS. 
The microneedle patch was imaged before and after dissolution using a Leica MZ16FA 
macroscope in brightfield mode. 
3.4.5 Skin Penetration Studies 
Patches were tested on nude murine skin ex vivo with permission of the UNC Institutional 
Animal Care and Use Committee (IACUC). All samples were stored at -20°C until testing 
occurred. Prior to testing, skin was thawed briefly at room temperature and pinned over 
corkboard. CLIP microneedles were post-cured under a mercury lamp for 5 minutes to improve 
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mechanical strength prior to application.  Microneedle patches were then applied to the skin with 
10 seconds of thumb pressure before patch removal. A 50:50 mixture of Green tissue marking 
dye (Cancer Diagnostics) and isopropanol was then applied to the site for 3 minutes before being 
wiped away with water and isopropanol. Skin was imaged to visualize sites of microneedle 
insertion using brightfield macroscopy (Leica M420).  
To further confirm skin penetration using histology, polyacrylic acid microneedles were 
applied to murine skin ex vivo with 10 seconds of thumb pressure before patch removal. Murine 
skin sections were then embedded in Tissue-Tec Optimum Temperature Cutting Medium 
(Sakura Finetek), bisected, and sectioned in 12 micron slices at -25°C (Leica Cryostat). Samples 
were H&E stained (Cryo-KIT, Cancer Diagnostics) and visualized using brightfield microscopy 
(Olympus BX61 Upright Brightfield Microscope).  
To test for dye release via histology, polyacrylic acid microneedle patches containing 
0.1wt% rhodamine B were applied to murine skin ex vivo and left to dissolve in the skin for 30 
minutes. Samples were then briefly fixed in FROZEN-FIX (Cancer Diagnostics) for 10 seconds 
and visualized using fluorescence microscopy (Olympus BX61 Upright Fluorescence 
microscope).  
To test for dye release from tip-loaded microneedles, tip-loaded microneedles were 
fabricated from blank polycaprolactone and a polyacrylic acid tip containing 0.1wt% rhodamine 
B base, as previously described. Microneedles were applied to murine skin ex vivo with gentle 
thumb pressure for a period of 10 seconds. Microneedles were then allowed to remain the the 
skin for a period of 30 minutes prior to imaging using a Leica MZ16FA macroscope in 
brightfield mode. 
134 
 
3.4.6 Characterization of Extractable Fractions 
PEG and PCL MN soluble fractions were determined by submerging three microneedle 
patches with 1mm backings in approximately 200mL of methanol (MeOH) over 24 hr. 
Microneedle patches were removed and heated to 100°C for 24 hr under vacuum. Microneedle 
patches were then removed from the vacuum and allowed to equilibrate to ambient humidity 
overnight prior to weighing to determine percent mass lost.  
PAA extractable fraction was determined by submerging a single microneedle patch with 
a 1mm backing in acetone for 24 hours. The supernatant was then removed and diluted in 
deionized water. The concentration of acid within the supernatant was determined via standard 
acid-base titration.  
3.4.7 Cytotoxicity of Photoreactive Monomer and Microneedle Arrays 
To assess monomer toxicity, cells were seeded in 200 μL of media [RMPI 1640 Medium 
for A549; HuMEC for HuVEC] at a density of 5000 cells per cm2 into a 96-well microtiter plate. 
Cells were allowed to adhere for 24 hr and subsequently incubated with medium containing 1 to 
0.0006% (v/v) monomer. After a 72 hr incubation period, all media were aspirated off cells. 100 
μL fresh medium was added back to cells, followed by the addition of 100 μL CellTiter-Glo® 
Luminescent Cell Viability Assay reagent (Promega, Madison, WI). Plates were placed on a 
microplate shaker for 2 min, then incubated at r.t. for 10 min to stabilize luminescent signal. The 
luminescent signal was recorded on a Molecular Dynamics SpectraMax M5 plate reader. The 
viability of the cells was expressed as a percentage of the viability of cells grown in the absence 
of monomer.  
To assess microneedle toxicity, cells were seeded in 1 mL of media at a density of 5000 
cells per cm2 into a 24-well microtiter plate. Cells were allowed to adhere for 24 hr and 
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subsequently incubated with 2mL of culture medium and a cell culture insert containing a 3µm 
pore size. A microneedle patch was added to each well at 72 hr, 48 hr, or 24 hr timepoints. After 
a 72 hr incubation period, all media were aspirated off cells. 1 mL fresh medium was added back 
to cells followed by the addition of 100 μL CellTiter-Glo® Luminescent Cell Viability Assay 
reagent (Promega, Madison, WI). Quantification was performed as previously described. 
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CHAPTER 4 MICRONEEDLE MECHANICAL PROPERTIES AND SKIN PENETRATION   
 
4.1  Introduction  
Microneedles have traditionally suffered from poorly controlled depth of penetration into 
the skin, which directly contributes to variability in delivered dose.  A recent review of 
microneedle penetration depth showed that microneedles insert to anywhere between 10 and 
80% of their total length.1  This variability is a concern for a majority (52%) of health care 
providers, who agreed that they “would not be confident that [they] had delivered the correct 
dose of a drug when using microneedles” in a 2011 survey published by Birchall et. al.2 
Therefore, characterizing the factors that influence the depth and consistency of microneedle 
penetration is crucial to the advancement of microneedle technology.3  
A multitude of different microneedle design parameters, including microneedle height,3-6 
shape,7-8 aspect ratio,9-11 tip radius,1, 11-12 and composition,13 are known to affect microneedle 
insertion to the skin. Chapter 2 and Chapter 3 demonstrate the unique ability of CLIP to 
systematically control such design variables in a high throughput fashion. Therefore, we 
hypothesized that CLIP would be an ideal tool for further investigation of microneedle insertion 
mechanics. Composition was selected as the first design variable to be studied (as opposed to 
size, shape, etc.) because 1) it began to affect preclinical microneedle development in our 
laboratory (Figure 5.2) and 2) composition is a contributing variable to any study investigating 
microneedle geometry. Therefore, the relationship between composition and insertion serves as 
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an important baseline that will inform future investigation of the role of CLIP microneedle 
geometry on insertion into the skin.   
A variety of materials with different mechanical properties have been utilized for 
microneedle device manufacturing. The relationship between the stress and strain of these 
materials, either in tension or compression, provides interesting insight into material 
performance. A representative example of two types of stress strain curves is given in Figure 4.1. 
Materials can be classified as brittle materials, which fracture with minimal deformation, and 
elastomeric materials, which exhibit large deformations prior to material failure. Both types of 
materials have been utilized for the manufacture of microneedle arrays.  
In order for a microneedle to successfully puncture the skin, the force required to insert 
the needle into the skin (Finsertion) must be less than the force applied to the back of the 
microneedle array (Fapplied). In order to prevent breakage, the insertion force and the applied force 
need to be less than the fracture force (Ffailure), which is the force that causes the needle to 
fracture (Equation 4.1).  
Figure 4.1 Typical Stress-Strain Curve 
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𝐹𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛 < 𝐹𝑎𝑝𝑝𝑙𝑖𝑒𝑑 < 𝐹𝑓𝑟𝑎𝑐𝑡𝑢𝑟𝑒    (4.1) 
Generally, microneedles can fail to insert into the skin via one of two different 
mechanisms, either 1) lack of penetration of an intact microneedle device or 2) fracture of the 
microneedle device. Device fracture is more likely for microneedles fabricated from brittle 
materials, such as silicon microneedles, which frequently fragment within the skin.14-15 In this 
case, the applied force is greater than the fracture force (𝐹𝑎𝑝𝑝𝑙𝑖𝑒𝑑 > 𝐹𝑓𝑟𝑎𝑐𝑡𝑢𝑟𝑒), causing the 
device to break. Microneedles can also fail to puncture the skin because the applied force is too 
small (e.g. 𝐹𝑎𝑝𝑝𝑙𝑖𝑒𝑑 < 𝐹𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛). Tough, rubbery microneedles are more likely to fail to insert 
by this mechanism due to their tendency to absorb a large portion of the applied force through 
deformation. Therefore, although Equation 1 holds true regardless of material selected for device 
manufacture, the dominant factor in the equation is dictated by the mechanical properties of the 
chosen material. 
The mechanical properties of a CLIP microneedle array can be controlled by deliberately 
altering the components of the photopolymerizable polymer network. This change in mechanical 
properties can be accomplished by either changing the chemical structure of the components, or, 
in our case, by changing the relative quantity of each component. In this chapter, we control the 
mechanical properties of PEG microneedles by changing the material’s crosslink density, defined 
as the number of crosslinked monomer units per main chain. Varying ratios of polyethylene 
glycol 550 dimethacrylate (PEG550dMa) and ethylene glycol dimethacrylate (EGdMa) are 
utilized to produce microneedles with a range of mechanical properties. The ability of these 
microneedles to insert into the skin using a range of application forces is assessed with the 
ultimate goal of defining the microneedle mechanical characteristics necessary for the production 
of a successful microneedle device.  
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4.2 Results and Discussion 
4.2.1 Skin Penetration of Biocompatible Microneedles on Murine Skin 
Chapter 3 demonstrated that CLIP microneedles composed of four different materials 
(TMPTA, PEG, PCL, and PAA) were capable of piercing murine skin ex vivo when applied 
using firm thumb pressure. Murine skin, however, is a poor model for human skin because it is 
much thinner than human skin (murine skin is typically 300-500μm in thickness, whereas human 
skin varies widely in thickness, ranging from 600-3,000μm)16-17 and is mechanically weaker than 
human skin.18 Porcine skin is widely used for microneedle insertion testing in literature, and is 
considered to be a good model for human skin due to its similar thickness, mechanical 
properties, and permeability.18-21Therefore, we tested the previously fabricated microneedle 
compositions (TMPTA, PEG, PCL, PAA) for insertion into porcine skin ex vivo, applying the 
patches to skin using 10 seconds of firm thumb pressure (Figure 4.2). Results show that only 
TMPTA and PAA microneedles were capable of puncturing porcine skin. It is almost certain that 
PAA and TMPTA microneedles pierce porcine skin more effectively due to their superior 
mechanical properties as compared to PCL and PEG. PAA and TMPTA both have glass 
 
Figure 4.2 Skin Penetration on Murine and Porcine Skin A) PAA, B) TMPTA, C) PCL, and D) PEG CLIP 
microneedles effectively pierce murine skin, but the E) negative control shows no sites of penetration. F) PAA 
and G) TMPTA microneedles effectively pierce porcine skin, but H) PCL microneedles, I) PEG microneedles 
and J) the negative control show no sites of penetration. Scale bars measure 1mm. 
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transition temperatures (Tg) above room temperature, whereas PCL and PEG have subzero glass 
transition temperatures. Therefore, PAA and TMPTA act as rigid, glassy materials at room 
temperature, whereas the PEG and PCL are elastomeric. This difference in the efficacy of 
insertion as a function of composition underscores the critical importance of microneedle 
composition in eliciting effective skin penetration. We therefore aimed to identify mechanical 
requirements necessary to enable microneedles to effectively insert into the skin.  
4.2.2 Fabrication of PEG Microneedles with Varying Crosslink Density 
Increasing the crosslink density of a polymeric network decreases segmental motion, 
resulting in an increase in Tg and stiffness (Young’s modulus, E) and decreased elongation 
(strain, ε) at break.22-24 In particular, increasing the crosslink density of (meth)acrylate 
functionalized PEG elastomers results a shift in mechanical behavior from that of a rubbery 
elastomeric material to that of a brittle plastic.25-26  These changes in the mechanical properties of 
PEG hydrogels are due to a combination of decreased segmental motion of the PEG chains due 
to the crosslinks and the increase in the concentration of (meth)acrylate end groups as chain 
lengths shorten, which results in an increase in the mass of the alkyl backbone generated by 
photopolymerization relative to the mass of the PEG chain. The ability to alter the mechanical 
properties of the PEG hydrogel as a function of crosslink density provides an ideal model system 
Table 4.1 Composition of PEG Blends Utilized in Chapter 4 
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to investigate how the mechanical properties of CLIP microneedles affect their skin penetration. 
Therefore, we aimed to fabricate CLIP microneedles from varying ratios of polyethylene glycol 
550 dimethacrylate (PEG550-dMa) and ethylene glycol dimethacrylate (EG-dMa) (Table 4.1) 
All resins were mixed with 2.5wt% TPO as a photoinitiator.  
It should be noted that PEG was selected as a model material because dimethacrylate 
functionalized PEG is commercially available in a number of different molecular weights. We do 
not, however, anticipate that PEG will be an ideal matrix for therapeutic applications because it 
has slow release rates (Figure 3.12.) even at crosslink densities that are too low to enable 
effective skin penetrations (Figure 5.2). Stronger materials will therefore be necessary for 
 
Figure 4.3 Stereolithographic Working Curve and Resin Properties for PEG Blends. A) The cure depth of 
microneedle resins as a function of applied dosage B) Absorption coefficient and critical exposure of 
microneedle resins determined from the working curves in figure A. The build parameters for each resin were 
calculated as described in Chapter 4 and are also listed.  
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translational applications. Nevertheless, dimethacrylate functionalized PEG provides an ideal 
model for this fundamental mechanics study. 
Build parameters for microneedle fabrication using PEG blends were determined using 
the method presented  in Chapter 3. This method compensates for differences in resin reactivity 
and reaction volume to identify the appropriate light intensity for the fabrication of microneedles 
using new resins. As in the previous chapter, all resins had approximately equivalent absorbance 
due to equal concentrations of the photoinitiator TPO. Microneedles were fabricated at 25mm/hr 
in order to ensure that resin was able to completely flow into the build area during the print. The 
working curve and resulting light intensity used for microneedle fabrication are given in Figure 
4.4. Generally, increasing the wt% EG-dMa led to an increase in the critical exposure required 
for cure. Therefore, more light was required for fabrication of highly crosslinked microneedles.  
 
Figure 4.4. CLIP Microneedles Fabricated from PEG Blends. CLIP Microneedles are fabricated from A) 
Neat PEG550-dMa and B)50-50, C)67-33, D) 59-41,and  E)50-50ratios of PEG550-dMa to EG-dMa. All 
formulations are mixed with 2.5wt% TPO as a photoinitiator. Scale bars measure 500µm. 
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Microneedles were then fabricated using calculated build parameters on the CLIP7 
additive manufacturing system. All PEG microneedles were found to have approximately 
equivalent structure, regardless of crosslinking density (Figure 4.4). Further analysis of 
microneedle dimensions demonstrated that all microneedle dimensions were found to be within 
2.5% of the intended dimensions (Table 4.2). No statistically significant differences in the 
height, width, or tip radius of the microneedle arrays were found. Therefore, we can conclude 
that the working curve method of build parameter identification developed in Chapter 4 
adequately calculates light intensity values that enable the production of dimensionally accurate 
CLIP microneedles. This result also underscores the “plug-and-play” nature of the CLIP 
microneedle fabrication process, which enables CLIP microneedles of virtually any composition 
to be fabricated with little to no lead time. We then proceeded to evaluate the mechanical 
properties of the PEG blends.  
4.2.3 Mechanical Properties of PEG Blends 
The mechanical properties of the photo-cured PEG blends were evaluated in compression 
according to ASTM Standard F451-08 “Standard Specification for Acrylic Bone Cement”. 
Compression testing (as opposed to testing in tension) was chosen to mimic microneedle 
application. Cylindrical test samples measuring 12mm in length and 6mm in diameter were 
Table 4.2 Dimensions of CLIP Microneedles Fabricated with PEG Blends. Data are presented as mean ±SD 
(n=9). No statistically significant difference in microneedle dimensions were found. Statistics were performed 
via one way ANOVA with Tukey’s honestly significantly different (HSD) post-test 
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fabricated by CLIP using the same light intensity and build speeds used for microneedle 
fabrication (Figure 4.3). Test cylinders were post-cured for 10 minutes under UV light 
(equivalent to microneedle arrays) prior to mechanical testing. The mechanical properties 
identified by analysis of the stress-strain curves are given in Figure 4.5.  
The mechanical properties of PEG blends follow expected trends. As crosslink density 
increases (i.e. as the weight percent EGdMa increases), the material becomes more stiff. Young’s 
moduli range from approximately 80MPa for pure PEG550dMa to approximately 1.5 GPa for the 
PEG550dMa-EGdMa 50-50 blend. Fracture stress also increased as the crosslink density 
increased between the PEG550dMa and the PEG550dMa-EGdMa. Further increases in crosslink 
density have essentially no effect on fracture stress. Similar results have been previously 
published by Ortega et. al., who showed that increases in fracture stress of PEG based 
photopolymers as a function of crosslink density are more dramatic at low crosslink densities.27  
The strain at failure decreases as crosslink density increases, as expected, due to the increased 
rigidity of the crosslinked networks. Therefore, we successfully produced photo-cured PEG 
 
Figure 4.5 Mechanical Properties of PEG Blends. A) Young’s moduli, B) Failure stress and C) Strain at failure 
for all PEG blends. Failure stress and strain at failure were determined using a zero slope method. Data are 
presented as mean ±SD (n=3) 
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blends with a range of mechanical properties that can  be utilized to assess how material 
properties affect microneedle insertion.  
Ideally, the mechanical properties of CLIP microneedles would be measured directly 
rather than using a macroscopic test cylinder to determine mechanical properties. However, 
measuring the mechanical properties of a microneedle is challenging because of the changing 
cross sectional area of a microneedle (which makes it difficult to accurately determine stress) and 
the small dimensions of the structure. Therefore, the gel fraction and solvent uptake of test 
cylinders and  microneedle patches were compared to confirm that they are composed of  
equivalent materials (Figure 4.6). Small differences in gel fraction and solvent uptake of the 
cylindrical test sample and the microneedle patch were found. In general, the gel fraction of the 
microneedle patches was less than that of the cylindrical test samples.  The solvent uptake of the 
microneedle patches was greater than that of the cylindrical test samples. These results suggest 
that the crosslink density of the microneedle patches may be slightly less than the crosslink 
density of the test cylinders. The shape of the structures may also play a role. Nevertheless, 
 
Figure 4.6 Gel Fraction and Solvent Uptake of PEG Networks. Cylindrical test samples and microneedle patches 
were found to have similar A) gel fractions and B) solvent uptakes. Data are presented as mean ± SD (n=3).  
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differences in solvent uptake between shapes are much less than the differences between 
compositions. Therefore, we assume that the test cylinders and microneedle patches are 
composed of relatively equivalent materials throughout the remainder of this chapter.  
4.2.4 Quantification of Microneedle Insertion Forces 
The force used to apply a microneedle device (Fapplication) is an important variable 
affecting the efficacy of insertion. In microneedle literature, investigators frequently apply 
microneedles to the skin by pressing firmly on the back of the patch with their thumb. Bearing in 
mind that the vast majority of microneedles in preclinical literature are applied using “force of 
thumb”, we aimed to quantify “force of thumb” for ten different people in order to determine 1) a 
relevant range of applications forces for studies where microneedles are inserted using a more 
quantitative application force and 2) to determine how much variability in “force of thumb” 
exists among potential microneedle users. It may be necessary to develop a simple microneedle 
applicator to improve the consistency of insertion between users in a clinical setting; the studies 
presented here will provide information regarding user to user variability to determine whether 
an applicator is necessary. 
 
Figure 4.7 Study Design for Quantifying Force of Thumb 
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Ten study participants were recruited, ranging in age from 21 to 70 years old. Each 
participant was asked to apply three equal forces of five second duration (Figure 4.7). First, each  
participant used their thumb to press against their upper arm to identify a comfortable force for 
application of a microneedle array (Figure 4.7A). Each participant was then asked to use the 
same force to apply pressure to the back of a microneedle array.  This microneedle array was 
resting on full-thickness porcine skin sitting on a piece of corkboard. The entire assembly was 
placed on top of an Instron compression plate connected to a load cell used to measure the 
application force (Figure 4.7B). Lastly, each participant applied the force directly to the Instron 
 
Figure 4.8. Quantification of Force of Thumb. A) Force vs. time curves for ten participants applying 
microneedle patches to porcine skin B) Quantification of the force applied by each of ten participants 
directly to the microneedle patch and to the compression plates. These forces correspond to the diagram in 
Figure 5.7 B and C, respectively   C) Rate at which the force is applied and released from the microneedle 
patch for each of the ten participants 
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compression plate. This final force acted as a control intended to determine whether the 
microneedle array/corkboard assembly would absorb enough energy to alter the force 
experienced by the load cell. No significant difference in applied force was found with and 
without the corkboard (data not shown). Therefore, the results were taken from force B (Figure 
4.7), where participants applied force directly to the microneedle patch. The force of thumb was 
taken by averaging the force applied during the 5 second plateau in force; force values during 
application and release were ignored in this quantification.  
Figure 4.8 shows that a large amount of variability in applied force was observed 
between participants. Force of thumb ranged from 4N to 80N, with an average application force 
of approximately 25N (Figure 4.8B). The rate of application and release of this force ranged 
from 5 to 130 N/s, with an average of approximately 25 N/s. These values fall within the same 
range as forces reported in a similar study by Larraneta et. al.21 Therefore, we decided to 
investigate microneedle insertion using controlled application forces of 6N, 12.5N, 25N, and 
75N applied and released at 25 N/s.These forces fall within the range of forces that can be 
applied via thumb pressure and may therefore provide a comfortable range of application forces 
for patients in a clinical setting.   
4.2.5 Percent Insertion as a Function of Composition and Applied Force 
We then aimed to investigate how microneedle composition and applied force affect 
microneedle insertion into the skin. Microneedles composed of all PEG blends (Figure 4.4, Table 
4.2) were applied to porcine skin ex vivo using a controlled application force of  6N, 12.5N, 25N, 
or 75N. Force was applied using an Instron Universal Testing Station with application and 
release rates of 25N/s. To determine whether microneedles fracture during/prior to insertion, all 
microneedles were imaged after application.  No evidence of microneedle fracture was found for 
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any of the compositions at any applied force; an image of intact microneedles after application to 
skin with 75N of force is shown in Figure 4.9. Based on this data, we can conclude that the 
microneedles that fail to insert into the skin because the force required to insert the array into the 
skin (Finsertion) is greater than the applied force (Fapplied), not due to microneedle fracture. 
After microneedle application  to porcine skin, sites of insertion were marked with tissue 
marking dye, as shown in Figure 4.10 The percentage of microneedles that insert into the skin 
was calculated by counting the number of insertion sites and dividing by the total number  of 
microneedles within the array. Figure 4.10 provides an example of a microneedle array that does 
not penetrate the skin (Figure 4.10A), an array that partially punctures the skin (Figure 4.10B) 
and an array that completely punctures the skin (Figure 4.10C). 
 
Figure 4.9 PEG Microneedle Arrays After Application with 75N Force. Microneedles composed of A) 
PEG550dMa, B)PEG550dMa-EGdMa 75-25, C) PEG550dMa-EGdMa 67-33, D) PEG550dMa-EGdMa 5941, 
E) PEGdMa-EGdMa 50-50, and F) PEG550dMa-EGdMa 75-25 remain intact after application. Scale bars 
measure 500µm.  
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Using this technique, the percent of needles within an array that insert into the skin with a 
given application force was calculated for six replicates of all five compositions (Figure 4.11). 
With a 6N application force (equivalent to 93.75 mN/microneedle), none of the tested 
compositions successfully punctured murine skin (Figure 4.11A), but insertion was material 
dependent at higher application forces. Therefore, data is also graphed according to microneedle 
composition for additional clarity (Figure 4.12). For this study, when 90% or more of the 
microneedles in an array (marked by the dotted line) puncture the skin’s surface, the array is 
considered to effectively insert. When less than 90% of needles in the array insert into the skin, 
the insertion is considered ineffective.  
Microneedles made of PEG550dMa did not insert into the skin, even with up to 75N of 
applied force (Figure 4.12A). Microneedles made of PEG550dMa-EGdMa 75-25 also exhibited 
poor insertion into the skin (Figure 4.12B). Although some of the needles in a given array do 
puncture the skin surface, less than 90% of the total number of needles in an array punctured in 
all cases. Substantial variability in the percentage of needles that insert is also present between 
applications, even though an automated device was used for application. Because neither of these 
 
Figure 4.10 Assessment of Percent Insertion Using Tissue Marking Dye. Some microneedles arrays A) do not 
insert into the skin, B) partially insert into the skin or C) completely insert into the skin. Percent penetration is taken 
by dividing the number of penetration sites visualized by the total number of microneedles in an array  (64 
microneedles). Scale bars measure 1mm. 
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Figure 4.11 Percent of needles that puncture skin as a function of composition. Arrays of 64 microneedles 
composed of A) PEG550dMa, B) PEG550dMa-EGdMa 75-25, C) PEG550dMa-EGdMa 67-33 D) PEG550dMa-
EGdMa 59-41 and E) PEG550dMa-EGdMa 50-50 microneedles were applied to full thickness porcine skin ex vivo 
using 6N, 12.5N, 25N, and 75N  of  force. The percentage of needles in an array that punctured skin is given. F) 
Young’s moduli for microneedle compositions in A)-E). Data are graphed as mean ± SD (n=6) 
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Figure 4.12 Percent of needles that puncture  skin as a function of insertion force. Arrays of 64 microneedles 
composed of a variety of PEG blends were applied to porcine  skin ex vivo with A) 6N,  B) 12.5N, C) 25N, or D) 
75N of force. Data is presented as mean ±SD (n=6) of the percent of microneedles inserting into skin, calculated 
by dividing the number of insertion sites by the total number of microneedles in the array.  The dotted line 
represents 90% of microneedles inserting into the skin. 
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compositions fractured during application (Figure 4.9A-B), future studies could investigate 
whether forces that are greater than 75N would enable these microneedles to effectively insert 
into the skin.  At some point, further increases in applied force may become uncomfortable for 
the patient; therefore, establishing a maximum tolerable force would be essential to such 
investigations. 
Microneedles composed of stiffer materials (PEG550dMa-EGdMa 67-33, PEG550dMa-
EGdMa 59-41, and PEG550dMa-EGdMa 50-50) effectively punctured porcine skin ex vivo 
within the tested range of application forces. While the stiffest microneedles (composed of 
PEG550dMa-EGdMa 59-41 and PEG550dMa-EGdMa 50-50) effectively punctured the skin 
when a force of 25N or greater was applied, microneedles composed of PEG550dMa-EGdMa 
50-50 required only 12.5N of force to insert into the skin. Therefore, a tradeoff between stiffness 
and the minimum required application force exists.  
As stated previously, none of the tested microneedle compositions fractured prior to 
insertion. Therefore, the elastic modulus of the microneedle matrix played a more important role 
in microneedle insertion than fracture strength for the tested microneedle arrays.  Further, this 
data demonstrates that the force required to insert a microneedle array decreases as the stiffness 
of the material increases. Although producing very stiff microneedle arrays is a straightforward 
method for ensuring effective insertion, some desirable properties of a microneedle matrix 
decrease the elastic modulus. For example, in crosslinked networks, the rate of diffusion of a 
therapeutic out of the matrix typically decreases as crosslink density and stiffness increase. Some 
therapeutics may also plasticize the polymer matrix, causing the material’s stiffness to decrease 
as the total therapeutic volume increases. Therefore, increasing the amount of the therapeutic or 
its rate of release would correspond to a decrease in stiffness.  For these reasons, a 
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comprehensive understanding of the required mechanical properties will continue to aid 
microneedle design for specific therapeutic applications.  
This data also suggests that for effective microneedle application via force of thumb, a 
modulus of approximately 1GPa or greater is recommended. This is of the same order of 
magnitude as results reported by Lee et. al.13 Throughout this study, other microneedle design 
variables, including tip radius and the number of needles per array, were held constant. Such 
variables would indubitably alter the required modulus. For example, the ability of a microneedle 
to insert into the skin has been previously shown to be determined by the applied force per 
microneedle, not the total force applied to the array. 28 Therefore, decreasing the number of 
microneedles in an array would increase the force applied to each needle; such an approach may 
lower the minimum modulus required. This hypothesis could be easily tested by altering the 
number of needles per array using the CLIP platform. Although decreasing the total number of 
microneedles in the array decreases the total volume available for drug loading, the tiered 
microneedles presented in Chapter 2 could potentially be used to decrease mechanical 
requirements by decreasing the number of microneedles inserting into the skin at a given 
moment in time, while maintaining high drug loading capacity on an array.  
Further, Davis et. al. demonstrated  that the force required to insert a microneedle into the 
skin depends on needle sharpness, quantified by the tip radius of the array.12 Microneedle 
insertion force was found to increase linearly with the surface area of the microneedle tip (i.e. tip 
radius squared). Therefore, this recommended modulus is also likely to be specific to 
microneedles that have a tip radius at or near 5µm. 
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4.2.6 Depth of Penetration vs. Force 
The insertion data presented in the previous section was obtained by using tissue marking 
dye to mark sites of penetration. Therefore, this data provides useful information about how 
many needles puncture the stratum corneum, but it does not provide any indication of each 
needle’s depth of penetration into the skin. Traditionally, assessing penetration depth requires the 
skin to be frozen and sectioned, which may alter the structure and dimensions of the tissue due to 
dehydration and extensive mechanical manipulation.3 Optical coherence tomography (OCT), a 
noninvasive imaging technique that is considered an optical equivalent to ultrasound, has been 
used by Donnelly3 and others29-30 to assess microneedle penetration depth in skin. This 
technique, which has been used to image up to 2mm deep into tissue,31 allows  microneedle 
penetration depth to be accurately measured without manipulating the structure of the skin.  
Here, we use optical coherence tomography to assess the depth of penetration of 
microneedle arrays as a function of composition and applied force. Microneedle arrays were 
applied to full thickness porcine skin ex vivo using an Instron Universal Testing Station, as 
previously described. Microneedle compositions and applied forces were down-selected from 
Figures 5.11 and 5.12 by to select force-composition combinations that allowed >90% of the 
microneedles within the array to puncture the skin surface. Other compositions were not tested 
because the tissue marking dye experiments already indicated that they do not effectively 
penetrate skin. 
 Microneedles were then imaged using OCT by pointing the laser through the back of the 
microneedle array (Figure 5.13A) while it was embedded in porcine skin. Data was collected in 
two different channels, a co-polarized signal (HH, where input and output polarization was 
equal, which contrasts optically isotropic light scatterers) and a cross-polarized signal (HV, 
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where input and output polarization were orthogonal, which contrasts optically anisotropic 
material). Initial OCT images in the HH signal (Figure 5.13B) showed that the microneedle 
backing and the surface of the skin could be visualized. The surface of the skin was visible in 
white due to the strongly scattering nature of the skin tissue. The edges of the microneedle 
backing could likewise be visualized in white. The microneedles themselves, however, were not 
strongly scattering, but appeared as dark voids in the skin. The tips of the microneedles could not 
be visualized within the tissue (Figure 5.13B). 
 
Figure 4.13 OCT Experimental Setup and Images. A) Images were obtained by pointing the laser through the 
backing of the applied microneedle patch into skin. B) HH image of blank microneedle array in porcine skin. C) 
HV-HH overlay of microneedle array containing GNRs 
 
Figure 5.13 OCT Experimental Setup and Images. A) Images were obtained by shining the laser through the 
backing of the applied microneedle patch into skin. B) HH image of blank microneedle array in porcine skin. C) 
HV-HH overlay of microneedle array containing GNRs. 
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 In an attempt to improve the image such that the entire length of the microneedle could 
be visualized, 2wt% 84x22nm gold nanorods (GNRs) were incorporated  into microneedle 
devices by mixing GNRs with the photoreactive resin prior to fabrication. GNRs were not 
incorporated into the patch backing. Because these GNRs have a plasmon resonance of 800nm, 
they were strongly scattering, producing a distinct contrast in the HV output of the OCT 
system,37 allowing for clear visualization of the needle. The HH and HV outputs were stacked, 
where HH is in red and HV is in green, to produce the image of GNR containing microneedles 
shown in Figure 5.13C. The microneedles in this image show up strongly in green due to the 
cross-polarized signal from the GNRs.  Figure 5.13C confirms that the voids seen in Figure 
5.13B are indeed due to microneedles penetrating into the skin. Unfortunately, the microneedle 
tip could still not be clearly visualized. Therefore, the penetration depth of the microneedle was 
determined by subtracting the distance between the MN backing and the skin surface from the 
total microneedle length (measured by ESEM). Although these GNRs were useful to validate the 
measurement technique, they were not included in the tested samples because the GNRs may 
alter the mechanical properties of the materials under investigation.  
The measured depth of penetration as a function of composition and applied force is 
given in Figure 4.14. All microneedles penetrate to approximately 650µm deep into the porcine 
skin, regardless of the material properties of the array and the application force used to 
administer the array. The variation in penetration depth between arrays ranged from 4.8µm up to 
approximately 40 µm for most conditions. The variability between arrays was found to be similar 
to the variability in microneedle insertion within a single array (data not shown). Much of the 
variability within a single array appeared to be due to the undulating surface topology of the skin 
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rather than actual variability in needle penetration. Therefore, skin penetration was determined to 
be very consistent using this method of application.  
This pilot study seems to indicate that once microneedles penetrate the outer layer of the 
skin, they insert to the same depth, regardless of composition and insertion force. This study, 
however, contradicts an existing report by Donnelly et. al. showing that microneedle penetration 
depth increases with increases in application force for 600µm  tall microneedles composed of a 
mixture of methylvinylether and maleic anhydride(PMVE/MA) applied with 0.48 to 1.82N of 
force per microneedle. 3 Forces of 0.09 to 1.17N per microneedle are tested here, for comparison. 
 
Figure 4.14  Depth of Penetration of PEG Blends. A) Depth of penetration of microneedle 
arrays as determined by OCT. B) The same data is given numerically. Data are presented as 
mean±SD between arrays (n=3 arrays), where the average penetration depth for each array is 
calculated from n=32 needles on that array. 
161 
 
No studies investigating depth of penetration as a function of material properties have been 
published, to our knowledge.  
A multitude of different theoretical models, ranging from simple to complex, have been 
applied to needle insertion into soft tissues. The development and evaluation of such a model is 
outside the scope of this dissertation, but the framework used to develop previous models may be 
useful to interpreting the results presented here. Models proposed by Mavash and Dupont,32 
Akamura,33  and Azar and Hayward34  describe needle insertion into soft tissues in four steps: 1) 
deformation, 2) puncture, 3) penetration, and 4) relaxation (Figure 4.15). Deformation spans the 
period of time over which the needle compresses the tissue until the pressure on the tissue is 
equal to its yield stress. Puncture is the moment where the tissue ruptures to produce a crack. 
Penetration spans the period of time over which the tissue is displaced to propagate the crack and 
allow the microneedle to continue to move further into the tissue. Relaxation occurs when the 
application force is removed, allowing the tissue to recoil due to its natural elasticity. This tissue 
 
Figure 4.15  Process of microneedle penetration into the skin. Adapted from reference 34. 
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recoil has been shown to decrease the penetration of an individual microneedle by approximately 
34% after relaxation, as reported by Romgens et. al.1  
This framework suggests that increasing the application force should result in an increase 
in the maximum penetration depth by providing more energy to displace the native tissue during 
the penetration phase. However, the role of tissue recoil on our measurements is currently 
unknown. Some OCT measurements were taken up to an hour after microneedle insertion; 
therefore, the relaxation/dehydration of the tissue over time may have masked differences in 
penetration depth. A time course study investigating the depth of penetration throughout 
insertion may be useful to determine whether the tissue’s elasticity plays a significant role in 
microneedle penetration depth. Insertion testing of the arrowhead microneedles fabricated in 
Chapter 2 may also provide more information about the role of tissue recoil on microneedle 
depth of penetration and may potentially increase total insertion depths. Nevertheless, taking 
depth of penetration measurements after recoil, as we did in this experiment, is a clinically 
relevant scenario that informs microneedle design. 
It is conceivable that microneedle stiffness has little effect on depth of penetration. The 
stiffness of skin tissue in compression has been shown to be on the order of 2 kPa, 35 but 
measurements also vary widely, according to age, environmental conditions, testing methods, 
and the anatomical location on the body, etc. Nevertheless, because the microneedles utilized 
here have much higher elastic moduli (and are therefore much stiffer) than skin, the 
microneedles may not deform substantially after the initial puncture.  Further experiments are 
necessary to conclusively determine whether force and composition affect microneedle 
penetration depth. 
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4.3  Conclusion 
Here, we fabricate microneedle arrays from a variety of polyethylene glycol (PEG) blends 
with different mechanical properties. The moduli, strain at break, and failure stress of these 
materials are characterized. Moduli range from approximately 83 MPa to nearly 2 GPa. Strain at 
break and failure stress range from 0.05 to 0.4 and from 50MPa to 200MPa, respectively. The 
ability of these microneedles to penetrate porcine skin ex vivo when applied with a range of forces 
was assessed using tissue marking dye. Insertion efficacy was found to be dependent on both 
modulus and applied force. Stiffer microneedles effectively inserted into the skin at lower 
application forces, whereas higher forces were required to insert more rubbery materials.   Depth 
of penetration was quantified as a function of applied force and material properties using Optical 
Coherence Tomography (OCT). Future work will investigate how altering microneedle shape 
influences skin penetration to identify optimal microneedle designs.  
4.4 Experimental 
4.4.1 Identification of PEG Microneedle Build Parameters 
Methods for the determining critical exposure were adapted from Tumbleston et. al.36 
Briefly, 500µL of resin was placed on a cover slip on top of the printer window. Resin was 
exposed to a specified dosage of light (λ=365nm LED) in a circle pattern and residual, unreacted 
monomer was removed using an acetone wash. The height of polymerized circles was then 
measured using a Mitutoyo Electronic Indicator (McMaster Carr). Resins utilized in this study 
were blends of ethylene glycol dimethacrylate and polyethylene glycol dimethacrylate (Mn 550, 
Sigma Aldrich) mixed with 2.5 wt% Diphenyl(2,4,6-trimethyl-benzoyl-)phosphine oxide (Sigma 
Aldrich) as a photoinitiator. Specific ratios of each component are given in Table 4.1. The light 
intensity utilized for microneedle fabrication was then calculated as described in Section 4.2.2. 
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4.4.2 Fabrication of PEG Microneedles 
To produce microneedles of different heights, CAD files of square pyramidal 
microneedles measuring 1000µm tall with an aspect ratio of 3 (aspect ratio= height/width) were 
generated using Solidworks 2014. All microneedles were spaced at one base width apart on a 
base measuring 6x6x1mm. CAD files were then sliced at 1μm slice thickness using the open 
source software Slic3r. Microneedles were then produced using the CLIP7 additive 
manufacturing system (Carbon 3D, Redwood City, CA) using blends of PEG550-dMa, EG-dMa, 
and TPO with compositions provided in Table 5.1. PEG550dMa, PEG550dMa-EGdMa 75-25, 
PEG550dMa-EGdMa 67-33, PEG550dMa-EGdMa 59-41, and  PEG550dMa-EGdMa 50-
50microneedles were produced at 25mm/hr with 1.1, 2.4, 2.1, 2.5, and 3.5mW/cm2 of UV light 
(λ=370).All needles were washed briefly with acetone and dried using compressed air. All 
microneedles were post-cured for 10 minutes under a mercury lamp. Microneedles were imaged 
using an environmental scanning electron microscope (FEI Quanta 200) in low vacuum mode.  
4.4.3 Mechanical Testing of PEG Blends 
Test cylinders were fabricated by drawing a circle measuring 6mm in diameter directly 
into the .LUA script using the addcircle function. This circle was projected continuously as the 
build elevator moved upwards a distance of 12mm to produce a cylindrical test part. All test 
cylinders were produced using the E20 CLIP additive manufacturing system (Carbon3D, 
Redwood City, CA) using light intensities specified in Section 4.4.2. All parts were postcured for 
10 minutes under a mercury lamp.  
Test cylinder stress-strain curves were obtained using an Instron 5566 Universal Testing 
Machine. Compression was applied at a rate of 1mm/s with a 1N preload until part failure. The 
instrument was equipped with a 10kN load cell. The Young’s modulus, strain at fracture, and 
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stress at fracture were automatically calculated using Bluehill3 Software, where fracture was 
automatically identified using a zero slope method.  
4.4.4 Gel Fraction and Solvent Uptake 
The gel fraction and solvent uptake of PEG550dMa cylinders, PEG550dMa 
microneedles, PEG550dMa-EGdMa 50-50 cylinders, and PEG550dMa-EGdMa 50-50 
microneedles were determined as follows. Three microneedle patches with 1mm backings and 
one cylindrical test part were each weighed (Wi) and then submerged in separate amber bottles 
containing approximately 200mL of methanol (MeOH) over 24 hr. After this extraction of the 
soluble fraction, parts were then removed from the methanol, dried using a Kimwipe, and 
weighed again (Ws) to determine solvent uptake. Solvent uptake was calculated by taking (Ws-
Wi)/Wi. Parts were then heated to 100°C for 24 hr under vacuum to remove residual methanol, 
removed from vacuum to equilibrate to ambient humidity overnight and then weighed again 
(Wd) to determine weight percent mass lost. Gel fraction was calculated by taking (Wd/Wi). 
4.4.5 Quantification of Force of Thumb 
Ten study participants were recruited, ranging in age from 21 to 70 years old. Each 
participant was asked to apply three equal forces of five second duration. First, each participant 
used their thumb to press against their upper arm using a force that they deemed acceptable for 
insertion of a microneedle array. They were then asked to use the same force to apply pressure to 
the back of a microneedle array resting on top of a sample of full-thickness porcine skin on top 
of a corkboard. This entire assembly was placed on top of an Instron 5566 Universal Testing 
Machine compression plate connected to a 500N load cell used to measure the application force. 
Lastly, each participant applied the force directly to the Instron compression plate. All data was 
collected using Bluehill3 Software.  
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4.4.6 Skin Insertion Tests 
For Figure 5.1, PEG550dMa, PCL, and PAA microneedles were applied to murine and 
porcine skin by applying firm thumb pressure to the back of the patch for 10 seconds. Murine 
skin excised from nude mice with permission of the UNC Institutional Animal Care and Use 
Committee (IACUC). Full thickness porcine skin was purchased from Stellen Medical.  
To assess microneedle application using a controlled force, microneedle patches were 
placed needle side down on a section of full thickness porcine skin resting on corkboard. An 
Instron 5566 Universal Testing Machine equipped with a 100N load cell was utilized to apply 
controlled forces by bringing the intron compression plates into contact with the microneedle 
array prior to force application. Forces of 6N, 12.5N, 25N, and 75N were applied for 5 seconds; 
force was applied and released at a rate of 25 N/s. The transducer gain was set at 0.0025 to 
enable load control.  
4.4.7 Optical Coherence Tomography (OCT) 
Images were acquired using a custom built, ultra-high resolution, polarization-sensitive, 
spectral-domain optical coherence tomography system, as previously described.39  Briefly, the 
OCT system was comprised of a Michelson interferometer with a Titanium:Sapphire laser 
(Griffin, KMLabs, Inc.) source (λ=800nm, Δλ=120nm).  Polarization sensitivity was obtained by 
isolating horizontally polarized light at the input of the interferometer.  A quarter-wave plate in 
the reference arm was used to obtain equal portions of horizontal and vertically polarized 
light.  The reference and sample beams were recombined and split into two outputs using a 
polarizing beam splitter, resulting in a co-polarized signal (HH, where input and output 
polarization was equal to contrastoptically isotropic light scatteres) and a cross-polarized signal 
(HV, where input and output polarization were orthogonal to contrastoptically anisotropic light 
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scatterers).  The resolution of the system, in air, was 3µm x 10µm (axial (z) vs. transverse 
(x)).  Images were acquired using a line-scan camera (Piranha, Dalsa Inc.) at a rate of 10 kHz 
with 70 µs exposure time. 
Three-dimensional scans were obtained for each sample.  For each 2D B-mode image 
(x,z), 1000 A-lines were collected as the imaging beam was scanned laterally over 5mm, 
resulting in Δx=5µm.  A total of 500 images were collected, scanned transversely (y) over 5mm, 
resulting in a spacing of Δy=10µm.  Since PS-SD-OCT collects images in the frequency domain, 
images were post processed to obtain intensity images, using a dispersion compensation 
algorithm,39 and re-contrasted using histogram stretching for visualization.  Final 3D images 
were 5x5x2.08mm (in air), collected into 1000x500x1024 pixels (x, y, z). Quantification was 
performed  according to Equation 4.2 
𝑑𝑧,𝑜𝑏𝑗𝑒𝑐𝑡 = 𝑛𝑝𝑖𝑥𝑒𝑙𝑠,𝑧 𝑜𝑏𝑗𝑒𝑐𝑡 ∙
ℎ𝑖𝑚𝑎𝑔𝑒,𝑎𝑖𝑟
𝑛𝑝𝑖𝑥𝑒𝑙𝑠,𝑧 𝑖𝑚𝑎𝑔𝑒
∙ 𝑁    (4.2) 
where dz,object is the , npixels, object is the number of pixels comprising the object in the z direction, 
himage, air is the total length of the image in air, npixels, z image is the total number of pixels along the 
z axis of the collected image, and N is the refractive index of the measured object. The distance 
between the patch backing and the surface of the skin was then subtracted from the total 
microneedle length to obtain depth of penetration.  
Samples doped with GNRs (84x22nm), fabricated as previously described,40 were used as 
a contrast agent to compare with images of needles containing no GNRs.  Since the plasmon 
resonance of these rods was 800nm, the rods were strongly scattering in the HV output of the PS-
SD-OCT system, allowing for clear visualization of the needle.  This allowed for validation of 
the markers used in measuring needle penetration depths in samples not containing GNRs. 
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CHAPTER 5 CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 Continuous Liquid Interface Production on the Micron Scale 
The work presented herein is the first report of Continuous Liquid Interface Production of 
parts measuring less than 1mm in height. CLIP enables fabrication of micron-scale features that 
cannot be generated using traditional silicon and/or micromolding based processes, such as the 
undercut arrowhead microneedles presented in this dissertation. While not demonstrated here, 
the fabrication of even more complex structures, such as hollow or porous features, is also 
feasible using this technique. In addition, CLIP enables easy “plug-and-play” of material 
composition on the micron-scale, as demonstrated by the nine different microneedle 
compositions used in this dissertation. Such simultaneous control over shape and material 
properties is unprecedented in micro-manufacturing.  
Most traditional micro-manufacturing techniques require extensive expertise. Years of 
training are typically required to gain a working understanding of the benefits, process 
optimization, and limitations of various micro-manufacturing techniques (photolithography, wet 
and dry etching, machine milling, chemical vapor deposition, etc.). The expense of required 
equipment can be cost-prohibitive, especially in academic environments. Therefore, equipment is 
therefore usually located in centralized facilities, limiting access to this important technology. 
The CLIP process presented here, on the other hand, is undergoing development to become a 
push-button technique that produces desired structures on demand with little to no training. 
While traditional etching based techniques are accomplished at 60-300µm/hr in the z direction,1 
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the structures produced here are fabricated at rates of up to 100mm/hr. Therefore, prototyping 
micron-scale structures using CLIP is approximately 400-1600X faster per part than traditional 
micromanufacturing techniques, in addition to the dramatically reduced lead times. Therefore, 
with advantages in control over geometry, material flexibility, and speed, CLIP is poised to 
challenge existing microfabrication techniques and enable rapid production of micron-scale 
features for a number of different industries. Such capacity provides access to far-reaching and 
previously unimaginable opportunities in research and in product development. 
Many of the fundamental studies presented here lay a critical foundation for the future of 
small-scale production of parts via Continuous Liquid Interface Production. Particularly, we 
establish the dominant role that light distributions play in the fabrication of small parts through 
the following observations: 
 The optical system used to focus light on the window plays a dominant role in part 
quality on the small scale 
 Light intensity affects part dimensions as much as the dimensions of the input CAD file 
 A proposed model based on assuming each pixel’s light projection can be represented as 
a Gaussian light distribution qualitatively predicts the shape of the cure of a single frame 
In addition to establishing the importance of light intensity distributions, we also 
demonstrated that a technique called antialiasing is necessary to produce smooth parts on a small 
scale. The introduction of grayscale smooths the sharp transitions between individual pixel 
projections from the DLP chip. Here, antialiasing is utilized to smooth stair-stepping on the 
10µm size scale, but printers with larger pixel sizes are likely to produce surface stair-stepping at 
size scales that are equivalent to their projected pixel size. For example, a CLIP system with a 
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100µm pixel size would produce parts with 100 µm wide stair-stepping along the surface, rather 
than the 10 µm wide stair steps seen here (for a printer with a ~10µm projected pixel). Therefore, 
antialiasing is also an important consideration for production of both macroscopic and 
microscopic objects. 
The ability to continue to produce smaller and smaller objects via Continuous Liquid 
Interface Production will rely on further improvements in system optics. The dominant role of 
the light distribution (as opposed to the CAD file) suggests a need to expand the use of modeling 
to identify build parameters capable of producing dimensionally accurate parts in order to 
improve efficiency, accessibility and ease of use of this technology for production on the small 
scale. Although the model proposed here has been utilized to qualitatively predict the geometry 
resulting from exposure to a single frame, further model development may enable the exact 
dimensions of micron-scale three dimensional CLIP parts to be accurately predicted. 
5.2 Continuous Liquid Interface Production of Materials for Release of Therapeutics 
The work presented herein is also represents the first use of CLIP for biological 
applications, and, in particular, the first attempt at generating biocompatible materials for drug 
release using CLIP. CLIP microneedles were fabricated from resins containing acrylic acid, 
methacrylate functionalized polyethylene glycols (PEGs), and methacrylate functionalized 
polycaprolactone (PCL) mixed with the photoinitiator diphenyl(2,4,6-trimethyl-benzoyl-) 
phosphine oxide (TPO). Upon photopolymerization, these resins react to form water soluble 
polyacrylic acid (PAA) microneedles, swellable PEG hydrogel microneedles, and a 
hydrolytically degradable PCL based microneedle. The ability to rapidly adjust microneedle 
composition using CLIP demonstrates that it is a “plug-and-play” approach to producing 
microneedles with differing mechanisms of drug release. The fluorescent drug surrogate 
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rhodamine was homogeneously incorporated into all patches. Release rates of rhodamine from 
microneedle patches were found to vary from complete release within 15 minutes (for 
dissolvable polyacrylic acid microneedles) to less than 1% release over one week (for PCL 
microneedles) in aqueous solution. Therefore, the release rate of an encapsulated therapeutic 
from a CLIP microneedle can be tailored to specific applications through careful selection of the 
microneedle matrix. The wide range of matrix solubilities utilized here, from a very hydrophilic 
PAA to hydrophobic PCL suggests that therapeutics of a range of different solubilities could be 
encapsulated into CLIP microneedles.  
 Although the microneedles fabricated in this dissertation are strong proof of concept that 
CLIP can be used to directly manufacture microneedle arrays, further effort is necessary to 
identify an appropriate matrix for translational applications. All three microneedle compositions 
(PEG550dMa, PCL, PAA) effectively pierced murine skin, but both the PEG550dMa and PCL 
microneedles failed to penetrate porcine skin. Because human skin is more similar to porcine 
skin than murine skin, we anticipate that the PEG550dMa and PCL microneedles would also fail 
to puncture human skin. For this reason, PEG550dMa and PCL microneedles are not 
recommended for ongoing investigations. Other polyesters, such as PLA or PLGA may be more 
ideal, due to their improved mechanical properties and faster release rates. More densely 
crosslinked PEG microneedles did enable penetration of porcine skin (Chapter 5), but these 
highly crosslinked PEG microneedles reduced rhodamine release rates in solution to fractions of 
a percent over one week (data not shown). Complete drug release from such highly crosslinked 
materials would likely occur over the course of years; such slow release rates are not ideal for the 
vast majority of applications. For this reason, even highly crosslinked PEG microneedles are not 
suitable materials for translational applications.  
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The PAA microneedles exhibited a clinically relevant release profile, completely 
releasing cargo through dissolution within 15 minutes. The dissolvable nature of this matrix 
would make it easy to apply and would not require the patient to wear the patch over an extended 
period of time. Furthermore, a dissolving microneedle would eliminate sharp, biohazardous 
waste during patch application and potentially reduce disease transmission caused by needle re-
use. Unfortunately, PAA microneedles were cytotoxic to both A549 human non-small cell lung 
cancer cells and human umbilical vein cells (HuVECs) in cell culture, which suggests that they 
may produce undesirable side effects in vivo. Therefore, the development of strong, quick 
releasing, and biocompatible materials is important to the advancement of CLIP microneedle 
technology, as discussed in the following sections.  
5.3 Development of Biocompatible CLIP Matrices 
5.3.1 Biocompatibility of (Meth)acrylate Based Chemistry 
All materials used for CLIP must be photopolymerizable. Photopolymerization has been 
previously used for biomedical applications due to its inherent benefits, including rapid cure 
rates, low temperature operation, the ability to spatially and temporally control polymerization 
and the potential to perform  polymerization in vivo.2 Clinically, photopolymerization  is 
common  in dental restoration. 3-4 Photoreactive monomers are also used in acrylic bone cements 
during orthopedic surgery, although they are typically reacted via thermal or redox initiation 
mechanisms.5-7 Contact lenses are also fabricated by photopolymerization.8 Such applications 
utilize dimethacrylate based resins, which are typically composed of a combination of 
photoreactive oligomers, pre-reacted polymers, and filler materials designed to improve 
mechanical properties and reduce shrinkage. The structures of some commonly used oligomers 
are given in Figure 6.1. These include 2,2-bis[4-(2-hydroxy-3-
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methacrylolyloxypropyl)phenyl]propane (Bis-GMA), 1,6-bis-[2-
methacryloloxyethoxycarbonylamino]-2,4,4-trimethyl hexane (UDMA), and triethyleneglycol 
dimethacrylate (TEGDMA), hydroxyethyl methacrylate (HEMA) and methyl methacrylate 
(MMA).4,7  Together, these clinical applications demonstrate that dimethacrylate based 
photopolymerization is safe for use in clinical settings. Accordingly, our highly crosslinked 
PEG and PCL microneedles (which were produced with dimethacrylate based resins) had no 
adverse effects on cells over 72 hours. 
Nevertheless, residual, unreacted (meth)acrylates are known to induce toxicity.7,9-10 This 
toxicity is generally attributed to the reactivity of the acrylate double bond toward Michael 
Addition reactions with amino- or thiol-groups of proteins or DNA.11 Meth(acrylates) are also 
known skin irritants, possibly due to the effects of acrylic or methacrylic acids formed by ester 
hydrolysis of these compounds.7 In some cases, unreacted meth(acrylates) have also been found 
to be carcinogenic.7  Importantly, (meth)acrylate based materials used in clinical 
applications are designed to limit exposure to unreacted (meth)acrylate through high 
extents of reaction conversion and high crosslink density to ensure device safety..  
 
Figure 5.1 Methacrylate monomers and oligomers used commercially 
 
Figure 5.2Methacrylate monomers and oligomers u ilized in commercial products 
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Further characterization of unreacted (meth) acrylate within CLIP microneedle devices is 
essential to future development. Although current clinical applications of photochemistry limit 
free (meth)acrylate toxicity through high bond conversion, immobilization of remaining free 
(meth)acrylates through dense crosslinking is also essential to their biocompatibility.12 Therefore, 
the development of biocompatible CLIP materials that enable rapid drug release, but limit release 
of unreacted oligomer may be challenging.  Elimination of any and all unreacted 
(meth)acrylate from the final product is essential to the future development of CLIP 
microneedles. This could be accomplished by 1) further optimization of resin formulations and 
fabrication conditions to complete reaction conversion and 2) utilizing higher molecular weight 
oligomers to reduce the concentration of reactive endgroups. It is important to note that high 
molecular weight oligomers typically increase viscosity, which can result in a decrease in 
reaction conversion.3 Balancing these tradeoffs will be important in future studies. Previous work 
with high molecular weight, low viscosity branched polymers could be of interest.13 The high 
functionality of these materials also tether most of the unreacted groups into the matrix, which 
should reduce leachable (meth)acrylate concentrations. The effect of pendant unreacted groups 
on biocompatibility would need to be evaluated. 
Alternatively, additional post-fabrication steps could be used to purify unreacted 
materials out of the needle. Washing the part or applying heat or vacuum to remove residual 
monomer/oligomer could be feasible approaches to producing a biocompatible device. Although 
PAA microneedles were demonstrated to be cytotoxic in this dissertation, we still believe that 
this may be a promising material for further consideration. Additional optimization of the 
reaction conditions and purification steps may reduce the toxicity of PAA microneedle devices. 
178 
 
Importantly, such post-fabrication purification steps have a  risk of accidentally removing 
or damaging the therapeutic of interest during processing. Therefore, incorporating therapeutics 
into microneedles after fabrication and purification may be of interest. Coating the microneedle 
with the therapeutic or chemically conjugating the therapeutic to the matrix after fabrication may 
be viable approaches to producing toxin-free microneedle devices with active therapeutics. 
5.3.2 Alternatives to Meth(acrylate) Based Chemistry 
Some alternative radical photopolymerization chemistries have been developed to 
circumvent toxicity issues associated with (meth)acrylates. One common example is thiol-ene 
chemistry, which has been extensively investigated by Anseth, Bowman, and Hoyle.14 Unlike 
methacrylate mediated radical photopolymerization, thiol-ene reactions take place via a step-
growth mechanism, which reduces radical lifetimes.14-15 This reaction mechanism has been 
utilized to encapsulate bioactive cargos, such as cells, proteins, and enzymes with little loss of 
activity.15 Unfortunately, because this reaction is not susceptible to oxygen-induced inhibition14 
it is incompatible with CLIP. 
An interesting alternative chemistry, which may be suitable for use with CLIP, is radical 
photopolymerization with vinyl esters.16-17 The decrease in reactivity of the vinyl ester, as 
compared to the acrylate, decreases cytotoxicity by one to two orders of magnitude17. Vinyl 
esters have typically been associated with slower reaction rates, so polymerization kinetics 
would need to be carefully considered.16 
5.3.3 Role of Photoinitiators 
Although the role of photoinitiator cytotoxicity is understudied throughout this work, the 
role of the photoinitiator in the biocompatibility of the final part is an important consideration. 
Several studies have been performed to assess the role of photoinitiators on cytotoxicity for 
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applications in cell encapsulation within photopolymerizable scaffolds.18-20 For these 
applications, many photoinitiators have been associated with increases in the concentration of 
intracellular reactive oxygen species, which induce cell death.18 Some photoinitiators, such as 
Irgacure 2959 and camphorquinone (CQ), have been shown to have minimal cytotoxicity in 
these applications.18  
The use of photo initiators for the production of CLIP microneedles differs from such 
applications because no active radicals are placed in direct contact with cell populations during 
fabrication. In fact, the initiators react with monomers/oligomers to start the polymer chain, and 
are therefore chemically conjugated to the matrix. For this reason, the toxicity of leachable, 
unreacted photoinitiator is more relevant to CLIP microneedles than the toxicity of free radicals 
generated during initiation. Although photoinitiators are somewhat toxic in cell culture, the 
toxicity of native photoinitiator is much less than that of active free radicals.18 High molecular 
weight initiators may be less likely to be released from the matrix.21-22  The investigation of self-
initiating monomers and/or initiation by natural products24 may also be of interest, but may 
require different wavelengths of light for effective initiation.  
5.3.4 Characterization of Products and Degradation Products 
Further characterization of the nature of CLIP products is necessary. For PAA 
microneedles, characterization of the molecular weight distribution of the formed PAA will be 
essential to verify that dissolution products are of a molecular weight that is safe for clinical use. 
Similarly, further characterization of the degradation products of crosslinked CLIP materials will 
be necessary. Determining the molecular weight of the non-degradable alkyl backbone during 
photopolymerization and verifying its clearance from the body are critical to ensuring device 
safety.  
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5.4 Incorporation of Therapeutic Cargo 
As described in Chapter 1, microneedles have been used to deliver a wide variety of 
therapeutic agents, including small molecules, proteins, nucleic acids, and nanoparticles. 
Applications include delivery of vaccines, insulin, NSAIDs, chemotherapy and hormone 
delivery, among others. Microneedles are most useful, however, for the delivery of therapeutics 
which are not effectively delivered orally, such as proteins, nucleic acids, and large or 
hydrophobic compounds. Acrylate reactivity with proteins and nucleic acids may prevent these 
compounds from being encapsulated without damage. 15 A number of protein protection 
techniques have been investigated to ameliorate these issues.26 Some of these protein protection 
techniques may be of interest, but the vast majority do not completely recover protein activity. 
Ultimately, encapsulating the therapeutic after microneedle fabrication via coating or chemical 
conjugation may be a better approach to maintaining the activity of biotherapeutics. CLIP 
microneedle technology is strongly suited for the delivery of large and/or hydrophobic small 
molecules, nanoparticles and microparticles, which are less susceptible to damage than biologic 
drugs.   
5.5 Microneedle Mechanics 
The ability to use CLIP to rapidly alter microneedle composition was harnessed to 
investigate how a microneedle’s composition affects its ability to insert into the skin. 
Polyethylene glycol (PEG) based microneedles with varying crosslinking density were 
fabricated. Young’s modulus and stress at fracture increased  from approximately 80MPa to 
approximately 1600MPa with increasing crosslink density, whereas strain at break decreased 
with increasing crosslink density. The ability of microneedles to insert into the skin was found to 
depend on both the application force and the properties of the material used for device 
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manufacture. None of the tested compositions were found to fracture during insertion, suggesting 
that microneedle stiffness plays a more important role in skin penetration than fracture strength 
for these materials. A minimum Young’s modulus of approximately 1100 MPa is recommended 
for insertion of the tested microneedle array with reasonable application forces. This stiffness 
requirement is likely to vary with microneedle design parameters, such as shape, tip radius and 
the number of needles per array. The CLIP microneedle platform is ideal for investigating how 
such design parameters affect insertion.  
A pilot study demonstrated that depth of penetration was independent of both applied 
force and composition. Theoretical considerations cast doubt on this experiment. Additional 
experiments with undercut (arrowhead) CLIP microneedles could be performed to determine 
whether the elasticity of the skin pushes microneedles back out, masking differences in 
penetration depth. 
All evaluation was performed using porcine skin ex vivo. Further investigation with 
human subjects is necessary to evaluate how well ex vivo results correlate to clinical studies and 
to account for potential differences in the mechanical properties of human and porcine skin.  
5.6 CLIP Microneedles for the Advancement of Transdermal Drug Delivery 
This work demonstrates that Continuous Liquid Interface Production is a powerful tool 
for advancing microneedle technology. The unparalleled, rapid control over microneedle 
geometry achievable by this technique provides a unique opportunity to answer previously 
inaccessible research questions related to the role of microneedle geometry in therapeutic 
efficacy. Proof of concept for one step fabrication of CLIP microneedles containing a therapeutic 
agent is demonstrated, where the fluorescent drug surrogate rhodamine is encapsulated into the 
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microneedle through mixing with a photopolymerizable matrix used for needle fabrication. 
Further investigation of this one step fabrication approach may enable direct fabrication of 
biocompatible, commercial microneedle products. Alternatively, CLIP could easily be utilized as 
an approach to fabricating microneedle master templates, which could be utilized for subsequent 
micromolding. Such an approach would enable the improved geometrical control of CLIP to be 
combined with the proven biocompatibility of established micromolding processes previously 
utilized for microneedle fabrication.    
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APPENDIX A CONTINUOUS LUA SCRIPT 
 
model= "C:\\Users\\eipi\\desktop\\Microneedles\\1000_AR3.svg" 
- Provides .SVG file of the part to be generated 
speed=25 
--Defines build speed in z direction in mm/hr, which affects rate of upward movement of 
the build elevator and the rate at which the frames are displayed 
fill=82 
--Light intensity value between 0( black) and 255 (white)  
n_begin=1 
 --Sets the first slice to be projected 
n_end=loadslices(model) 
 Loads the model’s slices and sets the last slice to be projected 
z_begin=0.025 
 -- Sets the height of the build elevator (in mm) when the first slice projects 
 
for n=1,n_end, 1 do 
fillmask(fill,n-1) 
end 
 --Sets the light intensity of every slice 
moveto(2, 20000) 
moveto(0.15, 1000) 
moveto(z_begin,200) 
 -- Lowers the build elevator before the print begins 
showframe(-1) 
relay(true) 
 -- Turns the light source on 
for n= n_begin, n_end-1, 1 do 
z= sliceheight(n)+ z_begin 
showframe(n-1) 
moveto(z, speed) 
print(string.format("Layer: %d / %d. Height: %.3f mm.\n", n, n_end, z)) 
end 
 --moves the build elevator up as each slice projects 
relay(false) 
 --turns the light off 
moveto(70, 20000) 
 -- Moves the build elevator back to the start position 
  
186 
 
APPENDIX B MODELING OF SMALL SCALE CLIP PARTS 
 
Throughout Chapters 2 and 3, we showed that small objects tend to truncate in the z 
direction relative to the input CAD file, whereas the dimensions of large CLIP parts are accurate 
to the CAD file (Table 2.2, Figure 3.6). Here, we hypothesize that differences in the 
production of large and small parts are due to differences in the amount of light projected 
per unit area for small and large objects.  
In order to test this hypothesis, we calculated cure depth as a function of feature size after 
resin was exposed to a single frame of light. The cure depth equation (also called the “working 
curve”) derived in Chapter 3  
𝐶𝑇 =
1
𝛼
𝑙𝑛(
𝐸
 𝐸𝑐
) 
is a function of the resin specific coefficients Ec, which is the critical light exposure (in mJ/cm
2) 
required to induce cure of the resin and α, which is the absorption coefficient of the resin as well 
as light exposure. Therefore, if cure depth decreases as a function of feature size, this also 
suggests that the light exposure decreases with feature size because exposure is the only 
independent variable in the equation. Light intensity was not directly measured due to the 
difficulty of performing light intensity measurements with micron-scale spatial resolution. 
The experimental setup is given in Figure B.1. A drop of trimethylolpropane triacrylate 
(TMPTA) mixed with 2.5 wt% diphenyl (2,4,6- trimethylbenzoyl) phosphine oxide (TPO) 
initiator was placed on top of a glass coverslip sitting on the CLIP7 printer window. The resin 
was exposed to a single frame of light made up of a series of squares ranging in size from 40x40 
pixels (392.1µm x 392.1 µm) to 1x1 pixel (9.803µm x 9.803 µm). Illumination was performed 
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with Windows GDI+ to eliminate any affect that grayscale may have on cure dosage. Residual 
unreacted resin was then washed off of the coverslip with acetone and the cover slip was left to 
air dry over the course of one hour. An image of the cured objects on the glass slide and their 
measured heights are given in Figure B.2. A few important observations were made. First, as the 
width of the feature decreases, the cure depth also decreases. This observation supports the 
hypothesis that exposure decreases with feature size. Second, the shape of the cured object 
changes as the feature size becomes smaller. The larger square projections, such as the 40x40 
pixel square to the back left of Figure B.1, produce cured objects that are approximately square 
(back left of Figure B.2A). The smaller cured objects, such as the object resulting from the 
projection of a 2x2 pixel square at the front right of Figure B.2A are more conical in shape. 
 
Figure B.1 Experimental setup for testing cure depth as a function of feature size 
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Therefore, this experiment suggests that both the shape and the intensity of the light distribution 
change with decreasing feature size.  Note that some of the cured objects were accidentally 
removed from the coverslip during washing. Therefore, absent features are not indicative of lack 
of curing for this experiment. 
B.1   Pixel Blending 
Similar effects have been observed and are well documented for other DLP based light 
projection systems in literature and are known to be caused by blending of light distributions 
from neighboring pixels.1-3  Ideally, the light coming of each square micromirror (“pixel”) would 
 
Figure B.2 Cure depth as a function of feature size. A) Cured objects resulting from experiment described in 
Figure B.1 B) The heights of each cured object. 
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be a perfect step function, where the maximum exposure (which is the exposure specified by the 
user) would be projected inside the pixel, and no light would be projected outside that pixel. 
However, in actuality, this light actually exists as a distribution inside and outside of the pixel 
due to a number of factors, including diffraction, imperfect focus, and aberrations, which were 
thoroughly discussed in the introduction to Chapter 2 (Figure B.3).3 The overlap between 
neighboring pixels, which is sometimes referred to as “pixel blending”, is subject to 
superposition. Therefore, the projected light intensity per unit area increases as the number of 
neighboring pixels increases for small feature sizes (Figure B.4). When the number of 
neighboring pixels increases (e.g. as pixel size increases), the shape of each individual light 
distribution also becomes less apparent because the light distributions add together to create a 
light distribution that more closely resembles the idealized step function (Figure B.4).  
 
Figure B.3 Ideal versus actual light distributions and their resulting cured objects. Figure adapted from 3. 
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B.2   Application of Sun et. al. Model to CLIP 
Sun et. al. recently published a model for the light intensity distribution reflecting off of a 
DLP chip. This model assumes that the light distribution reflecting off of an individual 
micromirror can be represented using a Gaussian function, where the light intensity is defined by 
Equation B.1  
𝐼(𝑟) = 𝐼0𝑒
−(
𝑟
𝜔0
)2
     (1) 
where I0 is the maximum light intensity reflecting off of an infinite number of neighboring 
pixels, r is the distance from the center of the distribution, and ω0 is the radius of the Gaussian 
distribution. We aimed to apply the model developed by Sun et. al.1 to the CLIP7 additive 
manufacturing system in order to 1) confirm that the decrease in cure depth as a function 
of feature size can reasonably be attributed to reduced “pixel blending” due to a reduction 
in the number of neighboring (or near-neighboring) pixels and 2) determine whether the 
CLIP7 system can be adequately modeled by assuming that the light distribution from a 
 
Figure B.4 Representative light distribution of five neighboring pixels. The additive effect of neighboring pixels 
increases light intensity and results in a better approximation of an ideal light distribution, marked with a dotted line 
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single pixel is approximately a Gaussian function. We know that the output light intensity 
distribution can be represented by the convolution of the light entering the optical system and the 
impulse response of the system. Therefore, if the impulse response is wide relative to the size of 
each input light pixel for a non-ideal system, this Gaussian function may be a good 
approximation for the system output. However, if the impulse response is small relative to the 
size of each input light pixel (for a more ideal optical system), the system output may more 
closely resemble a square step function than a Gaussian distribution. 
Taking the Gaussian function (Equation B.1) 
𝐼(𝑟) = 𝐼0𝑒
−(
𝑟
𝜔0
)2
     (B.1) 
and using the Pythagorean theorem to solve for r, the light intensity at a coordinate (x,y) 
resulting from the projection of a single micromirror centered at coordinate (i,j) is given by 
𝐼(𝑥, 𝑦) = 𝐼0𝑒
−(
√(𝑥−𝑖)2+(𝑦−𝑗)2
𝜔0
)2
=  𝐼0𝑒
−
(𝑥−𝑖)2+(𝑦−𝑗)2
𝜔0
2
   (B.2) 
The total light intensity at x,y is a sum of all Gaussian distributions, such that 
𝐼(𝑥, 𝑦) = ∬ 𝐼0𝑒
−
(𝑥−𝑖)2+(𝑦−𝑗)2
𝜔0
2𝑤𝑥 𝑤𝑦
−𝑤𝑥−𝑤𝑦
 𝑑𝑗 𝑑𝑖   (B.3) 
where wx and wy are one half of the width and length of a rectangular projection. Integrating this 
equation gives 
𝐼(𝑥, 𝑦) =
𝐼𝑚𝑎𝑥
4
[erf (
𝑤𝑥+𝑥
𝑤0
) + erf (
𝑤𝑥−𝑥
𝑤0
)] [erf (
𝑤𝑦+𝑦
𝑤0
) + erf (
𝑤𝑦−𝑦
𝑤0
)] (B.4) 
which is the light intensity at a given point on the x,y plane.  
In order to determine w0, the radius of the Gaussian distribution used in the model, we 
use relationship between the maximum light intensity projecting from an infinite number of 
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neighboring pixels Imax and the light maximum intensity Iactual projecting from a square of width 
W. For a square of width W centered at the origin, the maximum light intensity will be found at 
x=0, y=0. Therefore, Equation B.4 can be written as 
𝐼(𝑥, 𝑦) =
𝐼𝑚𝑎𝑥
4
[erf (
𝑤𝑥
𝑤0
) + erf (
𝑤𝑥
𝑤0
)] [erf (
𝑤𝑦
𝑤0
) + erf (
𝑤𝑦
𝑤0
)]  (B.5) 
for a square projection, 𝑤𝑥 = 𝑤𝑦 =
𝑊
2
. Therefore,  
𝐼(𝑥, 𝑦) =
𝐼𝑚𝑎𝑥
4
[2 erf (
𝑊
2𝑤0
)] [2erf (
𝑊
2𝑤0
)]   (B.6) 
𝐼
𝐼𝑚𝑎𝑥
(𝑊) = [erf (
𝑊
2𝑤0
)]
2
    (B.7) 
 The relationship between I and  Imax as a function of feature width  is then calculated 
using the cure heights given in Figure B.2B by rearranging the working curve equation. Starting 
with the working curve, Equation B.8 
𝐶𝑇 =
1
𝛼
𝑙𝑛(
𝐸
 𝐸𝑐
)      (B.8) 
We solve for exposure 
𝐸 = 𝐸𝑐𝑒
𝛼𝐶𝑇      (B.9) 
and then divide by the maximum exposure, which occurs at CT, max to obtain 
𝐸
𝐸𝑚𝑎𝑥
=
𝑒𝛼𝐶𝑇
𝑒𝛼𝐶𝑇,𝑚𝑎𝑥
      (10) 
Given that exposure is the product of light intensity and exposure time t,  
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𝐼𝑡
𝐼𝑚𝑎𝑥𝑡
=
𝑒𝛼𝐶𝑇
𝑒𝛼𝐶𝑇,𝑚𝑎𝑥
     (B.11) 
which simplifies to 
𝐼
𝐼𝑚𝑎𝑥
=
𝑒𝛼𝐶𝑇
𝑒𝛼𝐶𝑇,𝑚𝑎𝑥
      (B.12) 
Using values for CT and CT, max from Figure B.2 and the absorption coefficient alpha for TMPTA 
+ 2.5 wt% DPO calculated in Chapter 3 yields the relationship shown in Figure B.5. As 
expected, the light intensity decreases as feature size decreases. Decreases in light intensity as a 
function of feature size begin to become relevant for parts that are less than 100µm wide at any 
location on that part. Much more experimentation should be performed to verify this conclusion 
by measuring cure depth at a wide range of light intensities and exposure times. Fitting the curve 
defined by Equation 5 to the data suggests that w0, the radius of the Gaussian light distribution, 
measures 35µm. Therefore, this model suggests that light from a single ~10 µm pixel spreads 
 
Figure B.5 Relationship between feature width and projected light intensity normalized by the maximum 
light intensity 
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over approximately seven pixels. Direct measurement of light intensity distributions is necessary 
to verify this conclusion.  
B.2.1 Predicted Light Intensity Distributions 
Having identified an appropriate radius for the model of the Gaussian light distributions, 
light distributions could be calculated for any point (x,y) along the build plane using equation 
B.4, which is reprinted below for clarity.  
𝐼(𝑥, 𝑦) =
𝐼𝑚𝑎𝑥
4
[erf (
𝑤𝑥+𝑥
𝑤0
) + erf (
𝑤𝑥−𝑥
𝑤0
)] [erf (
𝑤𝑦+𝑦
𝑤0
) + erf (
𝑤𝑦−𝑦
𝑤0
)] (B.13) 
An image of the calculated light distributions as a function of feature size is given in Figure B.6. 
As expected, the light intensity distributions at larger feature sizes, such as the 40x40 pixel 
projection shown in Figure B.6A, fall closer to the ideal step function than light intensity 
distributions for smaller feature sizes. Additionally, this theoretical model predicts decreases in 
the maximum light intensity output per unit area from approximately 25mW/cm2 for the large 
40x40 pixel object, down to less than 5mW/cm2 for the 3x3pixel object. These modeled light 
intensity distributions need to be validated through direct quantification of the projected light. 
Nevertheless, this theoretical framework supports the hypothesis that projected light intensity 
decreases with feature size on the micron scale in this system.  
In order to begin to investigate whether this model can be validated using experimental 
results, the profile of the cured object that should result from these light intensity distributions 
was calculated. Again, the working curve equation,  
𝐶𝑇(𝑥, 𝑦) =
1
𝛼
𝑙𝑛(
𝐼(𝑥,𝑦)𝑡
 𝐸𝑐
)    (B.14) 
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was use to establish cure thickness profiles using the calculated light intensity distributions in 
Figure B.6. Ec and α were taken from the working curve for TMPTA+2.5wt%TPO in Chapter 3. 
Exposure time was 2 seconds, as described for the experiment outlined in Figure B.1. The 
modeled cure thicknesses are given in Figures B.7-B.10. In order to compare this calculation to 
experimental cure profiles, the experiment described in Figure B.1 was repeated using 
TMPTA+2.5wt% TPO mixed with 0.1wt% rhodamine. The resulting cured objects (analogous to 
those shown in Figure B.2) were imaged via confocal microscopy and are shown in Figures B.7-
B.10. Although no quantitative assessment was performed, the modeled and experimental 
structures are qualitatively similar, indicating that a single-pixel based approach may more 
accurately describe CLIP fabrication on the micron-scale than traditional working curves. 
Altogether, these results support the hypothesis that part deviations from the input CAD 
file may be due to the limited spatial bandwidth of the imaging system. A model by Sun et. al., 
which calculates light distributions, and the resulting cured object based on Gaussian light 
distributions was investigated for potential application to CLIP. The modeled cured objects 
appear qualitatively similar to the actual objects (Figure B.7), suggesting that this may be a 
useful model for predicting how build parameters (light intensity and build speed) and resin 
properties (critical exposure, absorbance) dictate the size and shape of an object produced using 
CLIP on the micron-scale. While these single pixel based effects have little bearing on the 
working curve “calculator” used to identify parameters for the production of large objects, more 
investigation of pixel level effects will be important to understand CLIP of parts on the micron 
scale. 
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Figure B.6 Modeled light intensity distributions as a function of feature size. Light intensity distributions were 
modeled as described in Sun et.al for projections measuring A) 40x40 pixels, B) 30x30pixels, C) 15x15pixels, D) 
10x10pixels, E) 6x6 pixels and F) 3x3 pixels. Theoretical modeling indicates that light intensity decreases with 
feature size for this system.  
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Figure B.7 Modeled and experimental cure profiles of TMPTA exposed to a single frame of UV light 
measuring 40x40pixels (A-B) or 30x30pixels(C-D) 
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Figure B.9 Modeled and experimental cure profiles of TMPTA exposed to a single frame of UV light measuring 
15x15pixels (A-B) or 10x10pixels(C-D) 
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Figure B.10 Modeled and experimental cure profiles of TMPTA exposed to a single frame of UV light 
measuring 6x6pixels (A-B) or 3x3 pixels(C-D) 
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